<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Neurosci</journal-id>
<journal-id journal-id-type="publisher-id">Front. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Neuroscience</journal-title>
</journal-title-group>
<issn pub-type="ppub">1662-4548</issn>
<issn pub-type="epub">1662-453X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31333401</article-id>
<article-id pub-id-type="pmc">6614559</article-id>
<article-id pub-id-type="doi">10.3389/fnins.2019.00680</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neuroscience</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>From Cannabinoids and Neurosteroids to Statins and the Ketogenic Diet: New Therapeutic Avenues in Rett Syndrome?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Mouro</surname>
<given-names>Francisco Melo</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/637264/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Miranda-Lourenço</surname>
<given-names>Catarina</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/697180/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sebastião</surname>
<given-names>Ana Maria</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/138891/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Diógenes</surname>
<given-names>Maria José</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c002">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/30788/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Instituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa</institution>, <addr-line>Lisbon</addr-line>, <country>Portugal</country></aff>
<aff id="aff2"><sup>2</sup><institution>Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa</institution>, <addr-line>Lisbon</addr-line>, <country>Portugal</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Francisco Ciruela, University of Barcelona, Spain</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Maurizio Giustetto, University of Turin, Italy; Erik B. Oleson, University of Colorado Denver, United States</p>
</fn>
<corresp id="c001">*Correspondence: Francisco Melo Mouro, <email>fmouro@medicina.ulisboa.pt</email></corresp>
<corresp id="c002">Maria José Diógenes, <email>diogenes@medicina.ulisboa.pt</email></corresp>
<fn fn-type="other" id="fn004">
<p>This article was submitted to Neuropharmacology, a section of the journal Frontiers in Neuroscience</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>02</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>13</volume>
<elocation-id>680</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>4</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>6</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Mouro, Miranda-Lourenço, Sebastião and Diógenes.</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Mouro, Miranda-Lourenço, Sebastião and Diógenes</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Rett syndrome (RTT) is an X-linked neurodevelopmental disorder caused mainly by mutations in the <italic>MECP2</italic> gene, being one of the leading causes of mental disability in females. Mutations in the <italic>MECP2</italic> gene are responsible for 95% of the diagnosed RTT cases and the mechanisms through which these mutations relate with symptomatology are still elusive. Children with RTT present a period of apparent normal development followed by a rapid regression in speech and behavior and a progressive deterioration of motor abilities. Epilepsy is one of the most common symptoms in RTT, occurring in 60 to 80% of RTT cases, being associated with worsening of other symptoms. At this point, no cure for RTT is available and there is a pressing need for the discovery of new drug candidates to treat its severe symptoms. However, despite being a rare disease, in the last decade research in RTT has grown exponentially. New and exciting evidence has been gathered and the etiopathogenesis of this complex, severe and untreatable disease is slowly being unfolded. Advances in gene editing techniques have prompted cure-oriented research in RTT. Nonetheless, at this point, finding a cure is a distant reality, highlighting the importance of further investigating the basic pathological mechanisms of this disease. In this review, we focus our attention in some of the newest evidence on RTT clinical and preclinical research, evaluating their impact in RTT symptomatology control, and pinpointing possible directions for future research.</p>
</abstract>
<kwd-group>
<kwd>Rett syndrome</kwd>
<kwd>GABA<sub>A</sub>R</kwd>
<kwd>epilepsy</kwd>
<kwd>cholesterol</kwd>
<kwd>ketogenic diet</kwd>
<kwd>cannabinoids</kwd>
<kwd>neurosteroids</kwd>
</kwd-group>
<counts>
<fig-count count="5"></fig-count>
<table-count count="1"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="266"></ref-count>
<page-count count="22"></page-count>
<word-count count="0"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="S1">
<title>Introduction</title>
<p>In 1966, the neuro pediatrician Andreas Rett described and published a report concerning a neurodevelopmental disorder affecting females (<xref ref-type="bibr" rid="B200">Rett, 1966</xref>; <xref ref-type="bibr" rid="B184">Percy, 2016</xref>). In this report, Dr. Rett described a disease characterized as having an early onset of developmental delay followed by a rapid regression, loss of communication ability and fine motor capabilities, as well as, the occurrence of stereotypic hand movements and periodic breathing during wakefulness (<xref ref-type="bibr" rid="B184">Percy, 2016</xref>). Today, this disease is known as Rett syndrome (RTT). RTT is a severe neurodevelopmental X-linked disorder affecting almost exclusively female patients, with prevalence of approximately 1:10000 live births (<xref ref-type="bibr" rid="B218">Segatto et al., 2014</xref>) and with a high rate of sporadic mutations (<xref ref-type="bibr" rid="B182">Patankar, 2014</xref>). Despite its rareness, RTT is still the second most common cause of severe mental retardation in females (<xref ref-type="bibr" rid="B54">De Felice et al., 2012</xref>). The majority of RTT cases are characterized by an archetypal clinical scenario, comprised by loss of acquired cognitive, social, and motor skills, in an usual four-stage neurologic regression, occurring simultaneously with the development of autistic behavior (<xref ref-type="bibr" rid="B86">Hagberg, 2002</xref>; <xref ref-type="bibr" rid="B171">Neul et al., 2010</xref>; <xref ref-type="bibr" rid="B54">De Felice et al., 2012</xref>; <xref ref-type="bibr" rid="B21">Braat and Kooy, 2015</xref>). According to Hagberg, stage I is named “early onset stagnation,” occurs 6 months to 1.5 years after birth and is characterized by delays on the developmental progress. Subsequently, stage II, or “developmental regression,” occurs from year 1 to 4, being characterized by rapid loss of acquired skills and communication and manifestation of mental deficiency. Stage III is termed “pseudostationary period,” being characterized by apparent preserved ambulatory ability and restitution of some communicative abilities, while a slow neuromotor regression occurs. Lastly, stage IV or “later motor deterioration,” onsets when the ambulation of stage III ceases and its characterized by complete wheelchair dependence, severe disability, wasting and distal distortion. RTT patients can also experience gastrointestinal problems, hypoplasia, early-onset osteoporosis, bruxism and screaming spells (<xref ref-type="bibr" rid="B86">Hagberg, 2002</xref>). Reductions in brain weight and cortical atrophy/microencephaly, resulting in a smaller head circumference, were early reported as a common feature occurring in children diagnosed with RTT (<xref ref-type="bibr" rid="B104">Jellinger et al., 1988</xref>). As thoroughly reviewed in <xref ref-type="bibr" rid="B124">Kyle et al. (2018)</xref>, metabolic complications are also known as a common feature in RTT (<xref ref-type="bibr" rid="B112">Justice et al., 2013</xref>; <xref ref-type="bibr" rid="B218">Segatto et al., 2014</xref>). Also, as revised in <xref ref-type="bibr" rid="B224">Shulyakova et al. (2017)</xref>, important anomalies in mitochondrial structure and function (altered electron transport chain complex function, increased oxidative stress and elevated levels of lactate and pyruvate in blood and cerebrospinal fluid) have been demonstrated in RTT. The clinical diagnosis of RTT is performed following a battery of co-existing and well-defined set of inclusion and exclusion criteria, which were recently revised (<xref ref-type="bibr" rid="B171">Neul et al., 2010</xref>; <xref ref-type="bibr" rid="B124">Kyle et al., 2018</xref>).</p>
<p>In <xref ref-type="bibr" rid="B3">Amir et al. (1999)</xref>, using a systematic gene screening approach, identified mutations in the gene <italic>MECP2</italic> as cause of some cases of RTT. Today, several mutations in the X-linked <italic>MECP2</italic> gene are identified, being acknowledged as the cause of 95% of the classical RTT cases and of 40–50% of the atypical RTT cases (<xref ref-type="bibr" rid="B171">Neul et al., 2010</xref>; <xref ref-type="bibr" rid="B258">Zhang et al., 2017</xref>), resulting in a wide genetic and phenotypic heterogeneity of this disease (<xref ref-type="bibr" rid="B54">De Felice et al., 2012</xref>). <italic>MECP2</italic> is a globally expressed pleiotropic factor, assuming a key role in maintaining homeostasis in different cells and systems (<xref ref-type="bibr" rid="B224">Shulyakova et al., 2017</xref>). As expected for a neurological condition (<xref ref-type="bibr" rid="B172">Neul and Zoghbi, 2004</xref>), in RTT the higher levels of <italic>MECP2</italic> in the body are expressed in the brain (<xref ref-type="bibr" rid="B221">Shahbazian, 2002</xref>). Confirming the importance of <italic>MECP2</italic> presence in the brain, the selective elimination of this gene from neurons (<xref ref-type="bibr" rid="B84">Guy et al., 2007</xref>) and oligodendrocytes (<xref ref-type="bibr" rid="B173">Nguyen et al., 2012</xref>) triggers RTT-like phenotype in mice (<xref ref-type="bibr" rid="B224">Shulyakova et al., 2017</xref>). In atypical RTT variants, mutations in other loci rather than the <italic>MECP2</italic> have been identified (<xref ref-type="bibr" rid="B171">Neul et al., 2010</xref>).</p>
<p>A diversity of distinctive variant forms of RTT has been proposed, each of which presents different clinical features. Some of these variants have been identified and described in relatively small populations, which leads to difficulties in the definition of clear clinical characteristics (<xref ref-type="bibr" rid="B171">Neul et al., 2010</xref>). Nevertheless, according to <xref ref-type="bibr" rid="B171">Neul et al. (2010)</xref>, there are three distinctive variants of RTT that have been amply identified and that are well characterized: (1) the preserved speech variant (<xref ref-type="bibr" rid="B256">Zappella, 1992</xref>), (2) the congenital variant (<xref ref-type="bibr" rid="B207">Rolando, 1985</xref>), and (3) the early seizure variant (<xref ref-type="bibr" rid="B88">Hanefeld, 1985</xref>). From these three atypical forms of RTT, the preserved speech variant, or Zappella variant, is the most common one. This variant has clearly defined clinical features and mutations on the <italic>MECP2</italic> gene are identified in most of the diagnosed cases (<xref ref-type="bibr" rid="B256">Zappella, 1992</xref>; <xref ref-type="bibr" rid="B199">Renieri et al., 2009</xref>; <xref ref-type="bibr" rid="B171">Neul et al., 2010</xref>). On the contrary, in diagnosed cases belonging to the congenital and early seizure variants, mutations in the <italic>MECP2</italic> gene are rarely found, while mutations in different genes are reported (<xref ref-type="bibr" rid="B97">Huppke et al., 2000</xref>; <xref ref-type="bibr" rid="B6">Archer et al., 2006</xref>; <xref ref-type="bibr" rid="B171">Neul et al., 2010</xref>; <xref ref-type="bibr" rid="B54">De Felice et al., 2012</xref>). Namely, mutations in the <italic>CDKL5</italic> gene have been described in both males and females diagnosed with early-seizure-onset RTT variant (<xref ref-type="bibr" rid="B145">Mari et al., 2005</xref>; <xref ref-type="bibr" rid="B216">Scala et al., 2005</xref>; <xref ref-type="bibr" rid="B261">Zhao et al., 2014</xref>; <xref ref-type="bibr" rid="B258">Zhang et al., 2017</xref>). On the other hand, mutations in the FOXG1 gene have been identified in the congenital RTT variant (<xref ref-type="bibr" rid="B258">Zhang et al., 2017</xref>), first described by <xref ref-type="bibr" rid="B207">Rolando (1985)</xref>. The congenital variant of RTT is clinically characterized by hypotonia and developmental delay occurring earlier than in classical RTT variant (<xref ref-type="bibr" rid="B207">Rolando, 1985</xref>; <xref ref-type="bibr" rid="B103">Jacob et al., 2009</xref>). Importantly, the majority of children diagnosed with the congenital variant of RTT do not present mutations in the <italic>MECP2</italic> or <italic>CDKL5</italic> mutations (<xref ref-type="bibr" rid="B103">Jacob et al., 2009</xref>).</p>
<p>The available treatment for RTT is mainly symptomatic. With appropriate social and familiar care, attention to orthopedic complications, physiotherapy to treat and ease muscle rigidity, control of epileptic episodes, and a balanced and healthy nutrition, women with RTT can survive until middle age and older age (<xref ref-type="bibr" rid="B124">Kyle et al., 2018</xref>). There is a sudden death rate of 26% in RTT and patients mainly perish due to cardiac complications, respiratory infection and respiratory failure (<xref ref-type="bibr" rid="B124">Kyle et al., 2018</xref>). Most of the preclinical and clinical studies in RTT aims at finding ways to prevent or control epileptic episodes, due to the importance that it has for the outcome of RTT prognosis (<xref ref-type="bibr" rid="B121">Krajnc, 2015</xref>; <xref ref-type="bibr" rid="B43">Clarke and Abdala Sheikh, 2018</xref>). Therefore, preclinical research in RTT is majorly focused on finding ways of correcting detrimental modifications in neurotransmission occurring in this disease, using <italic>Mecp2</italic>-null mouse models (<xref ref-type="bibr" rid="B43">Clarke and Abdala Sheikh, 2018</xref>). Recently, however, a paradigm shift has been proposed. Through gene therapy it was proven that it is possible to reverse RTT symptoms in diseased adult mice by re-activating <italic>Mecp2</italic> expression (<xref ref-type="bibr" rid="B84">Guy et al., 2007</xref>). Also, a few years later, it was shown that switching-off the production of Mecp2 protein in adult mice leads to the development of symptoms equivalent to those of mice born with the mutation (<xref ref-type="bibr" rid="B153">McGraw et al., 2011</xref>; <xref ref-type="bibr" rid="B43">Clarke and Abdala Sheikh, 2018</xref>). Considering that, by rule, neurodevelopmental disorders tend to be non-reversible, such results were received with considerable enthusiasm (<xref ref-type="bibr" rid="B43">Clarke and Abdala Sheikh, 2018</xref>). Thus, these studies showed that gene therapy would have to necessarily deliver a working <italic>MECP2</italic> gene throughout the patient life (it would not be sufficient to do it just on child development) and that treatment could be administered regardless of disease stage and/or age (<xref ref-type="bibr" rid="B43">Clarke and Abdala Sheikh, 2018</xref>). Although exciting, the above-mentioned discoveries have to be taken carefully. Indeed, in order to work, <italic>MECP2</italic> gene therapy would have to deliver the precise amount of MECP2 protein in each cell of the body, as too much or too few MECP2 protein can trigger RTT-like symptoms (<xref ref-type="bibr" rid="B43">Clarke and Abdala Sheikh, 2018</xref>). As a particularly harsh example, in <italic>MECP2</italic> duplication syndrome, an overproduction of MECP2 protein leads to mental disability and autistic-like behavior (<xref ref-type="bibr" rid="B166">Moretti and Zoghbi, 2006</xref>; <xref ref-type="bibr" rid="B194">Ramocki et al., 2009</xref>). Moreover, even small deviations from the necessary MECP2 protein levels are related with modifications in brain function, which can lead to cognitive and mental disability (<xref ref-type="bibr" rid="B36">Chao and Zoghbi, 2012</xref>). Therefore, as mentioned in <xref ref-type="bibr" rid="B43">Clarke and Abdala Sheikh (2018)</xref>, gene therapy in RTT delivers two major challenges: (1) it potentially means that it would be necessary to deliver the exact right amount of <italic>MECP2</italic> to every cell and (2) in females, it would be necessary to avoid delivering additional copies of the gene to the cells that already express a healthy copy; two pitfalls that are extremely difficult to overcome with the available technology.</p>
<p>At this point, although possible, finding a cure for RTT is a distant reality. In the meanwhile, it is more important than ever to find new treatments to alleviate symptoms, reduce pain and discomfort and increase the quality of life of both the patient and the caregiver. Therefore, in this review we will turn our attention to new discoveries which show potential in RTT preclinical investigation.</p>
</sec>
<sec id="S2">
<title>Dysfunctional GABAR Signaling in RTT: Implications for Symptomatology</title>
<p>Rett syndrome is characterized by structural and molecular deficiencies in synaptic transmission. Evidence displays important modifications in basal transmission, in short and long-term plasticity processes and in neurotransmitter release (<xref ref-type="bibr" rid="B20">Boggio et al., 2010</xref>). Studies using different <italic>Mecp2</italic> genetic mutated mice have made it possible to understand that individual phenotypic characteristics of RTT can be associated with dysfunctions in very specific neuronal populations. Indeed, the selective deletion of the <italic>Mecp2</italic> gene from different neuronal populations, in different ages and in distinctive brain regions accounts for specific phenotypical traits of the disease. Thus, such data has led authors to claim that the phenotypical consequences of <italic>Mecp2</italic> deletion are time and region-dependent (<xref ref-type="bibr" rid="B35">Chao et al., 2010</xref>). In this regard, dysfunctional GABAergic signaling constitutes a vital element in RTT symptomatology.</p>
<p>The GABAergic signaling system comprises a key pathway commonly disturbed in neurodevelopmental diseases, such as RTT, fragile X syndrome, Dravet Syndrome, neurofibromatosis type I, Tourette syndrome, Down Syndrome and in Autism Spectrum Disorders (<xref ref-type="bibr" rid="B127">Lee and Tierney, 2011</xref>; <xref ref-type="bibr" rid="B65">El-Ansary and Al-Ayadhi, 2014</xref>; <xref ref-type="bibr" rid="B21">Braat and Kooy, 2015</xref>; <xref ref-type="bibr" rid="B120">Kim and Yoon, 2017</xref>). GABA is the main inhibitory neurotransmitter in the brain, exerting its actions via the activation of two subtypes of GABA receptors, the ionotropic GABA<sub>A</sub>R and the metabotropic GABA<sub>B</sub>R (<xref ref-type="bibr" rid="B40">Chebib and Johnston, 1999</xref>; <xref ref-type="bibr" rid="B208">Rombo et al., 2016</xref>). GABA<sub>A</sub>R are ligand-gated receptors responsible for mediating the majority of inhibitory synaptic transmission in the CNS (<xref ref-type="bibr" rid="B195">Reddy, 2010</xref>). Structurally, GABA<sub>A</sub>R are heteropentamers with five protein subunits that form the chloride ion channel (<xref ref-type="bibr" rid="B195">Reddy, 2010</xref>). GABA<sub>A</sub>R can be assembled by seven different classes of subunits, some of which comprised by different homologous variants (α<sub>1</sub><sub>–</sub><sub>6</sub>, β<sub>1</sub><sub>–</sub><sub>3</sub>, γ<sub>1</sub><sub>–</sub><sub>3</sub>, σ<sub>1</sub><sub>–</sub><sub>3</sub>, δ, θ, ε). Usually, most GABA<sub>A</sub>R are composed by α, β, and γ or δ-subunits (<xref ref-type="bibr" rid="B225">Sieghart, 2006</xref>). The binding site for the endogenous modulator GABA is located in the cleft between the α and β subunits. Apart from the GABA binding site, there are several other binding sites in the GABA<sub>A</sub>R which constitute targets for benzodiazepines and barbiturates (<xref ref-type="bibr" rid="B227">Smith, 2002</xref>). Furthermore, each pharmacological effect appears to be directly related with a specific binding site on the receptor surface, which depends on the subunit composition of the receptor (<xref ref-type="bibr" rid="B26">Cai et al., 2018</xref>). Post-synaptic GABA<sub>A</sub>R are ubiquitously distributed, being responsible for generating the phasic currents in response to presynaptic GABA release. On the other hand, extrasynaptic GABA<sub>A</sub>R are preferentially activated when GABA levels are low, being highly sensitive to extracellular GABA concentrations and responsible for generating non-desensitizing tonic inhibition (<xref ref-type="bibr" rid="B249">Wang, 2011</xref>; <xref ref-type="bibr" rid="B26">Cai et al., 2018</xref>). Despite being exclusively present in a minority of neurons, several clusters of GABAergic interneurons are responsible for regulating and controlling the majority of excitatory neurons. Thus, if an imbalance in the inhibitory system occurs, the following excessive excitatory output leads to disturbances on the excitation/inhibition balance, ultimately resulting in dysfunction of cognitive processes (<xref ref-type="bibr" rid="B21">Braat and Kooy, 2015</xref>). Importantly, genetic alterations in GABAergic signaling system has been shown to be involved in several neurodevelopmental diseases (for a detailed review see <xref ref-type="bibr" rid="B21">Braat and Kooy, 2015</xref>).</p>
<p>Evidence regarding dysfunctional GABAergic signaling in RTT has been mainly obtained in studies using RTT-mouse models. Such studies have been gathering substantial evidence confirming the critical involvement of GABAergic transmission in RTT symptomatology, highlighting the clinical relevance of this signaling system. Indeed, an incorrect balance between excitation and inhibition reflecting a dysfunction in GABAergic and glutamatergic signaling systems have been described in <italic>Mecp2</italic>-knockout mice (<xref ref-type="bibr" rid="B51">Dani et al., 2005</xref>; <xref ref-type="bibr" rid="B37">Chao et al., 2007</xref>; <xref ref-type="bibr" rid="B52">Dani and Nelson, 2009</xref>; <xref ref-type="bibr" rid="B27">Calfa et al., 2011</xref>). Also, as mentioned before regarding other neuromodulatory systems, the relationship between RTT phenotypical expression and GABAergic signaling is region, time and neuronal population dependent (<xref ref-type="bibr" rid="B66">El-Khoury et al., 2014</xref>). Confirming the critical involvement of the GABAergic system in RTT symptomatology, it has been shown that mice with <italic>Mecp2</italic>-deficiency exclusively in GABAergic neurons rapidly develop forepaw stereotyped movements, compulsive grooming, learning and memory deficits, abnormal social behavior, electroencephalography hyperexcitability, lack of motor coordination, severe respiratory dysrhythmias and premature lethality. Additionally, the results of this work also showed that the selective deletion of the <italic>Mecp2</italic> gene in a specific subset of forebrain GABAergic neurons was sufficient to trigger many of the aforementioned symptoms. Thus, these data strongly suggests that the loss of <italic>Mecp2</italic> in GABAergic neurons acts as a pivotal mediator for some characteristic RTT phenotypes (<xref ref-type="bibr" rid="B35">Chao et al., 2010</xref>).</p>
<p>The critical relevance of <italic>MECP2</italic> in GABAergic signaling was also shown in other brain regions, such as the hippocampus. Indeed, patch-clamp recordings performed in hippocampal slices obtained from <italic>Mecp2</italic> mutant mice, revealed that hippocampal circuits in CA3 neurons display diminished basal inhibitory rhythmic activity, which, consequently, leaves the circuitry susceptible to hyperexcitability (<xref ref-type="bibr" rid="B257">Zhang et al., 2008</xref>). Likewise, in the brain stem, an imbalance between inhibitory and excitatory transmission was reported to occur early at postnatal day 7 in <italic>Mecp2</italic> mutant mice. Additionally, GABAergic transmission was found to be significantly depressed in the same animals, which may be related with deficient presynaptic GABA release and diminished expression levels of subunits α2 and α4 on the post-synaptic GABA<sub>A</sub>R (<xref ref-type="bibr" rid="B154">Medrihan et al., 2008</xref>). In the thalamus, <italic>Mecp2</italic> differentially regulates the development of GABAergic synapses in excitatory or inhibitory neurons (<xref ref-type="bibr" rid="B260">Zhang Z.W. et al., 2010</xref>). Also, in <italic>Mecp2</italic> mutant mice, electrophysiological deficiencies have been reported in norepinephrinergic neurons of the locus coeruleus which receive GABA<sub>A</sub>ergic inhibitory inputs (<xref ref-type="bibr" rid="B106">Jin et al., 2013a</xref>; <xref ref-type="bibr" rid="B259">Zhang X. et al., 2010</xref>). In the locus coeruleus, <italic>Mecp2</italic> deficiency leads to simultaneous abnormalities in the pre- and post-synaptic GABAergic component, impairing GABA<sub>A</sub>ergic and GABA<sub>B</sub>ergic post-synaptic inhibitory currents and reducing the presynaptic release of GABA (<xref ref-type="bibr" rid="B106">Jin et al., 2013a</xref>). Indeed, it has been described that <italic>Mecp2</italic> deficiency abnormally increases extrasynaptic GABA<sub>A</sub>R activity, an effect suggested to occur as a compensatory response to the deficient GABA-mediate synaptic inhibition (<xref ref-type="bibr" rid="B262">Zhong et al., 2015</xref>).</p>
<p>The above-mentioned evidence highlights the critical role of <italic>MECP2</italic> gene for correct GABAergic signaling in different brain regions. Besides brain region and synaptic location of the receptor, in a recent study it was also shown that selective deletion of <italic>Mecp2</italic> from either parvalbumin-positive neurons or somatostatin-positive neurons leads to different phenotypical outcomes, that together comprise almost the full range of RTT-like phenotypes. Specifically, <italic>Mecp2</italic> deletion from parvalbumin-positive neurons leads to motor, sensory, cognitive and social deficits, while ablation of <italic>Mecp2</italic> from somatostatin-positive neurons originated stereotyped behavior and seizures (<xref ref-type="bibr" rid="B101">Ito-Ishida et al., 2015</xref>). Recently, reductions in GABAergic transmission in the nucleus tractus solitarius, a key brain region involved in the integration of respiratory sensory information, were reported (<xref ref-type="bibr" rid="B41">Chen et al., 2018</xref>).</p>
<p>Although scarce, there is available data collected from human samples supporting findings in rodent models of RTT (<xref ref-type="bibr" rid="B21">Braat and Kooy, 2015</xref>). GABA<sub>A</sub>R binding was found to be significantly altered in the basal ganglia (<xref ref-type="bibr" rid="B19">Blue et al., 1999</xref>) and in the frontotemporal cortex (<xref ref-type="bibr" rid="B252">Yamashita et al., 1998</xref>) in RTT patients. Additionally, a disturbed process of GABAergic neuronal maturation was described in the cerebrospinal fluid of RTT patients (<xref ref-type="bibr" rid="B61">Duarte et al., 2013</xref>) (for a more details see <xref ref-type="bibr" rid="B21">Braat and Kooy, 2015</xref>). Also, an analysis performed in <italic>post-mortem</italic> human brains, has shown defects in the expression of the GABR gene GABRB3, contained in the human chromosome 15q11-13, in RTT patients (<xref ref-type="bibr" rid="B215">Samaco et al., 2005</xref>). Congruently, subsequent evidence obtained with mice models, suggested that <italic>Mecp2</italic> gene is vital for the correct expression of both alleles of GABRB3 in neurons (<xref ref-type="bibr" rid="B94">Hogart et al., 2007</xref>).</p>
<p>Considering the anomalies observed in GABAergic signaling in RTT and their crucial role in symptomatology and disease progression, correction of these modifications has been proposed as a therapeutic strategy. Indeed, adjustment of the GABAergic system activity in <italic>Mecp2</italic> mutant mice leads to improvements in several phenotypical features (<xref ref-type="bibr" rid="B21">Braat and Kooy, 2015</xref>). In accordance, in a recent study, it was found that an <italic>in vivo</italic> treatment with the inhibitor of GABA reuptake, Tiagabine, significantly increased the life-spam of <italic>Mecp2</italic> knockout mice, although it did not ameliorate motor deficits (<xref ref-type="bibr" rid="B66">El-Khoury et al., 2014</xref>). In another study, the benzodiazepine Midazolam transiently abolished breathing abnormalities in <italic>Mecp2</italic> mutant mice (<xref ref-type="bibr" rid="B246">Voituron and Hilaire, 2011</xref>). Also, the enhancement of GABA<sub>A</sub>R-mediated signaling, either through blockade of GABA reuptake or through positive allosteric modulation of the GABA<sub>A</sub>R, resulted in a significant reduction on respiratory problems (<xref ref-type="bibr" rid="B2">Abdala et al., 2010</xref>). Recently, respiratory dysrhythmia has been related with deficient GABAergic signaling in the Kölliker-Fuse area, or subparabrachial nucleus, a brain area responsible for the regulation of breathing rate. Congruently, boosting GABA transmission reduced respiratory arrhythmia in a RTT-mouse model (<xref ref-type="bibr" rid="B1">Abdala et al., 2016</xref>). Also, early exposure to the extrasynaptic GABA<sub>A</sub>R agonist THIP was shown to regulate neuron hyperexcitability on the locus coeruleus, known to be involved in the regulation of breathing (<xref ref-type="bibr" rid="B263">Zhong et al., 2017</xref>). Finally, genetic re-expression of <italic>Mecp2</italic> only in GABAergic neurons of male and female <italic>Mecp2</italic> null mice enhanced inhibitory signaling. Also, it extended animal lifespan, mitigated ataxia, apraxia, and social withdrawal, displaying that the restoration of <italic>Mecp2</italic> expression in GABAergic neurons significantly improves the symptomatology of RTT (<xref ref-type="bibr" rid="B239">Ure et al., 2016</xref>; <xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>The potential of GABA<sub>A</sub>R modulators on RTT. <bold>(1)</bold> Exclusive deletion of <italic>Mecp2</italic> from GABAergic neurons results in almost the full range of neuropsychiatric symptoms of RTT (<xref ref-type="bibr" rid="B35">Chao et al., 2010</xref>). <bold>(2)</bold> Blocking GABA reuptake using tiagabine (<xref ref-type="bibr" rid="B66">El-Khoury et al., 2014</xref>) or enhancing GABA<sub>A</sub>R activity with the benzodiazepine Midazolam increases the life-spam and reduces symptoms in <italic>Mecp2</italic> mutant mice (<xref ref-type="bibr" rid="B246">Voituron and Hilaire, 2011</xref>).</p>
</caption>
<graphic xlink:href="fnins-13-00680-g001"></graphic>
</fig>
<p>Taken together, these results emphasize the crucial role of <italic>MECP2</italic> in GABAergic neurons. Also, they demonstrate a clear relationship between modifications in GABAergic signaling and symptomatology in RTT, highlining the potential of drug agents which correct these modifications to improve RTT symptoms. Therefore, on the following sections we will focus our attention on new findings that, directly or indirectly, involve the modulation of GABAergic signaling in RTT (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Research topics to be addressed in this review. <bold>In red:</bold> the use of direct and indirect modulators of GABAergic signaling, respectively, benzodiazepines (BZD) and GABA enhancers. <bold>In orange:</bold> Abnormal cholesterol metabolism occurring in RTT, the use of statins (STA) to improve RTT symptoms; the impact of deficits on cholesterol uptake on neurosteroidogenesis; the possible therapeutic actions of the neurosteroid allopregnanolone (ALLO). <bold>In blue:</bold> the use of derivatives of the cannabis plant to ameliorate RTT symptoms; cannabidiol (CBD) has shown promising anti-epileptic effects via GABA-dependent mechanisms; the effects of CBD on CB<sub>1</sub>R and TRPV<sub>1</sub> and its impact on RTT symptoms are still undisclosed; Cannabidivarin (CBDV) has been identified as a promising therapeutic drug in an RTT-mice model. <bold>In green:</bold> Ketogenic Diet (KD) has potent anticonvulsive actions via GABAergic and glutamatergic (GLU) signaling systems; the KD can also improve RTT symptoms via BDNF-mediated effects or through increases in adenosine production. BNDF signaling is known to be impaired in RTT (<xref ref-type="bibr" rid="B128">Li and Pozzo-Miller, 2014</xref>), while unpublished data obtained in our lab points to deregulations in adenosinergic signaling. Direct arrows denote direct interaction with GABAergic signaling system, while doted arrows denote known or undisclosed involvement on RTT pathophysiology.</p>
</caption>
<graphic xlink:href="fnins-13-00680-g002"></graphic>
</fig>
</sec>
<sec id="S3">
<title>RTT, a Brain Disease With a Metabolic Blueprint</title>
<sec id="S3.SS1">
<title>Cholesterol and Neurosteroids in Rett Syndrome</title>
<p>Rett syndrome was initially considered to be a metabolic disease (<xref ref-type="bibr" rid="B112">Justice et al., 2013</xref>). Indeed, originally, Dr. Rett, convinced of being in the presence of a disease with a clear metabolic component, named it “cerebroatrophic hyperammonaemia” (<xref ref-type="bibr" rid="B124">Kyle et al., 2018</xref>). Hyperammonemia is a clinical condition characterized by increased ammonia levels, which manifests itself in a variety of symptoms and signs, including significant CNS abnormalities (<xref ref-type="bibr" rid="B7">Auron and Brophy, 2012</xref>). The fact that hyperammonaemia has been detected only in a minority of RTT patients led to the abandonment of the hypothesis of cerebroatrophic hyperammonaemia as the central cause for RTT (<xref ref-type="bibr" rid="B28">Campos-Castelló et al., 1988</xref>; <xref ref-type="bibr" rid="B112">Justice et al., 2013</xref>). Recently, however, the metabolic components of RTT and its importance for disease progression have been brought again into light.</p>
<p>Cholesterol is a vital component of the cellular membrane structure and a precursor for numerous signaling molecules (<xref ref-type="bibr" rid="B168">Nagy and Ackerman, 2013</xref>). Cholesterol does not cross the BBB and therefore brain cholesterol has to be generated locally, which directly contrasts with other organs that are able of acquiring it from circulating lipoproteins (<xref ref-type="bibr" rid="B189">Pfrieger and Ungerer, 2011</xref>). In the brain, the production of cholesterol is a highly compartmentalized process presenting a very delicate balance. Its production takes place in the endoplasmic reticulum and requires, as an energy source, the correct functioning of the mitochondria (<xref ref-type="bibr" rid="B112">Justice et al., 2013</xref>). Importantly, mitochondrial function and structure is compromised in both RTT patients and <italic>Mecp2</italic> mutant mouse models (<xref ref-type="bibr" rid="B224">Shulyakova et al., 2017</xref>). After synthesis, brain cholesterol must be quickly renewed and turned-over, as it can be rapidly oxidized by reactive oxygen species (ROS), known to accumulate whenever mitochondria dysfunction occurs (<xref ref-type="bibr" rid="B112">Justice et al., 2013</xref>). To maintain homeostasis, cholesterol must be converted into the 24S-OHC by the neuron-specific enzyme Cyp46a1 (<xref ref-type="bibr" rid="B136">Lund et al., 2003</xref>; <xref ref-type="bibr" rid="B124">Kyle et al., 2018</xref>). Thus, a tight regulation of cholesterol homeostasis in the brain assumes particular importance: too much or too little cholesterol is detrimental, negatively impacting on cognitive processes, memory and motor skills (<xref ref-type="bibr" rid="B124">Kyle et al., 2018</xref>). Concordantly, a vast number of neurological diseases present abnormal lipid synthesis, storage and recycling (<xref ref-type="bibr" rid="B250">Waterham, 2006</xref>), namely, SLOS and Niemann–Pick type C disease, Alzheimer’s, Parkinson’s, and Huntington’s diseases, Amyotrophic lateral sclerosis, Fragile X syndrome, and, as recently discovered, RTT (<xref ref-type="bibr" rid="B112">Justice et al., 2013</xref>).</p>
<p>Using <italic>Mecp2</italic> mutant mice, a mutagenesis screening to identify genes that influence RTT-linked phenotypes was performed (<xref ref-type="bibr" rid="B24">Buchovecky et al., 2013</xref>; <xref ref-type="bibr" rid="B168">Nagy and Ackerman, 2013</xref>). To do so, descendent of <italic>MECP2</italic> mice were screened for limp gasping, tremors and activity, and mice that displayed reduced phenotypic features were bred to establish the hereditability of putative suppressor genes (<xref ref-type="bibr" rid="B24">Buchovecky et al., 2013</xref>). This screening highlighted that a mutation in the <italic>Sqle</italic> gene, encoding squalene epoxidase, which is a rate-limiting enzyme in cholesterol biosynthesis, was sufficient to restore function and longevity in <italic>Mecp2</italic> mutant mice. The authors also showed that cholesterol metabolism is perturbed in brains and livers of <italic>Mecp2</italic> mutant male mice, revealing profound and complex dysregulations in cholesterol metabolism. Furthermore, HMG-CoA reductase inhibitors, or statins, were able to ameliorate the systemic imbalance of lipid profile, alleviate motor symptoms and increase longevity in <italic>Mecp2</italic> mutant mice (<xref ref-type="bibr" rid="B24">Buchovecky et al., 2013</xref>). Studies with samples collected from human RTT patients have also shown modifications in lipid profile. Directly comparing with age-matched healthy donors, imbalances in both high (HDL) and low (LDL) density lipoprotein levels were found in RTT patients. Accompanying these abnormalities in plasma lipid profile, a marked reduction in SRB1 was detected. SRB1 is ubiquitously expressed, playing vital roles in cellular lipid uptake, mediating, for instance, the uptake of HDL-derived cholesterol in the liver (<xref ref-type="bibr" rid="B230">Sticozzi et al., 2013</xref>). Congruently, using freshly isolated human fibroblasts, it has been shown that total cholesterol and LDL levels are significantly increased in RTT patients, while SRB1 expression was quantified has being 70% lower in RTT patients compared with healthy controls (<xref ref-type="bibr" rid="B218">Segatto et al., 2014</xref>). On the other hand, and in accordance with data from <xref ref-type="bibr" rid="B24">Buchovecky et al. (2013)</xref>, cholesterol synthesis was found to be reduced in RTT fibroblasts (<xref ref-type="bibr" rid="B218">Segatto et al., 2014</xref>). Therefore, these data provided strong evidence toward the importance of cholesterol homeostasis in RTT. Also, imbalances in cholesterol metabolism can affect the synthesis of steroid hormones, among which neurosteroids can have an important role in several brain diseases, as it will be approached in the following section.</p>
</sec>
<sec id="S3.SS2">
<title>Neurosteroids: The Way Is Through the GABA<sub>A</sub>R</title>
<p>Neurosteroids were described, for the first time, has having anesthetic and anticonvulsive actions in the late 1940s (<xref ref-type="bibr" rid="B219">Selye, 1941</xref>; <xref ref-type="bibr" rid="B220">Selye and Masson, 1942</xref>; <xref ref-type="bibr" rid="B44">Clarke, 1973</xref>; <xref ref-type="bibr" rid="B197">Reddy and Estes, 2016</xref>). Almost half a century later, alphaxolone, a synthetic neurosteroid, was found to increase synaptic inhibition through GABA<sub>A</sub>R activation (<xref ref-type="bibr" rid="B90">Harrison and Simmonds, 1984</xref>), which constituted a major advanced in neurosteroid research (<xref ref-type="bibr" rid="B140">Majewska et al., 1986</xref>).</p>
<p>Neuroactive steroids are steroid molecules synthesized in the brain that modulate neuronal excitability by rapid non-genomic actions (<xref ref-type="bibr" rid="B195">Reddy, 2010</xref>). Cholesterol constitutes the raw material for the biosynthesis of all steroid hormones (<xref ref-type="bibr" rid="B96">Hu et al., 2010</xref>). <italic>De novo</italic> synthesis of neurosteroids is a sequential and highly compartmentalized process involving, as first step, the translocation of cholesterol from the cytoplasm to the inner mitochondrial membrane. Once inside the mitochondria, cholesterol is converted into pregnenolone, the precursor of all steroid hormones (<xref ref-type="bibr" rid="B195">Reddy, 2010</xref>; <xref ref-type="bibr" rid="B158">Melcangi et al., 2014</xref>). Pregnenolone is then transformed into progesterone by the action of the enzyme 3β-HSD (<xref ref-type="bibr" rid="B157">Melcangi et al., 2008</xref>). The conversion of cholesterol to pregnenolone in the mitochondria is, consequently, the first rate-limiting step in the biosynthesis of all steroid hormones (<xref ref-type="bibr" rid="B231">Stoffel-Wagner, 2003</xref>). ALLO is derived from progesterone by 5α-reductase and 3α-HSD (<xref ref-type="bibr" rid="B132">Liu and Wong-Riley, 2010</xref>), and is viewed as the most potent endogenous modulator of the GABAergic system via interaction with the GABA<sub>A</sub>R (<xref ref-type="bibr" rid="B95">Hosie et al., 2006</xref>; <xref ref-type="bibr" rid="B195">Reddy, 2010</xref>; <xref ref-type="fig" rid="F3">Figure 3</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p><italic>De novo</italic> synthesis of some important neurosteroids. <bold>(1)</bold> After being transported from the outer to the inner membrane, cholesterol is transported from the outer to the inner membrane of the mitochondria by steroidogenic acute regulatory protein (StAR). <bold>(2)</bold> Once inside the mitochondria, cholesterol is transformed in pregnenolone, the mother of all steroid hormones, by cytochrome P450 cholesterol side-chain cleavage (P450scc) enzyme (CYP11A1). <bold>(3)</bold> Pregnenolone can be, subsequently, transformed into progesterone by 3β-hydroxysteroid dehydrogenase (3β-HSD), which in turn, can originate allopregnanolone through the action of 3α-hydroxysteroid dehydrogenase (3α-HSD). <bold>(4)</bold> Allopregnanolone is viewed as the most potent endogenous modulator of the GABAergic system via interaction with the GABA<sub>A</sub> receptor (for a detailed review see <xref ref-type="bibr" rid="B158">Melcangi et al., 2014</xref>).</p>
</caption>
<graphic xlink:href="fnins-13-00680-g003"></graphic>
</fig>
<p>Recent studies indicate that neurosteroids have anxiolytic, antidepressant and antipsychotic properties. Furthermore, neurosteroids stimulate neurogenesis, facilitate regeneration of neurons after injury, promote myelinization, and improve cognition (<xref ref-type="bibr" rid="B197">Reddy and Estes, 2016</xref>; <xref ref-type="bibr" rid="B26">Cai et al., 2018</xref>). The development of new analogous neurosteroid agents with promising therapeutic properties has resulted in four compounds tested in clinical trials for epilepsy, traumatic brain injury, status epilepticus and Fragile X syndrome. Also, several synthetic neurosteroids have been prepared for therapeutic use in the past decades, among which, the best-known are, the aforementioned alphaxolone, and also alphadolone, minaxolone, and ganaxolone (<xref ref-type="bibr" rid="B197">Reddy and Estes, 2016</xref>).</p>
<p>Neurosteroids have been implicated in the behavioral profile of some neurologic diseases. In SLOS, an autosomal recessive disorder which develops due to an inborn error in cholesterol metabolism (<xref ref-type="bibr" rid="B235">Tint et al., 1994</xref>; <xref ref-type="bibr" rid="B5">Aneja and Tierney, 2008</xref>; <xref ref-type="bibr" rid="B127">Lee and Tierney, 2011</xref>), impaired neurosteroid synthesis or the synthesis of an inhibitory analog form of neurosteroids on the brain have been proposed to occur (<xref ref-type="bibr" rid="B190">Porter, 2002</xref>). Congruently, urinary analysis has allowed the identification of neurosteroid-like compounds in SLOS patients, being foreseeable that this abnormal synthesis also occurs in the brain (<xref ref-type="bibr" rid="B144">Marcos et al., 2004</xref>; <xref ref-type="bibr" rid="B127">Lee and Tierney, 2011</xref>). In Fragile X syndrome, patients show autism-like phenotypes characterized by cognitive impairment, anxiety, mood swings and behavioral and learning difficulties (<xref ref-type="bibr" rid="B197">Reddy and Estes, 2016</xref>). A clinical trial using ganaxolone was found to be safe but produced no significant effects on the outcome measures in the overall population of the study. However, specific subsets of the children with Fragile X syndrome enrolled on the clinical trial, particularly the ones with higher anxiety, lower cognitive abilities and who have frequent seizure episodes, might benefit from treatment with this neurosteroid (<xref ref-type="bibr" rid="B131">Ligsay et al., 2017</xref>).</p>
<p>Recently, it has been described that ALLO (<xref ref-type="bibr" rid="B159">Meletti et al., 2017</xref>) and progesterone (<xref ref-type="bibr" rid="B160">Meletti et al., 2018</xref>) are decreased in cerebrospinal fluid (CSF) of patients affected by status epilepticus. Progesterone levels were found to be 64% lower than in healthy controls (<xref ref-type="bibr" rid="B160">Meletti et al., 2018</xref>). Interestingly, neurosteroids are also being proposed for the treatment of schizophrenia, as neurosteroids show promising anti-psychotic potential (<xref ref-type="bibr" rid="B26">Cai et al., 2018</xref>).</p>
<p>The therapeutic potential of neurosteroids is mainly related with their ability to rapidly modulate the activity of the GABAergic neurons, known to be involved in the pathophysiology of several psychiatric disorders (<xref ref-type="bibr" rid="B161">Mellédo and Baker, 2002</xref>; <xref ref-type="bibr" rid="B62">Dubrovsky, 2005</xref>; <xref ref-type="bibr" rid="B148">Marx et al., 2006</xref>) and neurodegenerative diseases (<xref ref-type="bibr" rid="B31">Carunchio et al., 2008</xref>; <xref ref-type="bibr" rid="B129">Li et al., 2016</xref>; <xref ref-type="bibr" rid="B120">Kim and Yoon, 2017</xref>; <xref ref-type="bibr" rid="B135">Lozovaya et al., 2018</xref>), and commonly disturbed in neurodevelopmental diseases (see section “Dysfunctional GABAR Signalling in RTT: Implications for Symptomatology”). The modulatory effects of neurosteroids on GABA<sub>A</sub>R are unique and extremely complex, depending on several factors, such as, the subunit composition of the receptor, the receptor localization, concentration and the structure of the neurosteroid (<xref ref-type="bibr" rid="B225">Sieghart, 2006</xref>; <xref ref-type="bibr" rid="B195">Reddy, 2010</xref>; <xref ref-type="bibr" rid="B198">Reddy and Jian, 2010</xref>; <xref ref-type="bibr" rid="B249">Wang, 2011</xref>; <xref ref-type="bibr" rid="B197">Reddy and Estes, 2016</xref>; <xref ref-type="bibr" rid="B26">Cai et al., 2018</xref>). Previous studies have shown that specific combinations of subunits in the GABA<sub>A</sub>R confer more or less affinity for neurosteroids, but that ALLO enhances GABA<sub>A</sub>ergic transmission whenever the GABA<sub>A</sub>R are composed by any α subunit (<xref ref-type="bibr" rid="B191">Puia et al., 1993</xref>, <xref ref-type="bibr" rid="B192">2003</xref>; <xref ref-type="bibr" rid="B139">Maitra and Reynolds, 1999</xref>; <xref ref-type="bibr" rid="B12">Belelli et al., 2002</xref>). Importantly, both post-synaptic GABA<sub>A</sub>R and extrasynaptic GABA<sub>A</sub>R are highly sensible to neurosteroid modulation. In particular, extrasynaptic GABA<sub>A</sub>R containing the δ subunit located in specific brain regions as the hypothalamus, hippocampal dentate gyrus and cerebellum, are highly sensitive to neurosteroids, which may open a therapeutic window for the use of neurosteroids in several brain diseases, including RTT (<xref ref-type="bibr" rid="B227">Smith, 2002</xref>; <xref ref-type="bibr" rid="B197">Reddy and Estes, 2016</xref>). Indeed, neurosteroids have been proposed as a viable alternative to overcome benzodiazepine tolerance, as they can bind and enhance the activity of all GABA<sub>A</sub>R isoforms, including extrasynaptic GABA<sub>A</sub>R containing the highly neurosteroid sensitive δ subunit (<xref ref-type="bibr" rid="B23">Brown et al., 2002</xref>; <xref ref-type="bibr" rid="B240">Uusi-Oukari and Korpi, 2010</xref>; <xref ref-type="bibr" rid="B155">Meera et al., 2011</xref>; <xref ref-type="bibr" rid="B206">Rogawski et al., 2013</xref>; <xref ref-type="bibr" rid="B32">Carver and Reddy, 2016</xref>).</p>
<p>Also, unlike benzodiazepines, neurosteroids are able of modulating the activity of GABA<sub>A</sub>R that lack the mandatory γ subunit, which confers benzodiazepine sensitivity to the GABA<sub>A</sub>R (<xref ref-type="bibr" rid="B16">Bianchi and Macdonald, 2003</xref>). In this regard, neurosteroids have been tested in super refractory status epilepticus with mixed-results (<xref ref-type="bibr" rid="B22">Broomall et al., 2014</xref>; <xref ref-type="bibr" rid="B209">Rosenthal et al., 2017</xref>; <xref ref-type="bibr" rid="B241">Vaitkevicius et al., 2017</xref>). Analogs of ALLO were found to be protective against partial seizures induced by electrical stimulation in animals (<xref ref-type="bibr" rid="B113">Kaminski et al., 2004</xref>; <xref ref-type="fig" rid="F4">Figure 4</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Binding sites for neurosteroids on the postsynaptic and extrasynaptic GABA<sub>A</sub>R (<xref ref-type="bibr" rid="B196">Reddy, 2011</xref>; <xref ref-type="bibr" rid="B26">Cai et al., 2018</xref>). Contrary to benzodiazepines, which require the mandatory γ subunit, neurosteroids can act on GABA<sub>A</sub>R whenever they are composed by α subunits (<xref ref-type="bibr" rid="B16">Bianchi and Macdonald, 2003</xref>). The extrasynaptic GABA<sub>A</sub>R usually contains the highly neurosteroid sensitive δ subunit, which opens an exploitable therapeutic window, especially in cases of benzodiazepine tolerance (<xref ref-type="bibr" rid="B23">Brown et al., 2002</xref>; <xref ref-type="bibr" rid="B240">Uusi-Oukari and Korpi, 2010</xref>; <xref ref-type="bibr" rid="B155">Meera et al., 2011</xref>; <xref ref-type="bibr" rid="B206">Rogawski et al., 2013</xref>; <xref ref-type="bibr" rid="B32">Carver and Reddy, 2016</xref>).</p>
</caption>
<graphic xlink:href="fnins-13-00680-g004"></graphic>
</fig>
<p>The role of ALLO as a neuroprotective agent starts before birth. Indeed, ALLO levels fluctuate during perinatal periods (<xref ref-type="bibr" rid="B14">Bernardi et al., 1998</xref>; <xref ref-type="bibr" rid="B46">Concas et al., 1998</xref>; <xref ref-type="bibr" rid="B77">Genazzani et al., 1998</xref>; <xref ref-type="bibr" rid="B82">Grobin and Morrow, 2001</xref>; <xref ref-type="bibr" rid="B107">Jin et al., 2013b</xref>) and its actions are known to contribute to neuroprotection of the fetal brain (<xref ref-type="bibr" rid="B132">Liu and Wong-Riley, 2010</xref>). In rats, ALLO levels drop immediately after birth, keeping a steady decline until a temporary elevation at 10 to 14 days postnatal, then decrease to a steady low level 3 weeks after birth (<xref ref-type="bibr" rid="B82">Grobin and Morrow, 2001</xref>). The drop in ALLO levels seems to coincide with drastic reductions in progesterone levels immediately after birth (<xref ref-type="bibr" rid="B178">Paoletti et al., 2006</xref>). Relevantly, in <italic>MECP2</italic> mutant mice, the reductions in ALLO levels coincide with the onset of RTT symptoms in such animals (<xref ref-type="bibr" rid="B107">Jin et al., 2013b</xref>).</p>
<p>There are very few examples of the use of neurosteroids in RTT available on literature. <xref ref-type="bibr" rid="B107">Jin et al. (2013b)</xref>, using an optogenetic approach to directly stimulate GABA<sub>A</sub>R in the locus coeruleus, found that ALLO increases the amplitude, frequency and decay time of GABA<sub>A</sub>ergic inhibitory post-synaptic currents (IPSCs). In this study, the authors described a time-dependent modulation of GABA<sub>A</sub>ergic transmission by ALLO in <italic>Mecp2</italic> mutant mice. Like in wild-type mice, during the first 2 weeks of the postnatal period, ALLO increases GABA<sub>A</sub>ergic inhibitory post-synaptic potentials and suppresses neuronal excitability in locus coeruleus neurons of <italic>Mecp2</italic> mutant mice. However, such effect abruptly deteriorates at 3 weeks of age in <italic>Mecp2</italic> deficient mice, which coincides with the onset of RTT symptoms. Therefore, the authors hypothesize that, in <italic>MECP2</italic> mutant mice, declines in progesterone levels after birth may lead to decreases in ALLO biosynthesis which in turn, becomes insufficient to potentiate GABA<sub>A</sub>ergic transmission through the GABA<sub>A</sub>R (<xref ref-type="bibr" rid="B107">Jin et al., 2013b</xref>). There is, also, the possibility that the subunit composition of the GABA<sub>A</sub>R shifts during development (<xref ref-type="bibr" rid="B203">Rissman and Mobley, 2011</xref>; <xref ref-type="bibr" rid="B53">Datta et al., 2015</xref>) or in pathophysiological conditions (<xref ref-type="bibr" rid="B60">Drexel et al., 2013</xref>; <xref ref-type="bibr" rid="B80">Govindpani et al., 2017</xref>; <xref ref-type="bibr" rid="B123">Kwakowsky et al., 2018</xref>) and also that it varies accordingly to temporal and local constrains (<xref ref-type="bibr" rid="B247">Walton et al., 2017</xref>). Thus, these modifications in GABA<sub>A</sub>R composition may change the receptor sensibility to neurosteroids in <italic>Mecp2</italic> mutant mice (<xref ref-type="bibr" rid="B107">Jin et al., 2013b</xref>) (see <xref ref-type="fig" rid="F5">Figure 5</xref>). Also, GABA<sub>A</sub>R sensitivity toward ALLO can shift due to neurosteroid withdrawal (<xref ref-type="bibr" rid="B83">Gulinello et al., 2001</xref>; <xref ref-type="bibr" rid="B149">Mascia et al., 2002</xref>; <xref ref-type="bibr" rid="B20">Boggio et al., 2010</xref>), long-term steroid administration (<xref ref-type="bibr" rid="B72">Follesa et al., 2002</xref>) and age (<xref ref-type="bibr" rid="B222">Shen et al., 2007</xref>), amongst other factors [reviewed in <xref ref-type="bibr" rid="B162">Mellon (2007)</xref>]. Other studies have shown that ALLO stimulates GABA<sub>A</sub>ergic currents in the hippocampus (<xref ref-type="bibr" rid="B179">Park et al., 2011</xref>), cerebellum (<xref ref-type="bibr" rid="B48">Cooper et al., 1999</xref>), and neocortex (<xref ref-type="bibr" rid="B192">Puia et al., 2003</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Time-dependent modulation by allopregnanolone on GABA<sub>A</sub>R signaling. <bold>(1)</bold> Allopregnanolone actions are known to contribute to neuroprotection of the fetal brain (<xref ref-type="bibr" rid="B132">Liu and Wong-Riley, 2010</xref>). In rats, allopregnanolone levels change immediately after birth and during the first weeks of life (<xref ref-type="bibr" rid="B82">Grobin and Morrow, 2001</xref>). <bold>(2)</bold> By exclusively stimulating the GABA<sub>A</sub>-ergic neurons in the locus coeruleus it was found that allopregnanolone increases the amplitude, frequency and decay time of GABA<sub>A</sub>R inhibitory post-synaptic currents (IPSCs) both in wild-type and <italic>Mecp2</italic> mutant animals. <bold>(3)</bold> However, after the first 2 weeks, allopregnanolone effects are lost in <italic>Mecp2</italic>-null animals, coinciding with the onset of RTT symptoms in such animals (<xref ref-type="bibr" rid="B107">Jin et al., 2013b</xref>). The drop in allopregnanolone levels seems to coincide with drastic reductions in progesterone levels immediately after birth (<xref ref-type="bibr" rid="B178">Paoletti et al., 2006</xref>). Modifications in the composition of the GABA<sub>A</sub>R can also be responsible for the effect (<xref ref-type="bibr" rid="B107">Jin et al., 2013b</xref>).</p>
</caption>
<graphic xlink:href="fnins-13-00680-g005"></graphic>
</fig>
<p>Evidence displaying the existing of a time-dependent modulation of GABA<sub>A</sub>ergic transmission by ALLO in <italic>Mecp2</italic> mutant mice is certainly important, as it shows how the GABAergic system is vulnerable and mutable in RTT. However, there is an ample bulk of evidence displaying that, even in wild-type animals, changes in GABA<sub>A</sub>R sensitivity toward neurosteroids occur during embryonic development and even later in puberty. These changes can potentially lead to different effects of ALLO and other neurosteroids during development (<xref ref-type="bibr" rid="B72">Follesa et al., 2002</xref>). Thus, the GABA<sub>A</sub>R subunit composition may shift accordingly to the developmental stage. Therefore, the existing time-dependent GABA<sub>A</sub>R sensitivity to neurosteroids can reflect a changeable requirement of neurosteroid actions by the GABAergic system, which, in turn, may be related with the hormonal milieu of the specific period of life (<xref ref-type="bibr" rid="B45">Colciago and Magnaghi, 2016</xref>). Also, either physiological or pathophysiological conditions can change the way neurosteroids act on the GABAergic system. Understanding how the subunit composition of the GABA<sub>A</sub>R shifts in wild-type animals comparing to RTT mouse models, may offer important insight to elucidate the role and therapeutic potential of neurosteroids in RTT. Also, it would be relevant to study how the existent imbalances in cholesterol metabolism can impact the biosynthesis of neurosteroids in RTT.</p>
<p>The effects of ALLO on hippocampal-dependent memory are a great example of how the actions of neurosteroids can shift according to physiological/pathological conditions. GABA<sub>A</sub>R in the dentate gyrus, where ALLO is actively metabolized, display low sensitivity to this neurosteroid. In turn, lower ALLO metabolism in the CA1 region of the hippocampus suggests that local steroid metabolism plays a crucial role in the regulation of GABA<sub>A</sub>R-mediated inhibition in a regionally dependent manner (<xref ref-type="bibr" rid="B13">Belelli and Herd, 2003</xref>), specifically in brain regions devoted to memory formation and consolidation (<xref ref-type="bibr" rid="B45">Colciago and Magnaghi, 2016</xref>). This is strengthened by observations that ALLO increases neurogenesis, neuronal survival and reduces apoptosis in the hippocampus (<xref ref-type="bibr" rid="B39">Charalampopoulos et al., 2008</xref>; <xref ref-type="bibr" rid="B211">Rossetti et al., 2015</xref>). ALLO also increases the density of dendritic spines, the number of mature excitatory synapses and induces the formation of clusters of the actin binding protein debrin (<xref ref-type="bibr" rid="B223">Shimizu et al., 2015</xref>), which is known to be decreased in the brain of Alzheimer’s disease patients and individuals with mild cognitive impairment (<xref ref-type="bibr" rid="B89">Harigaya et al., 1996</xref>; <xref ref-type="bibr" rid="B49">Counts et al., 2012</xref>). Congruently, using an Alzheimer’s disease mice model, ALLO restored hippocampal-dependent learning and memory deficits and induced survival of newly generated cells in 3xTgAD mice and non-Tg aged mice (<xref ref-type="bibr" rid="B226">Singh et al., 2012</xref>). Thus, in 3xTgAD mice it has been proposed that an early deficit in neurosteroid synthesis may contribute to the cognitive phenotype of AD and that ALLO shows the potential to function as a regenerative therapeutic tool to delay or even prevent characteristic neurogenic and cognitive deficits of Alzheimer’s disease (<xref ref-type="bibr" rid="B248">Wang et al., 2010</xref>; <xref ref-type="bibr" rid="B226">Singh et al., 2012</xref>). In addition, ALLO was found to significantly reduce amyloid-β accumulation in the hippocampus, cortex and amygdala, to reduce microglia activation and increase expression of liver-X-receptor, pregnane-X-receptor and HMG-CoA-R, three vital proteins involved in cholesterol homeostasis and clearance from the brain (<xref ref-type="bibr" rid="B42">Chen et al., 2011</xref>). Despite the clear effects of ALLO on the molecular mechanisms of hippocampal memory, on the other hand, it has been described that ALLO impairs recognition memory consolidation and contextual fear memory in wild-type mice (<xref ref-type="bibr" rid="B164">Misane et al., 2013</xref>; <xref ref-type="bibr" rid="B193">Rabinowitz et al., 2014</xref>), and spatial learning in rats (<xref ref-type="bibr" rid="B108">Johansson et al., 2002</xref>; <xref ref-type="bibr" rid="B152">Matthews et al., 2002</xref>; <xref ref-type="bibr" rid="B237">Turkmen et al., 2004</xref>). Importantly, <italic>Mecp2</italic> mutant mice display learning and memory impairments, besides the classic breathing abnormalities, hypoactivity, motor deficits, anxiety alterations and stereotypies. Likewise, <italic>Mecp2</italic> mutant mice have reduced hippocampus, amygdala and striatum volumes and an overall reduction in brain volume (<xref ref-type="bibr" rid="B229">Stearns et al., 2007</xref>). Therefore, direct research on the possible restorative effects of neurosteroids in RTT could constitute an interesting and potentially successful approach.</p>
</sec>
<sec id="S3.SS3">
<title>Epilepsy in RTT: CBD to the Rescue?</title>
<p>Epilepsy is fairly a common comorbidity in RTT, with reports showing its presence in 60–80% of patients. In RTT, there is no unambiguous pattern of seizure episodes, and almost all seizure types are reported (<xref ref-type="bibr" rid="B121">Krajnc, 2015</xref>). The manifestations of seizures seems to constitute an age-related event (<xref ref-type="bibr" rid="B38">Chapleau et al., 2013</xref>), with onset usually in stage II or III (see section “Introduction”), around 4 years of age, but with possibility of maximal onset age between 7 and 12 years (<xref ref-type="bibr" rid="B121">Krajnc, 2015</xref>). In RTT, due to limited experience of epilepsy treatment, there are no definitive recommendations regarding treatment approach with the anticonvulsants currently available. Therefore, the choice of treatment for epilepsy in RTT can be challenging (<xref ref-type="bibr" rid="B121">Krajnc, 2015</xref>), being considered a major problem in RTT treatment (<xref ref-type="bibr" rid="B38">Chapleau et al., 2013</xref>). Additionally, evidence suggests that the prevalence of drug resistance epilepsy in patients with RTT is about the same as in other newly diagnosed epilepsies, in which 20 to 40% of the patients become refractory to treatment (<xref ref-type="bibr" rid="B76">French, 2007</xref>). However, prevention and efficient management of epileptic episodes is of major importance in RTT, as the severity and frequency of epileptic episodes are strong determinants to the clinical severity of RTT phenotype (<xref ref-type="bibr" rid="B121">Krajnc, 2015</xref>; <xref ref-type="bibr" rid="B43">Clarke and Abdala Sheikh, 2018</xref>).</p>
<p>A number of different AED are used in treatment of epilepsy in RTT, either in monotherapy or combined therapy, and its selection varies from case to case (<xref ref-type="bibr" rid="B121">Krajnc, 2015</xref>). Regardless of their many mechanisms of action, one of the main targets of several AEDs is the GABAergic signaling system (<xref ref-type="bibr" rid="B81">Greenfield, 2013</xref>). For instance, the effects of valproate acid, one of the most commonly prescribed AEDs, on the GABA signaling system (such as, increased GABA turnover and consequent enhancement of synaptic and extrasynaptic inhibition) are important for its antiseizure actions (<xref ref-type="bibr" rid="B134">Löscher, 1989</xref>; <xref ref-type="bibr" rid="B81">Greenfield, 2013</xref>; <xref ref-type="bibr" rid="B205">Rogawski et al., 2016</xref>). On the other hand, the effects of AEDs on GABAergic signaling can be more direct, like the ones of benzodiazepines, which act as direct agonists of GABA<sub>A</sub>R, known to have a specific binding site for this type of drugs. Benzodiazepines are known for augmenting the amplitude (<xref ref-type="bibr" rid="B138">Macdonald and Barker, 1978</xref>) or decay time (<xref ref-type="bibr" rid="B234">Tietz et al., 1999</xref>) of GABA<sub>A</sub>R-evoked IPSCs (<xref ref-type="bibr" rid="B81">Greenfield, 2013</xref>). However, in order to mediate increases in GABA<sub>A</sub>R currents, the receptor must have in its composition a γ subunit and the selectivity of each benzodiazepine depends on the specific α subunit (for detailed review see <xref ref-type="bibr" rid="B202">Riss et al., 2008</xref>). The clinical advantages of benzodiazepines relate with its efficacy against many seizure types (<xref ref-type="bibr" rid="B202">Riss et al., 2008</xref>), rapidity of onset, minimal toxicity, possibility of administration via several routes and high efficacy track-record (<xref ref-type="bibr" rid="B138">Macdonald and Barker, 1978</xref>). However, its use is limited by adverse side effects, such as cognitive impairment and sedation, tolerance, withdrawal and drug interactions (<xref ref-type="bibr" rid="B202">Riss et al., 2008</xref>). Tolerance to benzodiazepine treatment has been associated with time-dependent modifications in GABA<sub>A</sub>R subunit composition (<xref ref-type="bibr" rid="B15">Betjemann and Lowenstein, 2015</xref>). Namely, the internalization of subunits β<sub>1</sub><sub>–</sub><sub>3</sub> and γ<sub>2</sub> on the GABA<sub>A</sub>R, may lead do decreased inhibition of synaptic transmission (<xref ref-type="bibr" rid="B79">Goodkin et al., 2008</xref>). Although benzodiazepines are not commonly prescribed as AED in RTT cases, different studies using RTT-mice models have shown the promising effects of benzodiazepines midazolam (<xref ref-type="bibr" rid="B246">Voituron and Hilaire, 2011</xref>) and diazepam (<xref ref-type="bibr" rid="B2">Abdala et al., 2010</xref>), particularly attenuating respiratory defects.</p>
<p>Recently, natural constituents of the cannabis plant have been emerging as promising AEDs. Importantly, the ECBS stands as a promising pharmacological target in RTT (<xref ref-type="bibr" rid="B244">Vigli et al., 2018</xref>; <xref ref-type="bibr" rid="B255">Zamberletti et al., 2019</xref>). The ECBS is a complex neuromodulatory system that regulates important physiological processes (<xref ref-type="bibr" rid="B114">Kano et al., 2009</xref>), such as, anxiety and stress (<xref ref-type="bibr" rid="B105">Jenniches et al., 2016</xref>), social behavior (<xref ref-type="bibr" rid="B251">Wei et al., 2017</xref>), motor coordination (<xref ref-type="bibr" rid="B64">El Manira and Kyriakatos, 2010</xref>) and memory/learning (<xref ref-type="bibr" rid="B147">Marsicano and Lafenêtre, 2009</xref>). Importantly, these are behaviors usually compromised in RTT (<xref ref-type="bibr" rid="B244">Vigli et al., 2018</xref>). Cannabinoids modulate neuronal activity mainly via the CB<sub>1</sub>R and CB<sub>2</sub>R. CB<sub>1</sub>R activation is linked with neuroprotection by controlling excitotoxicity via inhibition of excessive excitatory transmission and consequent calcium release (<xref ref-type="bibr" rid="B243">Vendel and de Lange, 2014</xref>). Indeed, the control of excitotoxicity constitutes a major physiological role of the ECBS (<xref ref-type="bibr" rid="B114">Kano et al., 2009</xref>). Although the CB<sub>1</sub>R is classically denoted as a G<sub><italic>i/o</italic></sub> protein coupled receptor, mainly linked with inhibitory effects, CB<sub>1</sub>R coupling to G proteins is mutable. CB<sub>1</sub>R is now believed to have very few “intrinsic” properties, being the cellular consequences of its activation likely a reflex of cell type and/or location in which the receptor is situated, their activity in different brain regions and due to temporal constrains (<xref ref-type="bibr" rid="B25">Busquets-Garcia et al., 2018</xref>). Contrary to initial belief, which placed CB<sub>2</sub>R exclusively in the immune system (<xref ref-type="bibr" rid="B114">Kano et al., 2009</xref>), CB<sub>2</sub>R are now known to be present in neurons, microglia and astrocytes (for a review see <xref ref-type="bibr" rid="B228">Solymosi and Kofalvi, 2017</xref>). CB<sub>2</sub>R are involved in the control of glial activation and inflammation and on the regulation of neuronal excitability (<xref ref-type="bibr" rid="B228">Solymosi and Kofalvi, 2017</xref>). Moreover, CB<sub>2</sub>R levels can increase in neurons and astrocytes under very specific circumstances, such as, in situations of neuroinflammation and in certain diseases (<xref ref-type="bibr" rid="B176">Onaivi et al., 2012</xref>; <xref ref-type="bibr" rid="B57">Di Marzo et al., 2015</xref>; <xref ref-type="bibr" rid="B69">Fernández-Ruiz et al., 2015</xref>). Related with its physiological roles, the lack of psychoactivity associated with CB<sub>2</sub>R activation, has made this receptor a particular promising therapeutic target for cannabis-based therapies (<xref ref-type="bibr" rid="B33">Cassano et al., 2017</xref>). For thorough reviews on the ECBS and its actions, natural cannabinoids and their molecular targets, and the clinical applications of cannabinoids (see <xref ref-type="bibr" rid="B114">Kano et al., 2009</xref>; <xref ref-type="bibr" rid="B165">Morales et al., 2017</xref>; <xref ref-type="bibr" rid="B228">Solymosi and Kofalvi, 2017</xref>).</p>
<p>Today, more than 120 phytocannabinoids (natural occurring cannabinoids) have been identified as constituents of the cannabis plant. The most abundant cannabinoids in the cannabis plant are delta-9-tetrahydrocannabinoid, or Δ<sup>9</sup>-THC, followed by Δ<sup>8</sup>-THC, CBN, CBD, CBG, CBC, THCV, CBV, and CBDV (<xref ref-type="bibr" rid="B165">Morales et al., 2017</xref>). From all the natural constituents of the cannabis plant, CBD, a non-psychoactive cannabinoid (<xref ref-type="bibr" rid="B133">Loewe, 1946</xref>; <xref ref-type="bibr" rid="B185">Pertwee, 2009</xref>), is being widely studied given its high therapeutic value. CBD has been shown, both in humans and rodents, to have antiseizure (<xref ref-type="bibr" rid="B110">Jones et al., 2010</xref>; <xref ref-type="bibr" rid="B177">Pamplona and Coan, 2017</xref>; <xref ref-type="bibr" rid="B186">Perucca, 2017</xref>; <xref ref-type="bibr" rid="B254">Zaheer et al., 2018</xref>), anti-inflammatory (<xref ref-type="bibr" rid="B141">Malfait et al., 2000</xref>; <xref ref-type="bibr" rid="B167">Nagarkatti et al., 2009</xref>; <xref ref-type="bibr" rid="B188">Petrosino et al., 2018</xref>), antioxidant (<xref ref-type="bibr" rid="B87">Hampson et al., 2000</xref>), and anti-psychotic properties (<xref ref-type="bibr" rid="B264">Zuardi et al., 1991</xref>, <xref ref-type="bibr" rid="B265">2012</xref>; <xref ref-type="bibr" rid="B100">Iseger and Bossong, 2015</xref>), to have neuroprotective effects (<xref ref-type="bibr" rid="B102">Iuvone et al., 2009</xref>; <xref ref-type="bibr" rid="B70">Fernández-Ruiz et al., 2013</xref>), to reduce nausea (<xref ref-type="bibr" rid="B180">Parker et al., 2011</xref>; <xref ref-type="bibr" rid="B163">Mersiades et al., 2018</xref>) and to work as an anxiolytic and anti-depressive drug (<xref ref-type="bibr" rid="B55">de Mello Schier et al., 2014</xref>; <xref ref-type="bibr" rid="B18">Blessing et al., 2015</xref>; <xref ref-type="bibr" rid="B266">Zuardi et al., 2017</xref>). Furthermore, CBD is known to potentiate the clinical efficacy of Δ<sup>9</sup>-THC, increasing the durability of its beneficial effects, while preventing its psychoactive effects (<xref ref-type="bibr" rid="B214">Russo and Guy, 2006</xref>; <xref ref-type="bibr" rid="B228">Solymosi and Kofalvi, 2017</xref>). CBD acts as a surprisingly high potent antagonist at both the CB<sub>1</sub>R and the CB<sub>2</sub>R (<xref ref-type="bibr" rid="B233">Thomas et al., 2009</xref>). Recently, it has also been proposed that CBD acts as a negative allosteric modulator (NAM) at the CB<sub>1</sub>R (<xref ref-type="bibr" rid="B125">Laprairie et al., 2015</xref>). Many of CBD therapeutic properties have been suggested to occur due to its effect at the TRPV<sub>1</sub> (<xref ref-type="bibr" rid="B165">Morales et al., 2017</xref>).</p>
<p>The medical use of cannabis has been increasing and the full potential of the cannabis plant is yet to be unfold. Cannabis-based drugs are been used, or proposed for use, in neuropathic pain and muscle spasticity associated with Multiple Sclerosis (<xref ref-type="bibr" rid="B71">Fitzpatrick and Downer, 2017</xref>; <xref ref-type="bibr" rid="B228">Solymosi and Kofalvi, 2017</xref>; <xref ref-type="bibr" rid="B201">Rice and Cameron, 2018</xref>), neurodegenerative diseases (<xref ref-type="bibr" rid="B67">Fagan and Campbell, 2014</xref>; <xref ref-type="bibr" rid="B11">Basavarajappa et al., 2017</xref>; <xref ref-type="bibr" rid="B169">Navarro et al., 2018</xref>), chronic pain (<xref ref-type="bibr" rid="B30">Carter et al., 2015</xref>; <xref ref-type="bibr" rid="B181">Pascual et al., 2018</xref>), to alleviate AIDS-related weight loss (<xref ref-type="bibr" rid="B8">Badowski and Perez, 2016</xref>; <xref ref-type="bibr" rid="B204">Rock and Parker, 2016</xref>) and to reduce vomiting and nausea associated with chemotherapy (<xref ref-type="bibr" rid="B9">Badowski and Yanful, 2018</xref>). Most relevantly for this work, cannabinoid use is being increasingly proposed as a very promising anti-epileptic drug, even in cases of treatment-resistant epilepsy (<xref ref-type="bibr" rid="B137">Maa and Figi, 2014</xref>; <xref ref-type="bibr" rid="B175">O’Connell et al., 2017</xref>; <xref ref-type="bibr" rid="B177">Pamplona and Coan, 2017</xref>). In a recent clinical trial, CBD significantly reduced convulsive-seizure frequency in Dravet syndrome patients (<xref ref-type="bibr" rid="B56">Devinsky et al., 2017</xref>). In a double-blind placebo-controlled trial, 120 children suffering with Dravet syndrome and drug-resistance epilepsy received either CBD (oral solution 20 mg/kg per day) or placebo over 14 weeks. In the CBD group, 43% of the patients had a reduction of 50% in seizure frequency, as opposed to a 27% decrease in the placebo group. Furthermore, 5% of the patients treated with CBD became seizure-free compared with a 0% incident in the placebo group. On the CGIC, a Likert-like scale questionnaire which allows assessing improvement after a treatment comparing with a baseline period (ranging from 1, very much improved to 7 very much worse), in the CBD group, 62% of the patients increased at least one category on the CGIC compared with 27% on the placebo group. Treatment with CBD provoked more adverse side effects reflected on diarrhea, vomiting, fatigue, pyrexia, somnolence, and some abnormalities on liver-function tests (<xref ref-type="bibr" rid="B56">Devinsky et al., 2017</xref>). About 1 year after this clinical trial, the FDA approved Epidiolex<sup>®</sup> (CBD) oral solution for treatment in Dravet and Lennox–Gastaut syndromes, two diseases that, in resemblance with RTT, present refractory epilepsy and high mortality rates. Also, Nabiximols (Sativex<sup>®</sup>), a combination of CBD and Δ<sup>9</sup>-THC, is approved to treat muscle spasticity in Multiple Sclerosis (<xref ref-type="bibr" rid="B174">Novotna et al., 2011</xref>), an abnormality in muscle tone present in RTT (<xref ref-type="bibr" rid="B124">Kyle et al., 2018</xref>).</p>
<p>The mechanism by which CBD exerts anticonvulsive effects is still not completely clarified. Recently, however, using human recombinant GABA<sub>A</sub>R, CBD was shown to act as a positive allosteric modulator of the GABA<sub>A</sub>R, with the effects being selective for the β-subunit (higher in receptors with β2/β3 over β1 subunits) and the maximum effect being detected in receptors which included the α2-subunit (<xref ref-type="bibr" rid="B10">Bakas et al., 2017</xref>). The authors hypothesized that these results may explain the anticonvulsant and anxiolytic properties of this compound (<xref ref-type="bibr" rid="B10">Bakas et al., 2017</xref>). Indeed, previously, it was reported that CBD attenuated seizures in two well characterized seizure models, the acute pilocarpine TLE and the penicillin model of partial seizure (<xref ref-type="bibr" rid="B109">Jones et al., 2012</xref>). Curiously, in the acute epilepsy model using pilocarpine, a muscarinic acetylcholine receptor agonist, the antiseizure effects of CBD were modest and the drug was not able of reducing mortality and severity of episodes. On the other hand, using the penicillin model, a selective antagonist of the GABA<sub>A</sub>R, CBD had a powerful antiseizure effect, significantly reducing the number of animals experiencing tonic-clonic episodes and their mortality. Importantly, CBD exerted only minor negligible motor effects (<xref ref-type="bibr" rid="B109">Jones et al., 2012</xref>). At the time, the authors speculated that the antiseizure effect of CBD could be occurring via a GABAergic-mediated mechanism (<xref ref-type="bibr" rid="B109">Jones et al., 2012</xref>). In support of this hypothesis, a previous study had shown an anticonvulsive action of CBD on several seizure models mediated <italic>via</italic> disinhibition of GABA release (<xref ref-type="bibr" rid="B47">Consroe et al., 1982</xref>; <xref ref-type="bibr" rid="B109">Jones et al., 2012</xref>). In a very recent study, CBD was shown to have antiseizure effects in several models of acute epilepsy (<xref ref-type="bibr" rid="B183">Patra et al., 2019</xref>). Additionally, this study showed, for the first time, that chronic CBD administration improves seizure burden ratio, attenuates cognitive impairment and reduces motor comorbidities, well after the onset of symptoms in the RISE-SRS TLE (<xref ref-type="bibr" rid="B183">Patra et al., 2019</xref>). Thus, the results of this study are particularly relevant for research in RTT, considering the positive effects of a chronic administration of CBD on both seizures and motor impairment, which constitute two common comorbidities in RTT. Additionally, cognitive impairment is also characteristic of RTT and, therefore, finding that CBD improves cognition in models of acute and chronic epilepsy in also relevant for cannabinoid-related research in RTT.</p>
<p>Direct evidence of cannabinoid use in RTT mice models is objectively scarce in literature. To the best of our knowledge, there are only two reports evaluating the impact of a chronic treatment with a phytocannabinoid in an RTT-mice model. In both these reports (<xref ref-type="bibr" rid="B244">Vigli et al., 2018</xref>; <xref ref-type="bibr" rid="B255">Zamberletti et al., 2019</xref>), the authors used CBDV, a propyl analog of CBD devoid of psychoactive actions (<xref ref-type="bibr" rid="B165">Morales et al., 2017</xref>). CBDV has very weak activity at the CB<sub>1</sub>R and CB<sub>2</sub>R (<xref ref-type="bibr" rid="B93">Hill et al., 2013</xref>; <xref ref-type="bibr" rid="B210">Rosenthaler et al., 2014</xref>; <xref ref-type="bibr" rid="B165">Morales et al., 2017</xref>) and it has been proposed to activate the TRPV1 (<xref ref-type="bibr" rid="B99">Iannotti et al., 2014</xref>). Additionally, an effect of CBDV on the deorphanized cannabinoid receptor GPR55 has been described. Besides some cannabinoids, GPR55 is also activated by LPI. Notably, it has been found that CBDV is a potent inhibitor of LPI-induced GPR55 signaling (<xref ref-type="bibr" rid="B126">Lauckner et al., 2008</xref>; <xref ref-type="bibr" rid="B4">Anavi-Goffer et al., 2012</xref>). As stated in <xref ref-type="bibr" rid="B244">Vigli et al. (2018)</xref>, GPR55 has been implied in important cognitive processes, such as, spatial memory regulation (<xref ref-type="bibr" rid="B146">Marichal-Cancino et al., 2018</xref>), social behavior (<xref ref-type="bibr" rid="B122">Kramar et al., 2017</xref>) and motor function (<xref ref-type="bibr" rid="B17">Bjursell et al., 2016</xref>). Moreover, in a recent work, CBDV was shown to attenuate seizures and social withdrawal in a mice model of Dravet syndrome (<xref ref-type="bibr" rid="B115">Kaplan et al., 2017</xref>). Concerning cannabinoids and RTT, the administration of CBDV by intraperitoneal injection (escalating dose ranging from 2 to 100 mg/kg of body weight) to <italic>Mecp2</italic>-308 male mice during 14 days, rescued sociability impairments, improved the general health status and increased the brain weight of these animals. Furthermore, a molecular analysis of GPR55 levels, revealed an up-regulation of this receptor in the hippocampus (<xref ref-type="bibr" rid="B244">Vigli et al., 2018</xref>). These results showed, for the first time, the clinical potential of non-psychoactive constituents of the cannabis plant and also the important role of the GPR55 as a promising drug-target on RTT. Very recently, a new study using CBDV has confirmed the potential of this particular phytocannabinoid in RTT. In this study, chronic administration of CBDV (0.2 to 2 mg/kg) was shown to completely rescue cognitive deficits, delaying neurological (although transiently) and motor impairments in male <italic>MECP2</italic> mutant mice (<xref ref-type="bibr" rid="B255">Zamberletti et al., 2019</xref>). Importantly, CBDV administration normalized BDNF and insulin growth factor 1 (IGF1) levels and restored normal signaling in the PI3K/AKT/mTOR pathway at an advanced stage of the disease. Interestingly, <italic>Mecp2</italic> deletion in this RTT mouse model provoked upregulation of CB<sub>1</sub>R and CB<sub>2</sub>R and CBDV treatment led to a normalization of these changes (<xref ref-type="bibr" rid="B255">Zamberletti et al., 2019</xref>). Although these two independent studies suggest a promising role of CBDV as a therapeutic drug in RTT, the fact that different molecular modifications in the ECBS were detected in each model, highlight the necessity of further studies.</p>
<p>The promising antiseizure effects of CBD, even in cases of refractory-epilepsy, observed in both clinical trials with humans and in laboratory animals, the effects of combinations of CBD and Δ<sup>9</sup>-THC in controlling muscle spasticity and motor symptoms, and the positive results of CBDV administration in two different mouse models of RTT, place cannabinoids as a viable therapeutic strategy in RTT. Moreover, CBD positively modifies impairments in motor, cognitive and social processes in animal models, further highlighting the potential of cannabinoid molecules to tackle RTT-symptomology.</p>
</sec>
<sec id="S3.SS4">
<title>The Use of the Ketogenic Diet</title>
<p>Around 100 years ago, it was noted that a high fat diet could have long-lasting effects in preventing seizures without inducing significant caloric deprivation (<xref ref-type="bibr" rid="B205">Rogawski et al., 2016</xref>). These findings resulted on the creation of the KD, trademarked by an increase in the production in the liver of ketones bodies, such as BHB, acetoacetate and acetone (<xref ref-type="bibr" rid="B187">Peterman, 1924</xref>; <xref ref-type="bibr" rid="B75">Freeman and Kossoff, 2010</xref>; <xref ref-type="bibr" rid="B205">Rogawski et al., 2016</xref>). The fact that the KD was created in a time where the available AEDs were very limited, contributed for a rapid gain in popularity of this diet (<xref ref-type="bibr" rid="B205">Rogawski et al., 2016</xref>). However, the development of the antiepileptic drug phenytoin substantially decreased the use of the KD. In the last 30 years, interest in using the KD resurged, especially in children presenting refractory epilepsy (<xref ref-type="bibr" rid="B205">Rogawski et al., 2016</xref>).</p>
<p>An abnormal increase of ketone bodies in the blood was early suggested as the underlaying mechanism of the anticonvulsive properties of low carbohydrate KD (<xref ref-type="bibr" rid="B232">Talbot et al., 1927</xref>; <xref ref-type="bibr" rid="B98">Huttenlocher, 1976</xref>). Subsequently, many other possible mechanisms were enounced, such as, pH changes, anticonvulsive effects of hyperlipidemia, effects of the KD directly on sodium and potassium balance, and also an effect on cerebral metabolism, reflected on the change of glucose, as the main source of energy, to BHB, as a consequence of carbohydrate restriction (for details see <xref ref-type="bibr" rid="B98">Huttenlocher, 1976</xref>). To clarify these questions, Peter Huttenlocher designed a new KD in which ketonemia was induced by feeding of MCT. In his report of 1976, the MCT diet was administered to 18 children and he observed no differences in hyperlipidemia, no significant changes in pH, considerable reductions in blood glucose levels in one-third of the children and a gradual increase in plasma BHB and acetoacetate levels during a diet that was kept from 3 months to 4 years. Furthermore, plasma levels of BHB showed a significant correlation with the anticonvulsive effects of the MCT diet and, along with ketonemia, were rapidly abolished by intravenous infusion of glucose (<xref ref-type="bibr" rid="B98">Huttenlocher, 1976</xref>). Today, the mechanisms behind the anticonvulsive actions of the KD are fairly well characterized (for a detailed review see <xref ref-type="bibr" rid="B205">Rogawski et al., 2016</xref>).</p>
<p>One of the proposed mechanisms of action of the KD are increases in the synthesis of GABA and decreases in the synthesis of excitatory neurotransmitters, such as glutamate (<xref ref-type="bibr" rid="B205">Rogawski et al., 2016</xref>). Indeed, it has been suggested that one of the anticonvulsive mechanisms of the KD relates with modifications in the way glutamate is processed in the brain. Particularly, due to a more active astrocytic metabolism, the conversion of glutamate to glutamine is increased, resulting in a more efficient removal of glutamate and increased GABA synthesis (<xref ref-type="bibr" rid="B253">Yudkoff et al., 2008</xref>). A study with 26 children suffering from refractory epilepsy, revealed that the KD increases levels of GABA in the cerebrospinal fluid, without affecting glutamate concentration. In this study, the results showed higher GABA levels in the responders to the diet compared with non-responders. Furthermore, the anticonvulsive action of the diet was more evident (90% reduction in seizures) in children who had higher levels of GABA at the beginning of the treatment and in whom a gradual increase in GABA levels during treatment was registered. Also, the anticonvulsive effects of the diet seem to be age-dependent, with younger children being the best responders (<xref ref-type="bibr" rid="B50">Dahlin et al., 2005</xref>). However, studies with animal models performed to confirm a GABAergic-mediated mechanism of anticonvulsive actions of the KD have produced mixed-results (<xref ref-type="bibr" rid="B91">Hartman et al., 2007</xref>). If, on one hand, the KD administered to mice fails to confer protection against the clonic seizures induced by GABA<sub>A</sub>R antagonist pentylenetetrazol, on the other hand, it is much more effective protecting against seizures induced by the maximal electroshock test, a test in which the classical anticonvulsive drugs targeting the GABAergic system only confer weak protection (<xref ref-type="bibr" rid="B238">Uhlemann and Neims, 1972</xref>; <xref ref-type="bibr" rid="B91">Hartman et al., 2007</xref>). On the contrary, the KD was found to protect against seizures induced by GABA<sub>A</sub>R antagonists pentylenetetrazol, bicuculline, and picrotoxin in rats (for a detailed review see <xref ref-type="bibr" rid="B91">Hartman et al., 2007</xref>). It has also been suggested that ketone bodies, such as acetoacetate, compete with chloride for the allosteric binding site at the vesicular glutamate transporter, thus inhibiting exocytotic glutamate release (<xref ref-type="bibr" rid="B111">Juge et al., 2010</xref>). Additionally, the authors of this work showed that acetoacetate protected against seizure-like activity induced by 4-aminopyridine (<xref ref-type="bibr" rid="B111">Juge et al., 2010</xref>). Recently, using the spontaneously epileptic Kcna1-null mice, the ketone body BHB was shown to exert anti-seizure effects, restore impairments in synaptic plasticity processes and raise the threshold of mitochondrial permeability transition (<xref ref-type="bibr" rid="B119">Kim et al., 2015</xref>; <xref ref-type="bibr" rid="B205">Rogawski et al., 2016</xref>).</p>
<p>Concerning the clinical use of the KD in RTT, <xref ref-type="bibr" rid="B85">Haas et al. (1986)</xref>, reported a clinical study were the MCT KD was used in 7 girls diagnosed with RTT who presented anticonvulsive resistant seizures. Among the 5 girls capable of tolerating the diet, the KD improved seizure control, slightly ameliorated behavior and motor skills and increased bodyweight. The results from this work led the authors to suggest that, considering the defects in the carbohydrate metabolism occurring in RTT, the KD stands as a logical choice in this disease (<xref ref-type="bibr" rid="B85">Haas et al., 1986</xref>). Surprisingly, until very recently, this was the only clinical report of the use of KD in RTT. Indeed, evidence of the application of the KD in RTT is extremely hard to find in the literature. In <xref ref-type="bibr" rid="B130">Liebhaber et al. (2003)</xref> reported a case of an RTT patient who was treated with the KD for 4 years. The treatment started when the patient was 8 years old and presented a refractory epilepsy. The diet led to a 70% reduction in seizure frequency and improved contact and behavior. In <xref ref-type="bibr" rid="B78">Giampietro et al. (2006)</xref> reported a case with a female patient suffering from an atypical RTT variant in which the KD significantly reduced seizure occurrence. In 2011, a long-term follow-up of the use of the KD in 226 patients with refractory epilepsy was reported. This report included one patient with RTT, which presented a 75–99% seizure reduction after KD (<xref ref-type="bibr" rid="B29">Caraballo et al., 2011</xref>). Evidence on the use of the KD in RTT-mouse models is also scarce. In the only direct approach available in the literature, it has been described that a restricted KD positively impacts anxiety and motor measures in a male mutant <italic>Mecp2</italic> mice. However, the authors also showed that the results of the KD were very similar to the ones from a calorie restriction diet, concluding that, most likely, it was the caloric restriction that produced the positive outcomes, rather than the composition of the KD by itself (<xref ref-type="bibr" rid="B143">Mantis et al., 2009</xref>).</p>
<p>Reports on the use of the KD in autism spectrum disorders and other brain diseases are also available in literature. With relevance for the phenotypic expression of RTT, it has been described that 4 weeks of a KD regime increases the social behavior of wild-type rats, registered in three different social interaction protocols. On the other hand, the exogenous administration of ketone bodies had no effects on social interaction in the same paradigms (<xref ref-type="bibr" rid="B116">Kasprowska-Liśkiewicz et al., 2017</xref>). Also, in an EL mice model (<xref ref-type="bibr" rid="B156">Meidenbauer et al., 2011</xref>), which presents autism spectrum disorders phenotype and comorbid epilepsy, the KD was shown to improve sociability and reduce repetitive behavior (<xref ref-type="bibr" rid="B212">Ruskin et al., 2017</xref>). Using the same animal model, the KD was shown to induce a 1 month delay in epileptogenesis (<xref ref-type="bibr" rid="B236">Todorova et al., 2000</xref>) and to have anticonvulsive actions (<xref ref-type="bibr" rid="B142">Mantis et al., 2004</xref>). In an Huntington’s disease mice model, the KD was shown to produce positive outcomes on weight lose without affecting cognitive processes (<xref ref-type="bibr" rid="B213">Ruskin et al., 2011</xref>). More recently, in an animal model of autism induced by prenatal exposure to valproic acid, the KD was, once again, associated with improvement in social behavior (<xref ref-type="bibr" rid="B34">Castro et al., 2017</xref>).</p>
<p>Another potential mechanism of action underlying the anticonvulsive effects of the KD involves the modulation of adenosine receptor activity (<xref ref-type="bibr" rid="B150">Masino et al., 2013</xref>; <xref ref-type="bibr" rid="B205">Rogawski et al., 2016</xref>). Adenosine is an ubiquitous neuromodulator affecting the action and activity of several neurotransmitter receptors (<xref ref-type="bibr" rid="B217">Sebastião and Ribeiro, 2015</xref>). A<sub>1</sub>R activity mediates the inhibitory effects of adenosine, including inhibition of neurotransmitter release and changes in post-synaptic membrane conductance (<xref ref-type="bibr" rid="B63">Dunwiddie and Masino, 2001</xref>). On the other hand, the A<sub>2A</sub>R mediates the excitatory effects of adenosine by coupling to G<sub><italic>s</italic></sub> proteins, consequently leading to stimulation of adenylate cyclase, increases in intracellular cAMP levels and PKA activation (<xref ref-type="bibr" rid="B217">Sebastião and Ribeiro, 2015</xref>). Relevantly, caffeine, the most widely consumed legal drug in the world, is a non-selective antagonist at the A<sub>1</sub>R and A<sub>2A</sub>R (<xref ref-type="bibr" rid="B74">Fredholm et al., 1999</xref>). Recently, the KD was demonstrated to suppress seizures in a transgenic mice model with spontaneous seizures by activation of the A<sub>1</sub>R (<xref ref-type="bibr" rid="B151">Masino et al., 2011</xref>) and similar results were shown in an <italic>in vitro</italic> mimic of the KD (<xref ref-type="bibr" rid="B118">Kawamura et al., 2010</xref>). Adenosine is directly synthetized from ATP and given that ATP levels are increased in the KD it is feasible that it results in an increase in adenosine synthesis (<xref ref-type="bibr" rid="B205">Rogawski et al., 2016</xref>). Adenosine receptor activity, particularly A<sub>2A</sub>R activity, is also known to directly facilitate the actions of the important BDNF (<xref ref-type="bibr" rid="B59">Diógenes et al., 2004</xref>, <xref ref-type="bibr" rid="B58">2007</xref>; <xref ref-type="bibr" rid="B68">Fernandes et al., 2008</xref>; <xref ref-type="bibr" rid="B73">Fontinha et al., 2008</xref>; <xref ref-type="bibr" rid="B242">Vaz et al., 2015</xref>). Importantly, BDNF expression is impaired in RTT and it has been suggested that it can have important therapeutic actions in RTT (reviewed in <xref ref-type="bibr" rid="B117">Katz, 2014</xref>; <xref ref-type="bibr" rid="B128">Li and Pozzo-Miller, 2014</xref>).</p>
<p>In conclusion, if, on one hand, it is particularly well accepted and proven that the KD has powerful antiseizure actions (although the mechanisms of action are still not completely described) (<xref ref-type="bibr" rid="B245">Vining et al., 1998</xref>; <xref ref-type="bibr" rid="B92">Hassan et al., 1999</xref>; <xref ref-type="bibr" rid="B170">Neal et al., 2008</xref>), on the other hand, reports on the application of this diet to RTT cases and in RTT-mice models are scarce. The lack of research is even more surprising considering the positive results shown in both clinical studies with humans and in RTT mouse-models. Relevantly, a prospective study with 145 children aged between 2 and 16 years, suffering from intractable epilepsy and who had never experienced the KD, showed that 3 months of diet resulted in a 75% seizure reduction rate, with 38% of the children in the experimental group experiencing a reduction of 50% in seizures. Also, five children experienced reductions of 90% in seizures and one child became seizure free (<xref ref-type="bibr" rid="B170">Neal et al., 2008</xref>). Importantly, in children allocated to the control group who continued their usual treatment with AED, some of them experienced worsening of symptoms and none became seizure-free (<xref ref-type="bibr" rid="B170">Neal et al., 2008</xref>; <xref ref-type="bibr" rid="B150">Masino et al., 2013</xref>).</p>
</sec>
</sec>
<sec id="S4">
<title>Conclusion and Final Remarks</title>
<p>The present review summarizes important recent evidence concerning metabolic, synaptic, functional and molecular dysfunctions occurring in RTT (see <xref ref-type="table" rid="T1">Table 1</xref>). Due to the ubiquitous role of <italic>MECP2</italic> gene, it has been a tremendous challenge to comprehend and characterize the mechanisms through which <italic>MECP2</italic> mutations lead to symptomatology in RTT. With the development and improvement of gene-editing technologies, research in RTT has drifted from “therapy-directed” to “cure-oriented” investigation. However, the path for a definitive cure is paved with many challenges and, most likely, this achievement in not around the corner. Meanwhile, it is paramount to better understand this disease and to improve the available treatment by exploring new therapeutic avenues. In this work, we reviewed promising evidence on different research lines that may have an important impact in the field. From modulators of GABAergic signaling, to cannabinoids and the KD, and cleverly exploiting the metabolic features of this disease, an ample bulk of evidence has been gathered, creating a plethora of research lines to be followed in the future. RTT is a devastating disease, both for the patient and for the caregivers, and clinical and preclinical research directed at finding new therapeutic approaches are more important than ever, now that we are beginning to understand some of the mechanisms of this disease.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Summary of the main topics of this review and future directions.</p>
</caption>
<table cellpadding="5" cellspacing="5" frame="hsides" rules="groups">
<thead>
<tr>
<td align="center" colspan="5" rowspan="1" valign="top">
<bold>From cannabinoids and neurosteroids to statins and the ketogenic diet: new therapeutic avenues in Rett syndrome?</bold>
</td>
</tr>
</thead>
<tbody>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top">
<bold>
<italic>GABAergic signaling</italic>
</bold>
</td>
<td align="justify" colspan="1" rowspan="1" valign="top">
<bold>
<italic>Cholesterol metabolism</italic>
</bold>
</td>
<td align="justify" colspan="1" rowspan="1" valign="top">
<bold>
<italic>Neurosteroids</italic>
</bold>
</td>
<td align="justify" colspan="1" rowspan="1" valign="top">
<bold>
<italic>Cannabinoids</italic>
</bold>
</td>
<td align="justify" colspan="1" rowspan="1" valign="top">
<bold>
<italic>Ketogenic diet</italic>
</bold>
</td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top">The GABAergic signaling system comprises a key pathway commonlydisturbed in neurodevelopmental diseases (<xref ref-type="bibr" rid="B21">Braat and Kooy, 2015</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">Cholesterol metabolism is abnormal in brain and livers of <italic>Mecp2</italic> mutant mice (<xref ref-type="bibr" rid="B24">Buchovecky et al., 2013</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">Allopregnanolone (ALLO) is the most powerful endogenous allosteric modulator of the GABA<sub>A</sub>R (<xref ref-type="bibr" rid="B95">Hosie et al., 2006</xref>; <xref ref-type="bibr" rid="B195">Reddy, 2010</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">The endocannabinoid system (ECBS) is involved in the regulation of several behavioral processes found to be compromised in RTT (<xref ref-type="bibr" rid="B244">Vigli et al., 2018</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">The ketogenic diet (KD) has strong antiepileptic actions (<xref ref-type="bibr" rid="B205">Rogawski et al., 2016</xref>). The anticonvulsive actions of the KD can be mediated via GABAergic signaling mechanism (<xref ref-type="bibr" rid="B205">Rogawski et al., 2016</xref>), or be related with increases in adenosine and BDNF signaling (<xref ref-type="bibr" rid="B151">Masino et al., 2011</xref>).</td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top">In RTT, GABA<sub>A</sub>ergic transmission is intimately related with symptoms and disease progression (<xref ref-type="bibr" rid="B35">Chao et al., 2010</xref>; <xref ref-type="bibr" rid="B66">El-Khoury et al., 2014</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">A mutation in the Sqle gene was sufficient to restore function and longevity in <italic>Mecp2</italic> mutant mice (<xref ref-type="bibr" rid="B24">Buchovecky et al., 2013</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">Neurosteroids are being proposed as an alternative to benzodiazepines (<xref ref-type="bibr" rid="B197">Reddy and Estes, 2016</xref>) and also as antipsychotics (<xref ref-type="bibr" rid="B26">Cai et al., 2018</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">Cannabis-based therapies are being proposed as anti-epileptic drugs (AED) even in cases of drug resistant epilepsy (<xref ref-type="bibr" rid="B137">Maa and Figi, 2014</xref>; <xref ref-type="bibr" rid="B175">O’Connell et al., 2017</xref>; <xref ref-type="bibr" rid="B177">Pamplona and Coan, 2017</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">The use of the KD in RTT has shown promising results in controlling epilepsy (<xref ref-type="bibr" rid="B85">Haas et al., 1986</xref>; <xref ref-type="bibr" rid="B130">Liebhaber et al., 2003</xref>; <xref ref-type="bibr" rid="B78">Giampietro et al., 2006</xref>; <xref ref-type="bibr" rid="B29">Caraballo et al., 2011</xref>).</td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top">An incorrect balance between excitation and inhibition reflecting a dysfunction in GABAergic and glutamatergic signaling systems have been described in <italic>Mecp2</italic>-KO mice (<xref ref-type="bibr" rid="B37">Chao et al., 2007</xref>; <xref ref-type="bibr" rid="B27">Calfa et al., 2011</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">Statins ameliorate the systemic imbalance of lipid profile, alleviated motor symptoms and conferred increased longevity in Mecp2 mutant mice (<xref ref-type="bibr" rid="B24">Buchovecky et al., 2013</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">In <italic>MECP2</italic> mutant mice, allopregnanolone increases the amplitude, frequency and decay time of GABA<sub>A</sub>R IPSCs (<xref ref-type="bibr" rid="B107">Jin et al., 2013b</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">Nabiximols (Sativex), a combination of CBD and Δ<sup>9</sup>-THC, is approved to treat muscle spasticity in Multiple Sclerosis (<xref ref-type="bibr" rid="B174">Novotna et al., 2011</xref>), a comorbidity frequently reported in RTT (<xref ref-type="bibr" rid="B124">Kyle et al., 2018</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">The KD has also shown positive results in refractory epilepsy and in intractable epilepsy (<xref ref-type="bibr" rid="B170">Neal et al., 2008</xref>; <xref ref-type="bibr" rid="B205">Rogawski et al., 2016</xref>).</td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top">The relationship between RTT phenotypical expression and GABAergic signaling is region, time and neuronal population dependent (<xref ref-type="bibr" rid="B35">Chao et al., 2010</xref>; <xref ref-type="bibr" rid="B66">El-Khoury et al., 2014</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">In samples collected from RTT patients the total cholesterol level is altered (<xref ref-type="bibr" rid="B230">Sticozzi et al., 2013</xref>; <xref ref-type="bibr" rid="B218">Segatto et al., 2014</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">Changes in subunit composition on the GABA<sub>A</sub>R might be responsible for different responses to allopregnanolone (<xref ref-type="bibr" rid="B178">Paoletti et al., 2006</xref>; <xref ref-type="bibr" rid="B107">Jin et al., 2013b</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">Epidiolex (CBD) has been approved to treat epilepsy in Dravet syndrome (<xref ref-type="bibr" rid="B56">Devinsky et al., 2017</xref>), a disease that present refractory epilepsy and high mortality rates. The antiepileptic actions of CBD can be mediated via GABAergic signaling (<xref ref-type="bibr" rid="B10">Bakas et al., 2017</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">In <italic>Mecp2</italic> null mice models, the KD ameliorated anxiety and motor measurements, although clarification is required (<xref ref-type="bibr" rid="B143">Mantis et al., 2009</xref>).</td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top"><italic>MECP2</italic> absence exclusively in GABAergic neurons has been found to trigger almost the full range of RTT symptomatology in mice (<xref ref-type="bibr" rid="B35">Chao et al., 2010</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">Modifications in mitochondrial structure and function have been described (<xref ref-type="bibr" rid="B224">Shulyakova et al., 2017</xref>). Cholesterol influences the production of neurosteroids (<xref ref-type="bibr" rid="B195">Reddy, 2010</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">Reductions in neurosteroids were found on status epilepticus (<xref ref-type="bibr" rid="B159">Meletti et al., 2017</xref>, <xref ref-type="bibr" rid="B160">2018</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">Administration of CBDV to <italic>Mecp2</italic>-null mice rescued sociability impairments, improved the general health status and increased the brain weight of these animals (<xref ref-type="bibr" rid="B244">Vigli et al., 2018</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">In Autism and Huntington’s disease mice models, the KD has been shown to improve sociability, to reduce repetitive behavior and increase body weight (<xref ref-type="bibr" rid="B236">Todorova et al., 2000</xref>; <xref ref-type="bibr" rid="B142">Mantis et al., 2004</xref>; <xref ref-type="bibr" rid="B156">Meidenbauer et al., 2011</xref>; <xref ref-type="bibr" rid="B213">Ruskin et al., 2011</xref>, <xref ref-type="bibr" rid="B212">2017</xref>; <xref ref-type="bibr" rid="B34">Castro et al., 2017</xref>; <xref ref-type="bibr" rid="B116">Kasprowska-Liśkiewicz et al., 2017</xref>).</td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top">The use of benzodiazepines, acting as agonists of the GABA<sub>A</sub>R, improve RTT symptoms in mice (<xref ref-type="bibr" rid="B246">Voituron and Hilaire, 2011</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top">In SLOS, an abnormal synthesis of neurosteroids occurs (<xref ref-type="bibr" rid="B144">Marcos et al., 2004</xref>; <xref ref-type="bibr" rid="B127">Lee and Tierney, 2011</xref>). Ganaxolone showed promising results in a clinical trial in Fragile X syndrome (<xref ref-type="bibr" rid="B131">Ligsay et al., 2017</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top">Íncreasing GABA availability by blocking its reuptake with Tiagabine, has been shown to reduce RTT symptoms.</td>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="justify" colspan="5" rowspan="1" valign="top">
<hr/>
</td>
</tr>
<tr>
<td align="center" colspan="5" rowspan="1" valign="top">
<bold>Future directions</bold>
<hr/>
</td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top">To better characterize the modifications occurring in GABA<sub>A</sub>R composition during RTT progression (<xref ref-type="bibr" rid="B107">Jin et al., 2013b</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">To comprehend the cellular mechanisms behind the dysregulations in cholesterol metabolism (<xref ref-type="bibr" rid="B24">Buchovecky et al., 2013</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">To directly evaluate the impact of neurosteroid treatment in <italic>Mecp2</italic> mutant mice phenotype.</td>
<td align="justify" colspan="1" rowspan="1" valign="top">Study the ECBS in RTT mice models.</td>
<td align="justify" colspan="1" rowspan="1" valign="top">Reinstate the interest in the use of the KD in RTT, particularly considering its antiseizure actions, advancing with new studies, both in humans and in RTT-mice models.</td>
</tr>
<tr>
<td align="justify" colspan="1" rowspan="1" valign="top">To further evaluate the impact of strategies which, directly or indirectly, increase GABAergic signaling in RTT mice models.</td>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
<td align="justify" colspan="1" rowspan="1" valign="top">To understand how modifications occurring in GABA<sub>A</sub>R composition during RTT progression affect neurosteroid actions (<xref ref-type="bibr" rid="B107">Jin et al., 2013b</xref>).</td>
<td align="justify" colspan="1" rowspan="1" valign="top">Understand the impact of CBD and THC in RTT symptoms in trials with humans and in preclinical studies using RTT mice models.</td>
<td align="justify" colspan="1" rowspan="1" valign="top"></td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Summarizing, in the future it would be interesting to: (1) better characterize the modifications occurring in GABA<sub>A</sub>R composition during RTT disease progression; (2) study how cholesterol imbalances impact on neurosteroid production in RTT and their potential therapeutic use in this disease; (3) disclose the cellular mechanisms behind the dysregulations in cholesterol metabolism; (4) directly study the immense potentiality of CBD and other cannabinoids on RTT mouse-models and in controlled clinical trials with humans; (5) reinstate the interest in the use of the KD in RTT, particularly considering its antiseizure actions, advancing with new studies, both in humans and in RTT-mouse models; (6) to design further studies on the therapeutic properties of statins in RTT, and (7) continue to research mitochondria dynamics in RTT and its role on the disease progression and symptomatology.</p>
</sec>
<sec id="S5">
<title>Author Contributions</title>
<p>FM and MD wrote the manuscript. CM-L revised and assisted on manuscript writing. AS revised the manuscript. All authors contributed to the final version of the manuscript.</p>
</sec>
<sec id="conf1">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> FM was in receipt of a fellowship (IMM/CT/8-2018). The authors would like to thank the following organizations for their funding: AdoRett – LISBOA-01-0145-FEDER-031929; the Association Française du Syndrome de Rett Program “Educação pela Ciência” | Bolsas CHLN/FMUL; GAPIC. Project No. 20190017; Twinning action (SynaNet) from the EU H2020 Programme; and the UID/BIM/50005/2019, project financed by the FCT/Ministério da Ciência, Tecnologia e Ensino Superior (MCTES), through the Fundos do Orçamento de Estado.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdala</surname><given-names>A. P.</given-names></name><name><surname>Toward</surname><given-names>M. A.</given-names></name><name><surname>Dutschmann</surname><given-names>M.</given-names></name><name><surname>Bissonnette</surname><given-names>J. M.</given-names></name><name><surname>Paton</surname><given-names>J. F. R.</given-names></name></person-group> (<year>2016</year>). <article-title>Deficiency of GABAergic synaptic inhibition in the kölliker-fuse area underlies respiratory dysrhythmia in a mouse model of Rett syndrome.</article-title>
<source/><italic>J. Physiol.</italic>
<volume>594</volume>
<fpage>223</fpage>–<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1113/JP270966</pub-id>
<pub-id pub-id-type="pmid">26507912</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdala</surname><given-names>A. P. L.</given-names></name><name><surname>Dutschmann</surname><given-names>M.</given-names></name><name><surname>Bissonnette</surname><given-names>J. M.</given-names></name><name><surname>Paton</surname><given-names>J. F. R.</given-names></name></person-group> (<year>2010</year>). <article-title>Correction of respiratory disorders in a mouse model of Rett syndrome.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>107</volume>
<fpage>18208</fpage>–<lpage>18213</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1012104107</pub-id>
<pub-id pub-id-type="pmid">20921395</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amir</surname><given-names>R. E.</given-names></name><name><surname>Van den Veyver</surname><given-names>I. B.</given-names></name><name><surname>Wan</surname><given-names>M.</given-names></name><name><surname>Tran</surname><given-names>C. Q.</given-names></name><name><surname>Francke</surname><given-names>U.</given-names></name><name><surname>Zoghbi</surname><given-names>H. Y.</given-names></name></person-group> (<year>1999</year>). <article-title>Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2.</article-title>
<source/><italic>Nat. Genet.</italic>
<volume>23</volume>
<fpage>185</fpage>–<lpage>188</lpage>. <pub-id pub-id-type="doi">10.1038/13810</pub-id>
<pub-id pub-id-type="pmid">10508514</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anavi-Goffer</surname><given-names>S.</given-names></name><name><surname>Baillie</surname><given-names>G.</given-names></name><name><surname>Irving</surname><given-names>A. J.</given-names></name><name><surname>Gertsch</surname><given-names>J.</given-names></name><name><surname>Greig</surname><given-names>I. R.</given-names></name><name><surname>Pertwee</surname><given-names>R. G.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Modulation of l-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by Cannabinoids.</article-title>
<source/><italic>J. Biol. Chem.</italic>
<volume>287</volume>
<fpage>91</fpage>–<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.296020</pub-id>
<pub-id pub-id-type="pmid">22027819</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aneja</surname><given-names>A.</given-names></name><name><surname>Tierney</surname><given-names>E.</given-names></name></person-group> (<year>2008</year>). <article-title>Autism: the role of cholesterol in treatment.</article-title>
<source/><italic>Int. Rev. Psychiatry</italic>
<volume>20</volume>
<fpage>165</fpage>–<lpage>170</lpage>. <pub-id pub-id-type="doi">10.1080/09540260801889062</pub-id>
<pub-id pub-id-type="pmid">18386207</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Archer</surname><given-names>H. L.</given-names></name><name><surname>Evans</surname><given-names>J.</given-names></name><name><surname>Edwards</surname><given-names>S.</given-names></name><name><surname>Colley</surname><given-names>J.</given-names></name><name><surname>Newbury-Ecob</surname><given-names>R.</given-names></name><name><surname>O’Callaghan</surname><given-names>F.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients.</article-title>
<source/><italic>J. Med. Genet.</italic>
<volume>43</volume>
<fpage>729</fpage>–<lpage>734</lpage>. <pub-id pub-id-type="doi">10.1136/jmg.2006.041467</pub-id>
<pub-id pub-id-type="pmid">16611748</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auron</surname><given-names>A.</given-names></name><name><surname>Brophy</surname><given-names>P. D.</given-names></name></person-group> (<year>2012</year>). <article-title>Hyperammonemia in review: pathophysiology, diagnosis, and treatment.</article-title>
<source/><italic>Pediatr. Nephrol.</italic>
<volume>27</volume>
<fpage>207</fpage>–<lpage>222</lpage>. <pub-id pub-id-type="doi">10.1007/s00467-011-1838-5</pub-id>
<pub-id pub-id-type="pmid">21431427</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badowski</surname><given-names>M. E.</given-names></name><name><surname>Perez</surname><given-names>S. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS.</article-title>
<source/><italic>HIV AIDS</italic>
<volume>8</volume>
<fpage>37</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.2147/HIV.S81420</pub-id>
<pub-id pub-id-type="pmid">26929669</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badowski</surname><given-names>M. E.</given-names></name><name><surname>Yanful</surname><given-names>P. K.</given-names></name></person-group> (<year>2018</year>). <article-title>Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer.</article-title>
<source/><italic>Ther. Clin. Risk Manag.</italic>
<volume>14</volume>
<fpage>643</fpage>–<lpage>651</lpage>. <pub-id pub-id-type="doi">10.2147/TCRM.S126849</pub-id>
<pub-id pub-id-type="pmid">29670357</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakas</surname><given-names>T.</given-names></name><name><surname>van Nieuwenhuijzen</surname><given-names>P. S.</given-names></name><name><surname>Devenish</surname><given-names>S. O.</given-names></name><name><surname>McGregor</surname><given-names>I. S.</given-names></name><name><surname>Arnold</surname><given-names>J. C.</given-names></name><name><surname>Chebib</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors.</article-title>
<source/><italic>Pharmacol. Res.</italic>
<volume>119</volume>
<fpage>358</fpage>–<lpage>370</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2017.02.022</pub-id>
<pub-id pub-id-type="pmid">28249817</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basavarajappa</surname><given-names>B. S.</given-names></name><name><surname>Shivakumar</surname><given-names>M.</given-names></name><name><surname>Joshi</surname><given-names>V.</given-names></name><name><surname>Subbanna</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Endocannabinoid system in neurodegenerative disorders.</article-title>
<source/><italic>J. Neurochem.</italic>
<volume>142</volume>
<fpage>624</fpage>–<lpage>648</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.14098</pub-id>
<pub-id pub-id-type="pmid">28608560</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belelli</surname><given-names>D.</given-names></name><name><surname>Casula</surname><given-names>A.</given-names></name><name><surname>Ling</surname><given-names>A.</given-names></name><name><surname>Lambert</surname><given-names>J. J.</given-names></name></person-group> (<year>2002</year>). <article-title>The influence of subunit composition on the interaction of neurosteroids with GABA(A) receptors.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>43</volume>
<fpage>651</fpage>–<lpage>661</lpage>. <pub-id pub-id-type="pmid">12367610</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belelli</surname><given-names>D.</given-names></name><name><surname>Herd</surname><given-names>M. B.</given-names></name></person-group> (<year>2003</year>). <article-title>The contraceptive agent Provera enhances GABA(A) receptor-mediated inhibitory neurotransmission in the rat hippocampus: evidence for endogenous neurosteroids?</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>23</volume>
<fpage>10013</fpage>–<lpage>10020</lpage>. <pub-id pub-id-type="pmid">14602815</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernardi</surname><given-names>F.</given-names></name><name><surname>Salvestroni</surname><given-names>C.</given-names></name><name><surname>Casarosa</surname><given-names>E.</given-names></name><name><surname>Nappi</surname><given-names>R. E.</given-names></name><name><surname>Lanzone</surname><given-names>A.</given-names></name><name><surname>Luisi</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>1998</year>). <article-title>Aging is associated with changes in allopregnanolone concentrations in brain, endocrine glands and serum in male rats.</article-title>
<source/><italic>Eur. J. Endocrinol.</italic>
<volume>138</volume>
<fpage>316</fpage>–<lpage>321</lpage>. <pub-id pub-id-type="pmid">9539307</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betjemann</surname><given-names>J. P.</given-names></name><name><surname>Lowenstein</surname><given-names>D. H.</given-names></name></person-group> (<year>2015</year>). <article-title>Status epilepticus in adults.</article-title>
<source/><italic>Lancet Neurol.</italic>
<volume>14</volume>
<fpage>615</fpage>–<lpage>624</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(15)00042-3</pub-id>
<pub-id pub-id-type="pmid">25908090</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianchi</surname><given-names>M. T.</given-names></name><name><surname>Macdonald</surname><given-names>R. L.</given-names></name></person-group> (<year>2003</year>). <article-title>Neurosteroids shift partial agonist activation of GABA(A) receptor channels from low- to high-efficacy gating patterns.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>23</volume>
<fpage>10934</fpage>–<lpage>10943</lpage>. <pub-id pub-id-type="pmid">14645489</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bjursell</surname><given-names>M.</given-names></name><name><surname>Ryberg</surname><given-names>E.</given-names></name><name><surname>Wu</surname><given-names>T.</given-names></name><name><surname>Greasley</surname><given-names>P. J.</given-names></name><name><surname>Bohlooly-Y</surname><given-names>M.</given-names></name><name><surname>Hjorth</surname><given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>Deletion of Gpr55 results in subtle effects on energy metabolism, motor activity and thermal pain sensation.</article-title>
<source/><italic>PLoS One</italic>
<volume>11</volume>:<issue>e0167965</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0167965</pub-id>
<pub-id pub-id-type="pmid">27941994</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blessing</surname><given-names>E. M.</given-names></name><name><surname>Steenkamp</surname><given-names>M. M.</given-names></name><name><surname>Manzanares</surname><given-names>J.</given-names></name><name><surname>Marmar</surname><given-names>C. R.</given-names></name></person-group> (<year>2015</year>). <article-title>Cannabidiol as a potential treatment for anxiety disorders.</article-title>
<source/><italic>Neurotherapeutics</italic>
<volume>12</volume>
<fpage>825</fpage>–<lpage>836</lpage>. <pub-id pub-id-type="doi">10.1007/s13311-015-0387-1</pub-id>
<pub-id pub-id-type="pmid">26341731</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blue</surname><given-names>M. E.</given-names></name><name><surname>Naidu</surname><given-names>S.</given-names></name><name><surname>Johnston</surname><given-names>M. V.</given-names></name></person-group> (<year>1999</year>). <article-title>Altered development of glutamate and GABA receptors in the basal ganglia of girls with Rett syndrome.</article-title>
<source/><italic>Exp. Neurol.</italic>
<volume>156</volume>
<fpage>345</fpage>–<lpage>352</lpage>. <pub-id pub-id-type="doi">10.1006/exnr.1999.7030</pub-id>
<pub-id pub-id-type="pmid">10328941</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boggio</surname><given-names>E. M.</given-names></name><name><surname>Lonetti</surname><given-names>G.</given-names></name><name><surname>Pizzorusso</surname><given-names>T.</given-names></name><name><surname>Giustetto</surname><given-names>M.</given-names></name></person-group> (<year>2010</year>). <article-title>Synaptic determinants of Rett syndrome.</article-title>
<source/><italic>Front. Synapt. Neurosci.</italic>
<volume>2</volume>:<issue>28</issue>. <pub-id pub-id-type="doi">10.3389/fnsyn.2010.00028</pub-id>
<pub-id pub-id-type="pmid">21423514</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braat</surname><given-names>S.</given-names></name><name><surname>Kooy</surname><given-names>R. F.</given-names></name></person-group> (<year>2015</year>). <article-title>The GABAA receptor as a therapeutic target for neurodevelopmental disorders.</article-title>
<source/><italic>Neuron</italic>
<volume>86</volume>
<fpage>1119</fpage>–<lpage>1130</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2015.03.042</pub-id>
<pub-id pub-id-type="pmid">26050032</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broomall</surname><given-names>E.</given-names></name><name><surname>Natale</surname><given-names>J. E.</given-names></name><name><surname>Grimason</surname><given-names>M.</given-names></name><name><surname>Goldstein</surname><given-names>J.</given-names></name><name><surname>Smith</surname><given-names>C. M.</given-names></name><name><surname>Chang</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Pediatric super-refractory status epilepticus treated with allopregnanolone.</article-title>
<source/><italic>Ann. Neurol.</italic>
<volume>76</volume>
<fpage>911</fpage>–<lpage>915</lpage>. <pub-id pub-id-type="doi">10.1002/ana.24295</pub-id>
<pub-id pub-id-type="pmid">25363147</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>N.</given-names></name><name><surname>Kerby</surname><given-names>J.</given-names></name><name><surname>Bonnert</surname><given-names>T. P.</given-names></name><name><surname>Whiting</surname><given-names>P. J.</given-names></name><name><surname>Wafford</surname><given-names>K. A.</given-names></name></person-group> (<year>2002</year>). <article-title>Pharmacological characterization of a novel cell line expressing human alpha(4)beta(3)delta GABA(A) receptors.</article-title>
<source/><italic>Br. J. Pharmacol.</italic>
<volume>136</volume>
<fpage>965</fpage>–<lpage>974</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0704795</pub-id>
<pub-id pub-id-type="pmid">12145096</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchovecky</surname><given-names>C. M.</given-names></name><name><surname>Turley</surname><given-names>S. D.</given-names></name><name><surname>Brown</surname><given-names>H. M.</given-names></name><name><surname>Kyle</surname><given-names>S. M.</given-names></name><name><surname>McDonald</surname><given-names>J. G.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome.</article-title>
<source/><italic>Nat. Genet.</italic>
<volume>45</volume>
<fpage>1013</fpage>–<lpage>1020</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2714</pub-id>
<pub-id pub-id-type="pmid">23892605</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busquets-Garcia</surname><given-names>A.</given-names></name><name><surname>Bains</surname><given-names>J.</given-names></name><name><surname>Marsicano</surname><given-names>G.</given-names></name></person-group> (<year>2018</year>). <article-title>CB1 receptor signaling in the brain: extracting specificity from ubiquity.</article-title>
<source/><italic>Neuropsychopharmacology</italic>
<volume>43</volume>
<fpage>4</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2017.206</pub-id>
<pub-id pub-id-type="pmid">28862250</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>H.</given-names></name><name><surname>Cao</surname><given-names>T.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Yao</surname><given-names>J. K.</given-names></name></person-group> (<year>2018</year>). <article-title>Neurosteroids in schizophrenia: pathogenic and therapeutic implications.</article-title>
<source/><italic>Front. Psychiatry</italic>
<volume>9</volume>:<issue>73</issue>. <pub-id pub-id-type="doi">10.3389/fpsyt.2018.00073</pub-id>
<pub-id pub-id-type="pmid">29568275</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calfa</surname><given-names>G.</given-names></name><name><surname>Hablitz</surname><given-names>J. J.</given-names></name><name><surname>Pozzo-Miller</surname><given-names>L.</given-names></name></person-group> (<year>2011</year>). <article-title>Network hyperexcitability in hippocampal slices from Mecp2 mutant mice revealed by voltage-sensitive dye imaging.</article-title>
<source/><italic>J. Neurophysiol.</italic>
<volume>105</volume>
<fpage>1768</fpage>–<lpage>1784</lpage>. <pub-id pub-id-type="doi">10.1152/jn.00800.2010</pub-id>
<pub-id pub-id-type="pmid">21307327</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campos-Castelló</surname><given-names>J.</given-names></name><name><surname>Peral Guerra</surname><given-names>M.</given-names></name><name><surname>Riviere Gómez</surname><given-names>A.</given-names></name><name><surname>Oliete García</surname><given-names>F.</given-names></name><name><surname>Herranz Tanarro</surname><given-names>J.</given-names></name><name><surname>Toledano Barrero</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>1988</year>). <article-title>[Rett’s syndrome: study of 15 cases].</article-title>
<source/><italic>An. Esp. Pediatr.</italic>
<volume>28</volume>
<fpage>286</fpage>–<lpage>292</lpage>.<pub-id pub-id-type="pmid">2456708</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caraballo</surname><given-names>R.</given-names></name><name><surname>Vaccarezza</surname><given-names>M.</given-names></name><name><surname>Cersósimo</surname><given-names>R.</given-names></name><name><surname>Rios</surname><given-names>V.</given-names></name><name><surname>Soraru</surname><given-names>A.</given-names></name><name><surname>Arroyo</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Long-term follow-up of the ketogenic diet for refractory epilepsy: multicenter Argentinean experience in 216 pediatric patients.</article-title>
<source/><italic>Seizure</italic>
<volume>20</volume>
<fpage>640</fpage>–<lpage>645</lpage>. <pub-id pub-id-type="doi">10.1016/j.seizure.2011.06.009</pub-id>
<pub-id pub-id-type="pmid">21763159</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>G. T.</given-names></name><name><surname>Javaher</surname><given-names>S. P.</given-names></name><name><surname>Nguyen</surname><given-names>M. H.</given-names></name><name><surname>Garret</surname><given-names>S.</given-names></name><name><surname>Carlini</surname><given-names>B. H.</given-names></name></person-group> (<year>2015</year>). <article-title>Re-branding cannabis: the next generation of chronic pain medicine?</article-title>
<source/><italic>Pain Manag.</italic>
<volume>5</volume>
<fpage>13</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.2217/pmt.14.49</pub-id>
<pub-id pub-id-type="pmid">25537695</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carunchio</surname><given-names>I.</given-names></name><name><surname>Mollinari</surname><given-names>C.</given-names></name><name><surname>Pieri</surname><given-names>M.</given-names></name><name><surname>Merlo</surname><given-names>D.</given-names></name><name><surname>Zona</surname><given-names>C.</given-names></name></person-group> (<year>2008</year>). <article-title>GABA A receptors present higher affinity and modified subunit composition in spinal motor neurons from a genetic model of amyotrophic lateral sclerosis.</article-title>
<source/><italic>Eur. J. Neurosci.</italic>
<volume>28</volume>
<fpage>1275</fpage>–<lpage>1285</lpage>. <pub-id pub-id-type="doi">10.1111/j.1460-9568.2008.06436.x</pub-id>
<pub-id pub-id-type="pmid">18973555</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carver</surname><given-names>C. M.</given-names></name><name><surname>Reddy</surname><given-names>D. S.</given-names></name></person-group> (<year>2016</year>). <article-title>Neurosteroid structure-activity relationships for functional activation of extrasynaptic δGABA(A) receptors.</article-title>
<source/><italic>J. Pharmacol. Exp. Ther.</italic>
<volume>357</volume>
<fpage>188</fpage>–<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.115.229302</pub-id>
<pub-id pub-id-type="pmid">26857959</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cassano</surname><given-names>T.</given-names></name><name><surname>Calcagnini</surname><given-names>S.</given-names></name><name><surname>Pace</surname><given-names>L.</given-names></name><name><surname>De Marco</surname><given-names>F.</given-names></name><name><surname>Romano</surname><given-names>A.</given-names></name><name><surname>Gaetani</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Cannabinoid receptor 2 signaling in neurodegenerative disorders: from pathogenesis to a promising therapeutic target.</article-title>
<source/><italic>Front. Neurosci.</italic>
<volume>11</volume>:<issue>30</issue>. <pub-id pub-id-type="doi">10.3389/fnins.2017.00030</pub-id>
<pub-id pub-id-type="pmid">28210207</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castro</surname><given-names>K.</given-names></name><name><surname>Baronio</surname><given-names>D.</given-names></name><name><surname>Perry</surname><given-names>I. S.</given-names></name><name><surname>Riesgo</surname><given-names>R. D. S.</given-names></name><name><surname>Gottfried</surname><given-names>C.</given-names></name></person-group> (<year>2017</year>). <article-title>The effect of ketogenic diet in an animal model of autism induced by prenatal exposure to valproic acid.</article-title>
<source/><italic>Nutr. Neurosci.</italic>
<volume>20</volume>
<fpage>343</fpage>–<lpage>350</lpage>. <pub-id pub-id-type="doi">10.1080/1028415X.2015.1133029</pub-id>
<pub-id pub-id-type="pmid">26856821</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>H.-T.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Samaco</surname><given-names>R. C.</given-names></name><name><surname>Xue</surname><given-names>M.</given-names></name><name><surname>Chahrour</surname><given-names>M.</given-names></name><name><surname>Yoo</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes.</article-title>
<source/><italic>Nature</italic>
<volume>468</volume>
<fpage>263</fpage>–<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1038/nature09582</pub-id>
<pub-id pub-id-type="pmid">21068835</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>H.-T.</given-names></name><name><surname>Zoghbi</surname><given-names>H. Y.</given-names></name></person-group> (<year>2012</year>). <article-title>MeCP2: only 100% will do.</article-title>
<source/><italic>Nat. Neurosci.</italic>
<volume>15</volume>
<fpage>176</fpage>–<lpage>177</lpage>. <pub-id pub-id-type="doi">10.1038/nn.3027</pub-id>
<pub-id pub-id-type="pmid">22281712</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>H.-T.</given-names></name><name><surname>Zoghbi</surname><given-names>H. Y.</given-names></name><name><surname>Rosenmund</surname><given-names>C.</given-names></name></person-group> (<year>2007</year>). <article-title>MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number.</article-title>
<source/><italic>Neuron</italic>
<volume>56</volume>
<fpage>58</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2007.08.018</pub-id>
<pub-id pub-id-type="pmid">17920015</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapleau</surname><given-names>C. A.</given-names></name><name><surname>Lane</surname><given-names>J.</given-names></name><name><surname>Pozzo-Miller</surname><given-names>L.</given-names></name><name><surname>Percy</surname><given-names>A. K.</given-names></name></person-group> (<year>2013</year>). <article-title>Evaluation of current pharmacological treatment options in the management of Rett syndrome: from the present to future therapeutic alternatives.</article-title>
<source/><italic>Curr. Clin. Pharmacol.</italic>
<volume>8</volume>
<fpage>358</fpage>–<lpage>369</lpage>. <pub-id pub-id-type="pmid">24050745</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charalampopoulos</surname><given-names>I.</given-names></name><name><surname>Remboutsika</surname><given-names>E.</given-names></name><name><surname>Margioris</surname><given-names>A. N.</given-names></name><name><surname>Gravanis</surname><given-names>A.</given-names></name></person-group> (<year>2008</year>). <article-title>Neurosteroids as modulators of neurogenesis and neuronal survival.</article-title>
<source/><italic>Trends Endocrinol. Metab.</italic>
<volume>19</volume>
<fpage>300</fpage>–<lpage>307</lpage>. <pub-id pub-id-type="doi">10.1016/j.tem.2008.07.004</pub-id>
<pub-id pub-id-type="pmid">18771935</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chebib</surname><given-names>M.</given-names></name><name><surname>Johnston</surname><given-names>G. A. R.</given-names></name></person-group> (<year>1999</year>). <article-title>The “ABC” of gaba receptors: a brief review.</article-title>
<source/><italic>Clin. Exp. Pharmacol. Physiol.</italic>
<volume>26</volume>
<fpage>937</fpage>–<lpage>940</lpage>. <pub-id pub-id-type="doi">10.1046/j.1440-1681.1999.03151.x</pub-id>
<pub-id pub-id-type="pmid">10561820</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C.-Y.</given-names></name><name><surname>Di Lucente</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>Y.-C.</given-names></name><name><surname>Lien</surname><given-names>C.-C.</given-names></name><name><surname>Rogawski</surname><given-names>M. A.</given-names></name><name><surname>Maezawa</surname><given-names>I.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Defective GABAergic neurotransmission in the nucleus tractus solitarius in Mecp2-null mice, a model of Rett syndrome.</article-title>
<source/><italic>Neurobiol. Dis.</italic>
<volume>109</volume>
<fpage>25</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2017.09.006</pub-id>
<pub-id pub-id-type="pmid">28927958</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>J. M.</given-names></name><name><surname>Irwin</surname><given-names>R. W.</given-names></name><name><surname>Yao</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Brinton</surname><given-names>R. D.</given-names></name></person-group> (<year>2011</year>). <article-title>Allopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer’s disease.</article-title>
<source/><italic>PLoS One</italic>
<volume>6</volume>:<issue>e24293</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0024293</pub-id>
<pub-id pub-id-type="pmid">21918687</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>A. J.</given-names></name><name><surname>Abdala Sheikh</surname><given-names>A. P.</given-names></name></person-group> (<year>2018</year>). <article-title>A perspective on “cure” for Rett syndrome.</article-title>
<source/><italic>Orphanet J. Rare Dis.</italic>
<volume>13</volume>:<issue>44</issue>. <pub-id pub-id-type="doi">10.1186/s13023-018-0786-6</pub-id>
<pub-id pub-id-type="pmid">29609636</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>R. S.</given-names></name></person-group> (<year>1973</year>). <article-title>Anaesthesia and carbohydrate metabolism.</article-title>
<source/><italic>Br. J. Anaesth.</italic>
<volume>45</volume>
<fpage>237</fpage>–<lpage>243</lpage>.<pub-id pub-id-type="pmid">4572998</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colciago</surname><given-names>A.</given-names></name><name><surname>Magnaghi</surname><given-names>V.</given-names></name></person-group> (<year>2016</year>). <article-title>Neurosteroids involvement in the epigenetic control of memory formation and storage.</article-title>
<source/><italic>Neural Plast.</italic>
<volume>2016</volume>:<issue>5985021</issue>. <pub-id pub-id-type="doi">10.1155/2016/5985021</pub-id>
<pub-id pub-id-type="pmid">28090360</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Concas</surname><given-names>A.</given-names></name><name><surname>Mostallino</surname><given-names>M. C.</given-names></name><name><surname>Porcu</surname><given-names>P.</given-names></name><name><surname>Follesa</surname><given-names>P.</given-names></name><name><surname>Barbaccia</surname><given-names>M. L.</given-names></name><name><surname>Trabucchi</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>1998</year>). <article-title>Role of brain allopregnanolone in the plasticity of gamma-aminobutyric acid type A receptor in rat brain during pregnancy and after delivery.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>95</volume>
<fpage>13284</fpage>–<lpage>13289</lpage>. <pub-id pub-id-type="pmid">9789080</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Consroe</surname><given-names>P.</given-names></name><name><surname>Benedito</surname><given-names>M. A.</given-names></name><name><surname>Leite</surname><given-names>J. R.</given-names></name><name><surname>Carlini</surname><given-names>E. A.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name></person-group> (<year>1982</year>). <article-title>Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice.</article-title>
<source/><italic>Eur. J. Pharmacol.</italic>
<volume>83</volume>
<fpage>293</fpage>–<lpage>298</lpage>. <pub-id pub-id-type="pmid">6129147</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>E. J.</given-names></name><name><surname>Johnston</surname><given-names>G. A.</given-names></name><name><surname>Edwards</surname><given-names>F. A.</given-names></name></person-group> (<year>1999</year>). <article-title>Effects of a naturally occurring neurosteroid on GABAA IPSCs during development in rat hippocampal or cerebellar slices.</article-title>
<source/><italic>J. Physiol.</italic>
<volume>521(Pt 2)</volume>, <fpage>437</fpage>–<lpage>449</lpage>.<pub-id pub-id-type="pmid">10581314</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Counts</surname><given-names>S. E.</given-names></name><name><surname>He</surname><given-names>B.</given-names></name><name><surname>Nadeem</surname><given-names>M.</given-names></name><name><surname>Wuu</surname><given-names>J.</given-names></name><name><surname>Scheff</surname><given-names>S. W.</given-names></name><name><surname>Mufson</surname><given-names>E. J.</given-names></name></person-group> (<year>2012</year>). <article-title>Hippocampal drebrin loss in mild cognitive impairment.</article-title>
<source/><italic>Neurodegener. Dis.</italic>
<volume>10</volume>
<fpage>216</fpage>–<lpage>219</lpage>. <pub-id pub-id-type="doi">10.1159/000333122</pub-id>
<pub-id pub-id-type="pmid">22310934</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahlin</surname><given-names>M.</given-names></name><name><surname>Elfving</surname><given-names>A.</given-names></name><name><surname>Ungerstedt</surname><given-names>U.</given-names></name><name><surname>Amark</surname><given-names>P.</given-names></name></person-group> (<year>2005</year>). <article-title>The ketogenic diet influences the levels of excitatory and inhibitory amino acids in the CSF in children with refractory epilepsy.</article-title>
<source/><italic>Epilepsy Res.</italic>
<volume>64</volume>
<fpage>115</fpage>–<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1016/j.eplepsyres.2005.03.008</pub-id>
<pub-id pub-id-type="pmid">15961283</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dani</surname><given-names>V. S.</given-names></name><name><surname>Chang</surname><given-names>Q.</given-names></name><name><surname>Maffei</surname><given-names>A.</given-names></name><name><surname>Turrigiano</surname><given-names>G. G.</given-names></name><name><surname>Jaenisch</surname><given-names>R.</given-names></name><name><surname>Nelson</surname><given-names>S. B.</given-names></name></person-group> (<year>2005</year>). <article-title>Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>102</volume>
<fpage>12560</fpage>–<lpage>12565</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0506071102</pub-id>
<pub-id pub-id-type="pmid">16116096</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dani</surname><given-names>V. S.</given-names></name><name><surname>Nelson</surname><given-names>S. B.</given-names></name></person-group> (<year>2009</year>). <article-title>Intact long-term potentiation but reduced connectivity between neocortical layer 5 pyramidal neurons in a mouse model of Rett syndrome.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>29</volume>
<fpage>11263</fpage>–<lpage>11270</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1019-09.2009</pub-id>
<pub-id pub-id-type="pmid">19741133</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datta</surname><given-names>D.</given-names></name><name><surname>Arion</surname><given-names>D.</given-names></name><name><surname>Lewis</surname><given-names>D. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Developmental expression patterns of GABAA receptor subunits in layer 3 and 5 pyramidal cells of monkey prefrontal cortex.</article-title>
<source/><italic>Cereb. Cortex</italic>
<volume>25</volume>
<fpage>2295</fpage>–<lpage>2305</lpage>. <pub-id pub-id-type="doi">10.1093/cercor/bhu040</pub-id>
<pub-id pub-id-type="pmid">24610118</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Felice</surname><given-names>C.</given-names></name><name><surname>Signorini</surname><given-names>C.</given-names></name><name><surname>Leoncini</surname><given-names>S.</given-names></name><name><surname>Pecorelli</surname><given-names>A.</given-names></name><name><surname>Durand</surname><given-names>T.</given-names></name><name><surname>Valacchi</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>The role of oxidative stress in Rett syndrome: an overview: oxidative stress and Rett syndrome.</article-title>
<source/><italic>Ann. N.Y. Acad. Sci.</italic>
<volume>1259</volume>
<fpage>121</fpage>–<lpage>135</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2012.06611.x</pub-id>
<pub-id pub-id-type="pmid">22758644</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Mello Schier</surname><given-names>A. R.</given-names></name><name><surname>de Oliveira Ribeiro</surname><given-names>N. P.</given-names></name><name><surname>Coutinho</surname><given-names>D. S.</given-names></name><name><surname>Machado</surname><given-names>S.</given-names></name><name><surname>Arias-Carrión</surname><given-names>O.</given-names></name><name><surname>Crippa</surname><given-names>J. A.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of <italic>Cannabis sativa</italic>.</article-title>
<source/><italic>CNS Neurol Disord. Drug Targets</italic>
<volume>13</volume>
<fpage>953</fpage>–<lpage>960</lpage>. <pub-id pub-id-type="pmid">24923339</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devinsky</surname><given-names>O.</given-names></name><name><surname>Cross</surname><given-names>J. H.</given-names></name><name><surname>Laux</surname><given-names>L.</given-names></name><name><surname>Marsh</surname><given-names>E.</given-names></name><name><surname>Miller</surname><given-names>I.</given-names></name><name><surname>Nabbout</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Trial of cannabidiol for drug-resistant seizures in the dravet syndrome.</article-title>
<source/><italic>N. Engl. J. Med.</italic>
<volume>376</volume>
<fpage>2011</fpage>–<lpage>2020</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1611618</pub-id>
<pub-id pub-id-type="pmid">28538134</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Marzo</surname><given-names>V.</given-names></name><name><surname>Stella</surname><given-names>N.</given-names></name><name><surname>Zimmer</surname><given-names>A.</given-names></name></person-group> (<year>2015</year>). <article-title>Endocannabinoid signalling and the deteriorating brain.</article-title>
<source/><italic>Nat. Rev. Neurosci.</italic>
<volume>16</volume>
<fpage>30</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3876</pub-id>
<pub-id pub-id-type="pmid">25524120</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diógenes</surname><given-names>M. J.</given-names></name><name><surname>Assaife-Lopes</surname><given-names>N.</given-names></name><name><surname>Pinto-Duarte</surname><given-names>A.</given-names></name><name><surname>Ribeiro</surname><given-names>J. A.</given-names></name><name><surname>Sebastião</surname><given-names>A. M.</given-names></name></person-group> (<year>2007</year>). <article-title>Influence of age on BDNF modulation of hippocampal synaptic transmission: interplay with adenosine A2A receptors.</article-title>
<source/><italic>Hippocampus</italic>
<volume>17</volume>
<fpage>577</fpage>–<lpage>585</lpage>. <pub-id pub-id-type="doi">10.1002/hipo.20294</pub-id>
<pub-id pub-id-type="pmid">17421024</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diógenes</surname><given-names>M. J.</given-names></name><name><surname>Fernandes</surname><given-names>C. C.</given-names></name><name><surname>Sebastião</surname><given-names>A. M.</given-names></name><name><surname>Ribeiro</surname><given-names>J. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Activation of adenosine A2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>24</volume>
<fpage>2905</fpage>–<lpage>2913</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4454-03.2004</pub-id>
<pub-id pub-id-type="pmid">15044529</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drexel</surname><given-names>M.</given-names></name><name><surname>Kirchmair</surname><given-names>E.</given-names></name><name><surname>Sperk</surname><given-names>G.</given-names></name></person-group> (<year>2013</year>). <article-title>Changes in the expression of GABAA receptor subunit mRNAs in parahippocampal areas after kainic acid induced seizures.</article-title>
<source/><italic>Front. Neural Circ.</italic>
<volume>7</volume>:<issue>142</issue>. <pub-id pub-id-type="doi">10.3389/fncir.2013.00142</pub-id>
<pub-id pub-id-type="pmid">24065890</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duarte</surname><given-names>S. T.</given-names></name><name><surname>Armstrong</surname><given-names>J.</given-names></name><name><surname>Roche</surname><given-names>A.</given-names></name><name><surname>Ortez</surname><given-names>C.</given-names></name><name><surname>Pérez</surname><given-names>A.</given-names></name><name><surname>O’Callaghan</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Abnormal expression of cerebrospinal fluid cation chloride cotransporters in patients with Rett syndrome.</article-title>
<source/><italic>PLoS One</italic>
<volume>8</volume>:<issue>e068851</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0068851</pub-id>
<pub-id pub-id-type="pmid">23894354</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubrovsky</surname><given-names>B. O.</given-names></name></person-group> (<year>2005</year>). <article-title>Steroids, neuroactive steroids and neurosteroids in psychopathology.</article-title>
<source/><italic>Progr. Neuro Psychopharmacol. Biol. Psychiatry</italic>
<volume>29</volume>
<fpage>169</fpage>–<lpage>192</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2004.11.001</pub-id>
<pub-id pub-id-type="pmid">15694225</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunwiddie</surname><given-names>T. V.</given-names></name><name><surname>Masino</surname><given-names>S. A.</given-names></name></person-group> (<year>2001</year>). <article-title>The role and regulation of adenosine in the central nervous system.</article-title>
<source/><italic>Annu. Rev. Neurosci.</italic>
<volume>24</volume>
<fpage>31</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.neuro.24.1.31</pub-id>
<pub-id pub-id-type="pmid">11283304</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Manira</surname><given-names>A.</given-names></name><name><surname>Kyriakatos</surname><given-names>A.</given-names></name></person-group> (<year>2010</year>). <article-title>The role of endocannabinoid signaling in motor control.</article-title>
<source/><italic>Physiology</italic>
<volume>25</volume>
<fpage>230</fpage>–<lpage>238</lpage>. <pub-id pub-id-type="doi">10.1152/physiol.00007.2010</pub-id>
<pub-id pub-id-type="pmid">20699469</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Ansary</surname><given-names>A.</given-names></name><name><surname>Al-Ayadhi</surname><given-names>L.</given-names></name></person-group> (<year>2014</year>). <article-title>GABAergic/glutamatergic imbalance relative to excessive neuroinflammation in autism spectrum disorders.</article-title>
<source/><italic>J. Neuroinflam.</italic>
<volume>11</volume>:<issue>189</issue>. <pub-id pub-id-type="doi">10.1186/s12974-014-0189-0</pub-id>
<pub-id pub-id-type="pmid">25407263</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Khoury</surname><given-names>R.</given-names></name><name><surname>Panayotis</surname><given-names>N.</given-names></name><name><surname>Matagne</surname><given-names>V.</given-names></name><name><surname>Ghata</surname><given-names>A.</given-names></name><name><surname>Villard</surname><given-names>L.</given-names></name><name><surname>Roux</surname><given-names>J.-C.</given-names></name></person-group> (<year>2014</year>). <article-title>GABA and glutamate pathways are spatially and developmentally affected in the brain of Mecp2-deficient mice.</article-title>
<source/><italic>PLoS One</italic>
<volume>9</volume>:<issue>e92169</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0092169</pub-id>
<pub-id pub-id-type="pmid">24667344</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagan</surname><given-names>S. G.</given-names></name><name><surname>Campbell</surname><given-names>V. A.</given-names></name></person-group> (<year>2014</year>). <article-title>The influence of cannabinoids on generic traits of neurodegeneration: cannabinoids and neurodegeneration.</article-title>
<source/><italic>Br. J. Pharmacol.</italic>
<volume>171</volume>
<fpage>1347</fpage>–<lpage>1360</lpage>. <pub-id pub-id-type="doi">10.1111/bph.12492</pub-id>
<pub-id pub-id-type="pmid">24172185</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>C. C.</given-names></name><name><surname>Pinto-Duarte</surname><given-names>A.</given-names></name><name><surname>Ribeiro</surname><given-names>J. A.</given-names></name><name><surname>Sebastião</surname><given-names>A. M.</given-names></name></person-group> (<year>2008</year>). <article-title>Postsynaptic action of brain-derived neurotrophic factor attenuates alpha7 nicotinic acetylcholine receptor-mediated responses in hippocampal interneurons.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>28</volume>
<fpage>5611</fpage>–<lpage>5618</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.5378-07.2008</pub-id>
<pub-id pub-id-type="pmid">18495895</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernández-Ruiz</surname><given-names>J.</given-names></name><name><surname>Moro</surname><given-names>M. A.</given-names></name><name><surname>Martínez-Orgado</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications.</article-title>
<source/><italic>Neurotherapeutics</italic>
<volume>12</volume>
<fpage>793</fpage>–<lpage>806</lpage>. <pub-id pub-id-type="doi">10.1007/s13311-015-0381-7</pub-id>
<pub-id pub-id-type="pmid">26260390</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernández-Ruiz</surname><given-names>J.</given-names></name><name><surname>Sagredo</surname><given-names>O.</given-names></name><name><surname>Pazos</surname><given-names>M. R.</given-names></name><name><surname>García</surname><given-names>C.</given-names></name><name><surname>Pertwee</surname><given-names>R.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?</article-title>
<source/><italic>Br. J. Clin. Pharmacol.</italic>
<volume>75</volume>
<fpage>323</fpage>–<lpage>333</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2125.2012.04341.x</pub-id>
<pub-id pub-id-type="pmid">22625422</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzpatrick</surname><given-names>J.-M. K.</given-names></name><name><surname>Downer</surname><given-names>E. J.</given-names></name></person-group> (<year>2017</year>). <article-title>Toll-like receptor signalling as a cannabinoid target in multiple sclerosis.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>113</volume>
<fpage>618</fpage>–<lpage>626</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2016.04.009</pub-id>
<pub-id pub-id-type="pmid">27079840</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Follesa</surname><given-names>P.</given-names></name><name><surname>Porcu</surname><given-names>P.</given-names></name><name><surname>Sogliano</surname><given-names>C.</given-names></name><name><surname>Cinus</surname><given-names>M.</given-names></name><name><surname>Biggio</surname><given-names>F.</given-names></name><name><surname>Mancuso</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2002</year>). <article-title>Changes in GABAA receptor gamma 2 subunit gene expression induced by long-term administration of oral contraceptives in rats.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>42</volume>
<fpage>325</fpage>–<lpage>336</lpage>. <pub-id pub-id-type="pmid">11897111</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontinha</surname><given-names>B. M.</given-names></name><name><surname>Diógenes</surname><given-names>M. J.</given-names></name><name><surname>Ribeiro</surname><given-names>J. A.</given-names></name><name><surname>Sebastião</surname><given-names>A. M.</given-names></name></person-group> (<year>2008</year>). <article-title>Enhancement of long-term potentiation by brain-derived neurotrophic factor requires adenosine A2A receptor activation by endogenous adenosine.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>54</volume>
<fpage>924</fpage>–<lpage>933</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.01.011</pub-id>
<pub-id pub-id-type="pmid">18384819</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fredholm</surname><given-names>B. B.</given-names></name><name><surname>Bättig</surname><given-names>K.</given-names></name><name><surname>Holmén</surname><given-names>J.</given-names></name><name><surname>Nehlig</surname><given-names>A.</given-names></name><name><surname>Zvartau</surname><given-names>E. E.</given-names></name></person-group> (<year>1999</year>). <article-title>Actions of caffeine in the brain with special reference to factors that contribute to its widespread use.</article-title>
<source/><italic>Pharmacol. Rev.</italic>
<volume>51</volume>
<fpage>83</fpage>–<lpage>133</lpage>.<pub-id pub-id-type="pmid">10049999</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>J. M.</given-names></name><name><surname>Kossoff</surname><given-names>E. H.</given-names></name></person-group> (<year>2010</year>). <article-title>Ketosis and the ketogenic diet, 2010: advances in treating epilepsy and other disorders.</article-title>
<source/><italic>Adv. Pediatr.</italic>
<volume>57</volume>
<fpage>315</fpage>–<lpage>329</lpage>. <pub-id pub-id-type="doi">10.1016/j.yapd.2010.08.003</pub-id>
<pub-id pub-id-type="pmid">21056745</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>French</surname><given-names>J. A.</given-names></name></person-group> (<year>2007</year>). <article-title>Refractory epilepsy: clinical overview.</article-title>
<source/><italic>Epilepsia</italic>
<volume>48</volume>
<fpage>3</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1167.2007.00992.x</pub-id>
<pub-id pub-id-type="pmid">17316406</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genazzani</surname><given-names>A. R.</given-names></name><name><surname>Petraglia</surname><given-names>F.</given-names></name><name><surname>Bernardi</surname><given-names>F.</given-names></name><name><surname>Casarosa</surname><given-names>E.</given-names></name><name><surname>Salvestroni</surname><given-names>C.</given-names></name><name><surname>Tonetti</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>1998</year>). <article-title>Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences.</article-title>
<source/><italic>J. Clin. Endocrinol. Metab.</italic>
<volume>83</volume>
<fpage>2099</fpage>–<lpage>2103</lpage>. <pub-id pub-id-type="doi">10.1210/jcem.83.6.4905</pub-id>
<pub-id pub-id-type="pmid">9626145</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giampietro</surname><given-names>P. F.</given-names></name><name><surname>Schowalter</surname><given-names>D. B.</given-names></name><name><surname>Merchant</surname><given-names>S.</given-names></name><name><surname>Campbell</surname><given-names>L. R.</given-names></name><name><surname>Swink</surname><given-names>T.</given-names></name><name><surname>Roa</surname><given-names>B. B.</given-names></name></person-group> (<year>2006</year>). <article-title>Widened clinical spectrum of the Q128P MECP2 mutation in Rett syndrome.</article-title>
<source/><italic>Childs Nerv. Syst.</italic>
<volume>22</volume>
<fpage>320</fpage>–<lpage>324</lpage>. <pub-id pub-id-type="doi">10.1007/s00381-005-1155-z</pub-id>
<pub-id pub-id-type="pmid">15875198</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodkin</surname><given-names>H. P.</given-names></name><name><surname>Joshi</surname><given-names>S.</given-names></name><name><surname>Mtchedlishvili</surname><given-names>Z.</given-names></name><name><surname>Brar</surname><given-names>J.</given-names></name><name><surname>Kapur</surname><given-names>J.</given-names></name></person-group> (<year>2008</year>). <article-title>Subunit-specific trafficking of GABA(A) receptors during status epilepticus.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>28</volume>
<fpage>2527</fpage>–<lpage>2538</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3426-07.2008</pub-id>
<pub-id pub-id-type="pmid">18322097</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Govindpani</surname><given-names>K.</given-names></name><name><surname>Calvo-Flores Guzmán</surname><given-names>B.</given-names></name><name><surname>Vinnakota</surname><given-names>C.</given-names></name><name><surname>Waldvogel</surname><given-names>H. J.</given-names></name><name><surname>Faull</surname><given-names>R. L.</given-names></name><name><surname>Kwakowsky</surname><given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Towards a better understanding of GABAergic remodeling in alzheimer’s disease.</article-title>
<source/><italic>Int. J. Mol. Sci.</italic>
<volume>18</volume>:<issue>1813</issue>. <pub-id pub-id-type="doi">10.3390/ijms18081813</pub-id>
<pub-id pub-id-type="pmid">28825683</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenfield</surname><given-names>L. J.</given-names></name></person-group> (<year>2013</year>). <article-title>Molecular mechanisms of antiseizure drug activity at GABAA receptors.</article-title>
<source/><italic>Seizure</italic>
<volume>22</volume>
<fpage>589</fpage>–<lpage>600</lpage>. <pub-id pub-id-type="doi">10.1016/j.seizure.2013.04.015</pub-id>
<pub-id pub-id-type="pmid">23683707</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grobin</surname><given-names>A. C.</given-names></name><name><surname>Morrow</surname><given-names>A. L.</given-names></name></person-group> (<year>2001</year>). <article-title>3Alpha-hydroxy-5alpha-pregnan-20-one levels and GABA(A) receptor-mediated 36Cl(-) flux across development in rat cerebral cortex.</article-title>
<source/><italic>Brain Res. Dev. Brain Res.</italic>
<volume>131</volume>
<fpage>31</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="pmid">11718833</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gulinello</surname><given-names>M.</given-names></name><name><surname>Gong</surname><given-names>Q. H.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Smith</surname><given-names>S. S.</given-names></name></person-group> (<year>2001</year>). <article-title>Short-term exposure to a neuroactive steroid increases alpha4 GABA(A) receptor subunit levels in association with increased anxiety in the female rat.</article-title>
<source/><italic>Brain Res.</italic>
<volume>910</volume>
<fpage>55</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="pmid">11489254</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guy</surname><given-names>J.</given-names></name><name><surname>Gan</surname><given-names>J.</given-names></name><name><surname>Selfridge</surname><given-names>J.</given-names></name><name><surname>Cobb</surname><given-names>S.</given-names></name><name><surname>Bird</surname><given-names>A.</given-names></name></person-group> (<year>2007</year>). <article-title>Reversal of neurological defects in a mouse model of Rett syndrome.</article-title>
<source/><italic>Science</italic>
<volume>315</volume>
<fpage>1143</fpage>–<lpage>1147</lpage>. <pub-id pub-id-type="doi">10.1126/science.1138389</pub-id>
<pub-id pub-id-type="pmid">17289941</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haas</surname><given-names>R. H.</given-names></name><name><surname>Rice</surname><given-names>M. A.</given-names></name><name><surname>Trauner</surname><given-names>D. A.</given-names></name><name><surname>Merritt</surname><given-names>T. A.</given-names></name><name><surname>Opitz</surname><given-names>J. M.</given-names></name><name><surname>Reynolds</surname><given-names>J. F.</given-names></name></person-group> (<year>1986</year>). <article-title>Therapeutic effects of a ketogenic diet in Rett syndrome.</article-title>
<source/><italic>Am. J. Med. Genet.</italic>
<volume>25</volume>
<fpage>225</fpage>–<lpage>246</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.1320250525</pub-id>
<pub-id pub-id-type="pmid">3087185</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagberg</surname><given-names>B.</given-names></name></person-group> (<year>2002</year>). <article-title>Clinical manifestations and stages of Rett syndrome.</article-title>
<source/><italic>Ment. Retardat. Dev. Disabil. Res. Rev.</italic>
<volume>8</volume>
<fpage>61</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1002/mrdd.10020</pub-id>
<pub-id pub-id-type="pmid">12112728</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hampson</surname><given-names>A. J.</given-names></name><name><surname>Grimaldi</surname><given-names>M.</given-names></name><name><surname>Lolic</surname><given-names>M.</given-names></name><name><surname>Wink</surname><given-names>D.</given-names></name><name><surname>Rosenthal</surname><given-names>R.</given-names></name><name><surname>Axelrod</surname><given-names>J.</given-names></name></person-group> (<year>2000</year>). <article-title>Neuroprotective antioxidants from marijuana.</article-title>
<source/><italic>Ann. N.Y. Acad. Sci.</italic>
<volume>899</volume>
<fpage>274</fpage>–<lpage>282</lpage>. <pub-id pub-id-type="pmid">10863546</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanefeld</surname><given-names>F.</given-names></name></person-group> (<year>1985</year>). <article-title>The clinical pattern of the Rett syndrome.</article-title>
<source/><italic>Brain Dev.</italic>
<volume>7</volume>
<fpage>320</fpage>–<lpage>325</lpage>.<pub-id pub-id-type="pmid">4061766</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harigaya</surname><given-names>Y.</given-names></name><name><surname>Shoji</surname><given-names>M.</given-names></name><name><surname>Shirao</surname><given-names>T.</given-names></name><name><surname>Hirai</surname><given-names>S.</given-names></name></person-group> (<year>1996</year>). <article-title>Disappearance of actin-binding protein, drebrin, from hippocampal synapses in Alzheimer’s disease.</article-title>
<source/><italic>J. Neurosci. Res.</italic>
<volume>43</volume>
<fpage>87</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.490430111</pub-id>
<pub-id pub-id-type="pmid">8838578</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>N. L.</given-names></name><name><surname>Simmonds</surname><given-names>M. A.</given-names></name></person-group> (<year>1984</year>). <article-title>Modulation of the GABA receptor complex by a steroid anaesthetic.</article-title>
<source/><italic>Brain Res.</italic>
<volume>323</volume>
<fpage>287</fpage>–<lpage>292</lpage>. <pub-id pub-id-type="pmid">6098342</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hartman</surname><given-names>A. L.</given-names></name><name><surname>Gasior</surname><given-names>M.</given-names></name><name><surname>Vining</surname><given-names>E. P. G.</given-names></name><name><surname>Rogawski</surname><given-names>M. A.</given-names></name></person-group> (<year>2007</year>). <article-title>The neuropharmacology of the ketogenic diet.</article-title>
<source/><italic>Pediatr. Neurol.</italic>
<volume>36</volume>
<fpage>281</fpage>–<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2007.02.008</pub-id>
<pub-id pub-id-type="pmid">17509459</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>A. M.</given-names></name><name><surname>Keene</surname><given-names>D. L.</given-names></name><name><surname>Whiting</surname><given-names>S. E.</given-names></name><name><surname>Jacob</surname><given-names>P. J.</given-names></name><name><surname>Champagne</surname><given-names>J. R.</given-names></name><name><surname>Humphreys</surname><given-names>P.</given-names></name></person-group> (<year>1999</year>). <article-title>Ketogenic diet in the treatment of refractory epilepsy in childhood.</article-title>
<source/><italic>Pediatr. Neurol.</italic>
<volume>21</volume>
<fpage>548</fpage>–<lpage>552</lpage>. <pub-id pub-id-type="pmid">10465141</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>T. D. M.</given-names></name><name><surname>Cascio</surname><given-names>M.-G.</given-names></name><name><surname>Romano</surname><given-names>B.</given-names></name><name><surname>Duncan</surname><given-names>M.</given-names></name><name><surname>Pertwee</surname><given-names>R. G.</given-names></name><name><surname>Williams</surname><given-names>C. M.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism.</article-title>
<source/><italic>Br. J. Pharmacol.</italic>
<volume>170</volume>
<fpage>679</fpage>–<lpage>692</lpage>. <pub-id pub-id-type="doi">10.1111/bph.12321</pub-id>
<pub-id pub-id-type="pmid">23902406</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogart</surname><given-names>A.</given-names></name><name><surname>Nagarajan</surname><given-names>R. P.</given-names></name><name><surname>Patzel</surname><given-names>K. A.</given-names></name><name><surname>Yasui</surname><given-names>D. H.</given-names></name><name><surname>LaSalle</surname><given-names>J. M.</given-names></name></person-group> (<year>2007</year>). <article-title>15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders.</article-title>
<source/><italic>Hum. Mol. Genet.</italic>
<volume>16</volume>
<fpage>691</fpage>–<lpage>703</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddm014</pub-id>
<pub-id pub-id-type="pmid">17339270</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosie</surname><given-names>A. M.</given-names></name><name><surname>Wilkins</surname><given-names>M. E.</given-names></name><name><surname>da Silva</surname><given-names>H. M. A.</given-names></name><name><surname>Smart</surname><given-names>T. G.</given-names></name></person-group> (<year>2006</year>). <article-title>Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites.</article-title>
<source/><italic>Nature</italic>
<volume>444</volume>
<fpage>486</fpage>–<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1038/nature05324</pub-id>
<pub-id pub-id-type="pmid">17108970</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Shen</surname><given-names>W.-J.</given-names></name><name><surname>Azhar</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones.</article-title>
<source/><italic>Nutr. Metab.</italic>
<volume>7</volume>:<issue>47</issue>. <pub-id pub-id-type="doi">10.1186/1743-7075-7-47</pub-id>
<pub-id pub-id-type="pmid">20515451</pub-id></mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huppke</surname><given-names>P.</given-names></name><name><surname>Laccone</surname><given-names>F.</given-names></name><name><surname>Krämer</surname><given-names>N.</given-names></name><name><surname>Engel</surname><given-names>W.</given-names></name><name><surname>Hanefeld</surname><given-names>F.</given-names></name></person-group> (<year>2000</year>). <article-title>Rett syndrome: analysis of MECP2 and clinical characterization of 31 patients.</article-title>
<source/><italic>Hum. Mol. Genet.</italic>
<volume>9</volume>
<fpage>1369</fpage>–<lpage>1375</lpage>. <pub-id pub-id-type="pmid">10814718</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huttenlocher</surname><given-names>P. R.</given-names></name></person-group> (<year>1976</year>). <article-title>Ketonemia and seizures: metabolic and anticonvulsant effects of two ketogenic diets in childhood epilepsy.</article-title>
<source/><italic>Pediatr. Res.</italic>
<volume>10</volume>
<fpage>536</fpage>–<lpage>540</lpage>. <pub-id pub-id-type="doi">10.1203/00006450-197605000-00006</pub-id>
<pub-id pub-id-type="pmid">934725</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iannotti</surname><given-names>F. A.</given-names></name><name><surname>Hill</surname><given-names>C. L.</given-names></name><name><surname>Leo</surname><given-names>A.</given-names></name><name><surname>Alhusaini</surname><given-names>A.</given-names></name><name><surname>Soubrane</surname><given-names>C.</given-names></name><name><surname>Mazzarella</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability.</article-title>
<source/><italic>ACS Chem. Neurosci.</italic>
<volume>5</volume>
<fpage>1131</fpage>–<lpage>1141</lpage>. <pub-id pub-id-type="doi">10.1021/cn5000524</pub-id>
<pub-id pub-id-type="pmid">25029033</pub-id></mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iseger</surname><given-names>T. A.</given-names></name><name><surname>Bossong</surname><given-names>M. G.</given-names></name></person-group> (<year>2015</year>). <article-title>A systematic review of the antipsychotic properties of cannabidiol in humans.</article-title>
<source/><italic>Schizophr Res.</italic>
<volume>162</volume>
<fpage>153</fpage>–<lpage>161</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2015.01.033</pub-id>
<pub-id pub-id-type="pmid">25667194</pub-id></mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito-Ishida</surname><given-names>A.</given-names></name><name><surname>Ure</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Swann</surname><given-names>J. W.</given-names></name><name><surname>Zoghbi</surname><given-names>H. Y.</given-names></name></person-group> (<year>2015</year>). <article-title>Loss of MeCP2 in parvalbumin-and somatostatin-expressing neurons in mice leads to distinct Rett syndrome-like phenotypes.</article-title>
<source/><italic>Neuron</italic>
<volume>88</volume>
<fpage>651</fpage>–<lpage>658</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2015.10.029</pub-id>
<pub-id pub-id-type="pmid">26590342</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iuvone</surname><given-names>T.</given-names></name><name><surname>Esposito</surname><given-names>G.</given-names></name><name><surname>De Filippis</surname><given-names>D.</given-names></name><name><surname>Scuderi</surname><given-names>C.</given-names></name><name><surname>Steardo</surname><given-names>L.</given-names></name></person-group> (<year>2009</year>). <article-title>Cannabidiol: a promising drug for neurodegenerative disorders?</article-title>
<source/><italic>CNS Neurosci. Ther.</italic>
<volume>15</volume>
<fpage>65</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1111/j.1755-5949.2008.00065.x</pub-id>
<pub-id pub-id-type="pmid">19228180</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>F. D.</given-names></name><name><surname>Ramaswamy</surname><given-names>V.</given-names></name><name><surname>Andersen</surname><given-names>J.</given-names></name><name><surname>Bolduc</surname><given-names>F. V.</given-names></name></person-group> (<year>2009</year>). <article-title>Atypical Rett syndrome with selective FOXG1 deletion detected by comparative genomic hybridization: case report and review of literature.</article-title>
<source/><italic>Eur. J. Hum. Genet.</italic>
<volume>17</volume>
<fpage>1577</fpage>–<lpage>1581</lpage>. <pub-id pub-id-type="doi">10.1038/ejhg.2009.95</pub-id>
<pub-id pub-id-type="pmid">19623215</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jellinger</surname><given-names>K.</given-names></name><name><surname>Armstrong</surname><given-names>D.</given-names></name><name><surname>Zoghbi</surname><given-names>H. Y.</given-names></name><name><surname>Percy</surname><given-names>A. K.</given-names></name></person-group> (<year>1988</year>). <article-title>Neuropathology of Rett syndrome.</article-title>
<source/><italic>Acta Neuropathol.</italic>
<volume>76</volume>
<fpage>142</fpage>–<lpage>158</lpage>. <pub-id pub-id-type="doi">10.1007/BF00688098</pub-id>
<pub-id pub-id-type="pmid">2900587</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenniches</surname><given-names>I.</given-names></name><name><surname>Ternes</surname><given-names>S.</given-names></name><name><surname>Albayram</surname><given-names>O.</given-names></name><name><surname>Otte</surname><given-names>D. M.</given-names></name><name><surname>Bach</surname><given-names>K.</given-names></name><name><surname>Bindila</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Anxiety, stress, and fear response in mice with reduced endocannabinoid levels.</article-title>
<source/><italic>Biol. Psychiatry</italic>
<volume>79</volume>
<fpage>858</fpage>–<lpage>868</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2015.03.033</pub-id>
<pub-id pub-id-type="pmid">25981172</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>X.</given-names></name><name><surname>Cui</surname><given-names>N.</given-names></name><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Jin</surname><given-names>X.-T.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name></person-group> (<year>2013a</year>). <article-title>GABAergic synaptic inputs of locus coeruleus neurons in wild-type and Mecp2-null mice.</article-title>
<source/><italic>Am. J. Physiol. Cell Physiol.</italic>
<volume>304</volume>
<fpage>C844</fpage>–<lpage>C857</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.00399.2012</pub-id>
<pub-id pub-id-type="pmid">23392116</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>X.</given-names></name><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name></person-group> (<year>2013b</year>). <article-title>Time-dependent modulation of GABAA-ergic synaptic transmission by allopregnanolone in locus coeruleus neurons of Mecp2-null mice.</article-title>
<source/><italic>Am. J. Physiol. Cell Physiol.</italic>
<volume>305</volume>
<fpage>C1151</fpage>–<lpage>C1160</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.00195.2013</pub-id>
<pub-id pub-id-type="pmid">24067915</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>I.-M.</given-names></name><name><surname>Birzniece</surname><given-names>V.</given-names></name><name><surname>Lindblad</surname><given-names>C.</given-names></name><name><surname>Olsson</surname><given-names>T.</given-names></name><name><surname>Bäckström</surname><given-names>T.</given-names></name></person-group> (<year>2002</year>). <article-title>Allopregnanolone inhibits learning in the morris water maze.</article-title>
<source/><italic>Brain Res.</italic>
<volume>934</volume>
<fpage>125</fpage>–<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-8993(02)02414-9</pub-id>
<pub-id pub-id-type="pmid">11955475</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>N. A.</given-names></name><name><surname>Glyn</surname><given-names>S. E.</given-names></name><name><surname>Akiyama</surname><given-names>S.</given-names></name><name><surname>Hill</surname><given-names>T. D. M.</given-names></name><name><surname>Hill</surname><given-names>A. J.</given-names></name><name><surname>Weston</surname><given-names>S. E.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures.</article-title>
<source/><italic>Seizure</italic>
<volume>21</volume>
<fpage>344</fpage>–<lpage>352</lpage>. <pub-id pub-id-type="doi">10.1016/j.seizure.2012.03.001</pub-id>
<pub-id pub-id-type="pmid">22520455</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>N. A.</given-names></name><name><surname>Hill</surname><given-names>A. J.</given-names></name><name><surname>Smith</surname><given-names>I.</given-names></name><name><surname>Bevan</surname><given-names>S. A.</given-names></name><name><surname>Williams</surname><given-names>C. M.</given-names></name><name><surname>Whalley</surname><given-names>B. J.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.</article-title>
<source/><italic>J. Pharmacol. Exp. Ther.</italic>
<volume>332</volume>
<fpage>569</fpage>–<lpage>577</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.109.159145</pub-id>
<pub-id pub-id-type="pmid">19906779</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juge</surname><given-names>N.</given-names></name><name><surname>Gray</surname><given-names>J. A.</given-names></name><name><surname>Omote</surname><given-names>H.</given-names></name><name><surname>Miyaji</surname><given-names>T.</given-names></name><name><surname>Inoue</surname><given-names>T.</given-names></name><name><surname>Hara</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Metabolic control of vesicular glutamate transport and release.</article-title>
<source/><italic>Neuron</italic>
<volume>68</volume>
<fpage>99</fpage>–<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2010.09.002</pub-id>
<pub-id pub-id-type="pmid">20920794</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Justice</surname><given-names>M. J.</given-names></name><name><surname>Buchovecky</surname><given-names>C. M.</given-names></name><name><surname>Kyle</surname><given-names>S. M.</given-names></name><name><surname>Djukic</surname><given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>A role for metabolism in Rett syndrome pathogenesis: new clinical findings and potential treatment targets.</article-title>
<source/><italic>Rare Dis.</italic>
<volume>1</volume>:<issue>e27265</issue>. <pub-id pub-id-type="doi">10.4161/rdis.27265</pub-id>
<pub-id pub-id-type="pmid">25003017</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaminski</surname><given-names>R. M.</given-names></name><name><surname>Livingood</surname><given-names>M. R.</given-names></name><name><surname>Rogawski</surname><given-names>M. A.</given-names></name></person-group> (<year>2004</year>). <article-title>Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice.</article-title>
<source/><italic>Epilepsia</italic>
<volume>45</volume>
<fpage>864</fpage>–<lpage>867</lpage>. <pub-id pub-id-type="doi">10.1111/j.0013-9580.2004.04504.x</pub-id>
<pub-id pub-id-type="pmid">15230714</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kano</surname><given-names>M.</given-names></name><name><surname>Ohno-Shosaku</surname><given-names>T.</given-names></name><name><surname>Hashimotodani</surname><given-names>Y.</given-names></name><name><surname>Uchigashima</surname><given-names>M.</given-names></name><name><surname>Watanabe</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Endocannabinoid-mediated control of synaptic transmission.</article-title>
<source/><italic>Physiol. Rev.</italic>
<volume>89</volume>
<fpage>309</fpage>–<lpage>380</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00019.2008</pub-id>
<pub-id pub-id-type="pmid">19126760</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>J. S.</given-names></name><name><surname>Stella</surname><given-names>N.</given-names></name><name><surname>Catterall</surname><given-names>W. A.</given-names></name><name><surname>Westenbroek</surname><given-names>R. E.</given-names></name></person-group> (<year>2017</year>). <article-title>Cannabidiol attenuates seizures and social deficits in a mouse model of dravet syndrome.</article-title>
<source/><italic>PNAS</italic>
<volume>114</volume>
<fpage>11229</fpage>–<lpage>11234</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1711351114</pub-id>
<pub-id pub-id-type="pmid">28973916</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasprowska-Liśkiewicz</surname><given-names>D.</given-names></name><name><surname>Liśkiewicz</surname><given-names>A. D.</given-names></name><name><surname>Nowacka-Chmielewska</surname><given-names>M. M.</given-names></name><name><surname>Nowicka</surname><given-names>J.</given-names></name><name><surname>Małecki</surname><given-names>A.</given-names></name><name><surname>Barski</surname><given-names>J. J.</given-names></name></person-group> (<year>2017</year>). <article-title>The ketogenic diet affects the social behavior of young male rats.</article-title>
<source/><italic>Physiol. Behav.</italic>
<volume>179</volume>
<fpage>168</fpage>–<lpage>177</lpage>. <pub-id pub-id-type="doi">10.1016/j.physbeh.2017.06.007</pub-id>
<pub-id pub-id-type="pmid">28623167</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>D. M.</given-names></name></person-group> (<year>2014</year>). “<article-title>Brain-Derived Neurotrophic Factor and Rett Syndrome</article-title>,” in <source/><italic>Neurotrophic Factors Handbook of Experimental Pharmacology</italic>, <role>eds</role>
<person-group person-group-type="editor"><name><surname>Lewin</surname><given-names>G. R.</given-names></name><name><surname>Carter</surname><given-names>B. D.</given-names></name></person-group> (<publisher-loc>Heidelberg</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>481</fpage>–<lpage>495</lpage>.</mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamura</surname><given-names>M.</given-names></name><name><surname>Ruskin</surname><given-names>D. N.</given-names></name><name><surname>Masino</surname><given-names>S. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Metabolic autocrine regulation of neurons involves cooperation among pannexin hemichannels, adenosine receptors, and KATP channels.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>30</volume>
<fpage>3886</fpage>–<lpage>3895</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0055-10.2010</pub-id>
<pub-id pub-id-type="pmid">20237259</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D. Y.</given-names></name><name><surname>Simeone</surname><given-names>K. A.</given-names></name><name><surname>Simeone</surname><given-names>T. A.</given-names></name><name><surname>Pandya</surname><given-names>J. D.</given-names></name><name><surname>Wilke</surname><given-names>J. C.</given-names></name><name><surname>Ahn</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Ketone bodies mediate anti-seizure effects through mitochondrial permeability transition.</article-title>
<source/><italic>Ann. Neurol.</italic>
<volume>78</volume>
<fpage>77</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1002/ana.24424</pub-id>
<pub-id pub-id-type="pmid">25899847</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y. S.</given-names></name><name><surname>Yoon</surname><given-names>B.-E.</given-names></name></person-group> (<year>2017</year>). <article-title>Altered GABAergic signaling in brain disease at various stages of life.</article-title>
<source/><italic>Exp. Neurobiol.</italic>
<volume>26</volume>:<issue>122</issue>. <pub-id pub-id-type="doi">10.5607/en.2017.26.3.122</pub-id>
<pub-id pub-id-type="pmid">28680297</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krajnc</surname><given-names>N.</given-names></name></person-group> (<year>2015</year>). <article-title>Management of epilepsy in patients with Rett syndrome: perspectives and considerations.</article-title>
<source/><italic>Therapeu. Clin. Risk Manag.</italic>
<volume>11</volume>
<fpage>925</fpage>–<lpage>932</lpage>. <pub-id pub-id-type="doi">10.2147/TCRM.S55896</pub-id>
<pub-id pub-id-type="pmid">26089674</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramar</surname><given-names>C.</given-names></name><name><surname>Loureiro</surname><given-names>M.</given-names></name><name><surname>Renard</surname><given-names>J.</given-names></name><name><surname>Laviolette</surname><given-names>S. R.</given-names></name></person-group> (<year>2017</year>). <article-title>Palmitoylethanolamide modulates GPR55 receptor signaling in the ventral hippocampus to regulate mesolimbic dopamine activity, social interaction, and memory processing.</article-title>
<source/><italic>Cannabis Cannabinoid Res.</italic>
<volume>2</volume>
<fpage>8</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1089/can.2016.0030</pub-id>
<pub-id pub-id-type="pmid">28861501</pub-id></mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwakowsky</surname><given-names>A.</given-names></name><name><surname>Calvo-Flores Guzmán</surname><given-names>B.</given-names></name><name><surname>Pandya</surname><given-names>M.</given-names></name><name><surname>Turner</surname><given-names>C.</given-names></name><name><surname>Waldvogel</surname><given-names>H. J.</given-names></name><name><surname>Faull</surname><given-names>R. L.</given-names></name></person-group> (<year>2018</year>). <article-title>GABAA receptor subunit expression changes in the human Alzheimer’s disease hippocampus, subiculum, entorhinal cortex and superior temporal gyrus.</article-title>
<source/><italic>J. Neurochem.</italic>
<volume>145</volume>
<fpage>374</fpage>–<lpage>392</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.14325</pub-id>
<pub-id pub-id-type="pmid">29485232</pub-id></mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kyle</surname><given-names>S. M.</given-names></name><name><surname>Vashi</surname><given-names>N.</given-names></name><name><surname>Justice</surname><given-names>M. J.</given-names></name></person-group> (<year>2018</year>). <article-title>Rett syndrome: a neurological disorder with metabolic components.</article-title>
<source/><italic>Open Biol.</italic>
<volume>8</volume>:<issue>170216</issue>. <pub-id pub-id-type="doi">10.1098/rsob.170216</pub-id>
<pub-id pub-id-type="pmid">29445033</pub-id></mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laprairie</surname><given-names>R. B.</given-names></name><name><surname>Bagher</surname><given-names>A. M.</given-names></name><name><surname>Kelly</surname><given-names>M. E. M.</given-names></name><name><surname>Denovan-Wright</surname><given-names>E. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor: negative allosteric modulation of CB 1 by cannabidiol.</article-title>
<source/><italic>Br. J. Pharmacol.</italic>
<volume>172</volume>
<fpage>4790</fpage>–<lpage>4805</lpage>. <pub-id pub-id-type="doi">10.1111/bph.13250</pub-id>
<pub-id pub-id-type="pmid">26218440</pub-id></mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauckner</surname><given-names>J. E.</given-names></name><name><surname>Jensen</surname><given-names>J. B.</given-names></name><name><surname>Chen</surname><given-names>H.-Y.</given-names></name><name><surname>Lu</surname><given-names>H.-C.</given-names></name><name><surname>Hille</surname><given-names>B.</given-names></name><name><surname>Mackie</surname><given-names>K.</given-names></name></person-group> (<year>2008</year>). <article-title>GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>105</volume>
<fpage>2699</fpage>–<lpage>2704</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0711278105</pub-id>
<pub-id pub-id-type="pmid">18263732</pub-id></mixed-citation>
</ref>
<ref id="B127">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>R. W. Y.</given-names></name><name><surname>Tierney</surname><given-names>E.</given-names></name></person-group> (<year>2011</year>). <article-title>Hypothesis: the role of sterols in autism spectrum disorder.</article-title>
<source/><italic>Autism Res. Treat.</italic>
<volume>2011</volume>
<fpage>1</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1155/2011/653570</pub-id>
<pub-id pub-id-type="pmid">22937253</pub-id></mixed-citation>
</ref>
<ref id="B128">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Pozzo-Miller</surname><given-names>L.</given-names></name></person-group> (<year>2014</year>). <article-title>BDNF deregulation in Rett syndrome.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>76(Pt C)</volume>, <fpage>737</fpage>–<lpage>746</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.03.024</pub-id>
<pub-id pub-id-type="pmid">23597512</pub-id></mixed-citation>
</ref>
<ref id="B129">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Bu</surname><given-names>G.</given-names></name><name><surname>Zheng</surname><given-names>H.</given-names></name></person-group> (<year>2016</year>). <article-title>Implications of GABAergic Neurotransmission in Alzheimer’s Disease.</article-title>
<source/><italic>Front Aging Neurosci.</italic>
<volume>8</volume>:<issue>31</issue>
<pub-id pub-id-type="doi">10.3389/fnagi.2016.00031</pub-id></mixed-citation>
</ref>
<ref id="B130">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liebhaber</surname><given-names>G. M.</given-names></name><name><surname>Riemann</surname><given-names>E.</given-names></name><name><surname>Matthias Baumeister</surname><given-names>F. A.</given-names></name></person-group> (<year>2003</year>). <article-title>Ketogenic diet in Rett syndrome.</article-title>
<source/><italic>J. Child Neurol.</italic>
<volume>18</volume>
<fpage>74</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1177/08830738030180011801</pub-id>
<pub-id pub-id-type="pmid">12661945</pub-id></mixed-citation>
</ref>
<ref id="B131">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ligsay</surname><given-names>A.</given-names></name><name><surname>Van Dijck</surname><given-names>A.</given-names></name><name><surname>Nguyen</surname><given-names>D. V.</given-names></name><name><surname>Lozano</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Bickel</surname><given-names>E. S.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome.</article-title>
<source/><italic>J. Neurodev. Disord.</italic>
<volume>9</volume>:<issue>26</issue>. <pub-id pub-id-type="doi">10.1186/s11689-017-9207-8</pub-id>
<pub-id pub-id-type="pmid">28764646</pub-id></mixed-citation>
</ref>
<ref id="B132">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Wong-Riley</surname><given-names>M. T. T.</given-names></name></person-group> (<year>2010</year>). <article-title>Postnatal development of N-methyl-D-aspartate receptor subunits 2A, 2B, 2C, 2D, and 3B immunoreactivity in brain stem respiratory nuclei of the rat.</article-title>
<source/><italic>Neuroscience</italic>
<volume>171</volume>
<fpage>637</fpage>–<lpage>654</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2010.09.055</pub-id>
<pub-id pub-id-type="pmid">20887777</pub-id></mixed-citation>
</ref>
<ref id="B133">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loewe</surname><given-names>S.</given-names></name></person-group> (<year>1946</year>). <article-title>Studies on the pharmacology and acute toxicity of compounds with marihuana activity.</article-title>
<source/><italic>J. Pharmacol. Exp. Ther.</italic>
<volume>88</volume>
<fpage>154</fpage>–<lpage>161</lpage>.<pub-id pub-id-type="pmid">20274537</pub-id></mixed-citation>
</ref>
<ref id="B134">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Löscher</surname><given-names>W.</given-names></name></person-group> (<year>1989</year>). <article-title>Valproate enhances GABA turnover in the substantia nigra.</article-title>
<source/><italic>Brain Res.</italic>
<volume>501</volume>
<fpage>198</fpage>–<lpage>203</lpage>.<pub-id pub-id-type="pmid">2508993</pub-id></mixed-citation>
</ref>
<ref id="B135">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lozovaya</surname><given-names>N.</given-names></name><name><surname>Eftekhari</surname><given-names>S.</given-names></name><name><surname>Cloarec</surname><given-names>R.</given-names></name><name><surname>Gouty-Colomer</surname><given-names>L. A.</given-names></name><name><surname>Dufour</surname><given-names>A.</given-names></name><name><surname>Riffault</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>GABAergic inhibition in dual-transmission cholinergic and GABAergic striatal interneurons is abolished in Parkinson disease.</article-title>
<source/><italic>Nat. Commun.</italic>
<volume>9</volume>:<issue>1422</issue>. <pub-id pub-id-type="doi">10.1038/s41467-018-03802-y</pub-id>
<pub-id pub-id-type="pmid">29651049</pub-id></mixed-citation>
</ref>
<ref id="B136">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lund</surname><given-names>E. G.</given-names></name><name><surname>Xie</surname><given-names>C.</given-names></name><name><surname>Kotti</surname><given-names>T.</given-names></name><name><surname>Turley</surname><given-names>S. D.</given-names></name><name><surname>Dietschy</surname><given-names>J. M.</given-names></name><name><surname>Russell</surname><given-names>D. W.</given-names></name></person-group> (<year>2003</year>). <article-title>Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover.</article-title>
<source/><italic>J. Biol. Chem.</italic>
<volume>278</volume>
<fpage>22980</fpage>–<lpage>22988</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M303415200</pub-id>
<pub-id pub-id-type="pmid">12686551</pub-id></mixed-citation>
</ref>
<ref id="B137">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maa</surname><given-names>E.</given-names></name><name><surname>Figi</surname><given-names>P.</given-names></name></person-group> (<year>2014</year>). <article-title>The case for medical marijuana in epilepsy.</article-title>
<source/><italic>Epilepsia</italic>
<volume>55</volume>
<fpage>783</fpage>–<lpage>786</lpage>. <pub-id pub-id-type="doi">10.1111/epi.12610</pub-id>
<pub-id pub-id-type="pmid">24854149</pub-id></mixed-citation>
</ref>
<ref id="B138">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macdonald</surname><given-names>R.</given-names></name><name><surname>Barker</surname><given-names>J. L.</given-names></name></person-group> (<year>1978</year>). <article-title>Benzodiazepines specifically modulate GABA-mediated postsynaptic inhibition in cultured mammalian neurones.</article-title>
<source/><italic>Nature</italic>
<volume>271</volume>
<fpage>563</fpage>–<lpage>564</lpage>.<pub-id pub-id-type="pmid">563985</pub-id></mixed-citation>
</ref>
<ref id="B139">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maitra</surname><given-names>R.</given-names></name><name><surname>Reynolds</surname><given-names>J. N.</given-names></name></person-group> (<year>1999</year>). <article-title>Subunit dependent modulation of GABAA receptor function by neuroactive steroids.</article-title>
<source/><italic>Brain Res.</italic>
<volume>819</volume>
<fpage>75</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="pmid">10082863</pub-id></mixed-citation>
</ref>
<ref id="B140">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majewska</surname><given-names>M. D.</given-names></name><name><surname>Harrison</surname><given-names>N. L.</given-names></name><name><surname>Schwartz</surname><given-names>R. D.</given-names></name><name><surname>Barker</surname><given-names>J. L.</given-names></name><name><surname>Paul</surname><given-names>S. M.</given-names></name></person-group> (<year>1986</year>). <article-title>Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor.</article-title>
<source/><italic>Science</italic>
<volume>232</volume>
<fpage>1004</fpage>–<lpage>1007</lpage>. <pub-id pub-id-type="pmid">2422758</pub-id></mixed-citation>
</ref>
<ref id="B141">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfait</surname><given-names>A. M.</given-names></name><name><surname>Gallily</surname><given-names>R.</given-names></name><name><surname>Sumariwalla</surname><given-names>P. F.</given-names></name><name><surname>Malik</surname><given-names>A. S.</given-names></name><name><surname>Andreakos</surname><given-names>E.</given-names></name><name><surname>Mechoulam</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2000</year>). <article-title>The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis.</article-title>
<source/><italic>PNAS</italic>
<volume>97</volume>
<fpage>9561</fpage>–<lpage>9566</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.160105897</pub-id>
<pub-id pub-id-type="pmid">10920191</pub-id></mixed-citation>
</ref>
<ref id="B142">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantis</surname><given-names>J. G.</given-names></name><name><surname>Centeno</surname><given-names>N. A.</given-names></name><name><surname>Todorova</surname><given-names>M. T.</given-names></name><name><surname>McGowan</surname><given-names>R.</given-names></name><name><surname>Seyfried</surname><given-names>T. N.</given-names></name></person-group> (<year>2004</year>). <article-title>Management of multifactorial idiopathic epilepsy in EL mice with caloric restriction and the ketogenic diet: role of glucose and ketone bodies.</article-title>
<source/><italic>Nutr. Metab.</italic>
<volume>1</volume>:<issue>11</issue>. <pub-id pub-id-type="doi">10.1186/1743-7075-1-11</pub-id>
<pub-id pub-id-type="pmid">15507133</pub-id></mixed-citation>
</ref>
<ref id="B143">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantis</surname><given-names>J. G.</given-names></name><name><surname>Fritz</surname><given-names>C. L.</given-names></name><name><surname>Marsh</surname><given-names>J.</given-names></name><name><surname>Heinrichs</surname><given-names>S. C.</given-names></name><name><surname>Seyfried</surname><given-names>T. N.</given-names></name></person-group> (<year>2009</year>). <article-title>Improvement in motor and exploratory behavior in Rett syndrome mice with restricted ketogenic and standard diets.</article-title>
<source/><italic>Epilepsy Behav.</italic>
<volume>15</volume>
<fpage>133</fpage>–<lpage>141</lpage>. <pub-id pub-id-type="doi">10.1016/j.yebeh.2009.02.038</pub-id>
<pub-id pub-id-type="pmid">19249385</pub-id></mixed-citation>
</ref>
<ref id="B144">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcos</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>L.-W.</given-names></name><name><surname>Wilson</surname><given-names>W. K.</given-names></name><name><surname>Porter</surname><given-names>F. D.</given-names></name><name><surname>Shackleton</surname><given-names>C.</given-names></name></person-group> (<year>2004</year>). <article-title>The implications of 7-dehydrosterol-7-reductase deficiency (smith-lemli-opitz syndrome) to neurosteroid production.</article-title>
<source/><italic>Steroids</italic>
<volume>69</volume>
<fpage>51</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="pmid">14715377</pub-id></mixed-citation>
</ref>
<ref id="B145">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mari</surname><given-names>F.</given-names></name><name><surname>Azimonti</surname><given-names>S.</given-names></name><name><surname>Bertani</surname><given-names>I.</given-names></name><name><surname>Bolognese</surname><given-names>F.</given-names></name><name><surname>Colombo</surname><given-names>E.</given-names></name><name><surname>Caselli</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome.</article-title>
<source/><italic>Hum. Mol. Genet.</italic>
<volume>14</volume>
<fpage>1935</fpage>–<lpage>1946</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddi198</pub-id>
<pub-id pub-id-type="pmid">15917271</pub-id></mixed-citation>
</ref>
<ref id="B146">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marichal-Cancino</surname><given-names>B. A.</given-names></name><name><surname>Fajardo-Valdez</surname><given-names>A.</given-names></name><name><surname>Ruiz-Contreras</surname><given-names>A. E.</given-names></name><name><surname>Méndez-Díaz</surname><given-names>M.</given-names></name><name><surname>Prospéro-García</surname><given-names>O.</given-names></name></person-group> (<year>2018</year>). <article-title>Possible role of hippocampal GPR55 in spatial learning and memory in rats.</article-title>
<source/><italic>Acta Neurobiol. Exp.</italic>
<volume>78</volume>
<fpage>41</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.21307/ane-2018-001</pub-id>
<pub-id pub-id-type="pmid">29694340</pub-id></mixed-citation>
</ref>
<ref id="B147">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Marsicano</surname><given-names>G.</given-names></name><name><surname>Lafenêtre</surname><given-names>P.</given-names></name></person-group> (<year>2009</year>). “<article-title>Roles of the Endocannabinoid System in Learning and Memory</article-title>,” in <source/><italic>Behavioral Neurobiology of the Endocannabinoid System</italic>, <role>eds</role>
<person-group person-group-type="editor"><name><surname>Kendall</surname><given-names>D.</given-names></name><name><surname>Alexander</surname><given-names>S.</given-names></name></person-group> (<publisher-loc>Berlin</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>201</fpage>–<lpage>230</lpage>.</mixed-citation>
</ref>
<ref id="B148">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marx</surname><given-names>C. E.</given-names></name><name><surname>Stevens</surname><given-names>R. D.</given-names></name><name><surname>Shampine</surname><given-names>L. J.</given-names></name><name><surname>Uzunova</surname><given-names>V.</given-names></name><name><surname>Trost</surname><given-names>W. T.</given-names></name><name><surname>Butterfield</surname><given-names>M. I.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics.</article-title>
<source/><italic>Neuropsychopharmacology</italic>
<volume>31</volume>
<fpage>1249</fpage>–<lpage>1263</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1300952</pub-id>
<pub-id pub-id-type="pmid">16319920</pub-id></mixed-citation>
</ref>
<ref id="B149">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mascia</surname><given-names>M. P.</given-names></name><name><surname>Biggio</surname><given-names>F.</given-names></name><name><surname>Mancuso</surname><given-names>L.</given-names></name><name><surname>Cabras</surname><given-names>S.</given-names></name><name><surname>Cocco</surname><given-names>P. L.</given-names></name><name><surname>Gorini</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2002</year>). <article-title>Changes in GABA(A) receptor gene expression induced by withdrawal of, but not by long-term exposure to, ganaxolone in cultured rat cerebellar granule cells.</article-title>
<source/><italic>J. Pharmacol. Exp. Ther.</italic>
<volume>303</volume>
<fpage>1014</fpage>–<lpage>1020</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.102.040063</pub-id>
<pub-id pub-id-type="pmid">12438522</pub-id></mixed-citation>
</ref>
<ref id="B150">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masino</surname><given-names>S. A.</given-names></name><name><surname>Kawamura</surname><given-names>M.</given-names></name><name><surname>Cote</surname><given-names>J. L.</given-names></name><name><surname>Williams</surname><given-names>R. B.</given-names></name><name><surname>Ruskin</surname><given-names>D. N.</given-names></name></person-group> (<year>2013</year>). <article-title>Adenosine and autism: a spectrum of opportunities.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>68</volume>
<fpage>116</fpage>–<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.08.013</pub-id>
<pub-id pub-id-type="pmid">22940000</pub-id></mixed-citation>
</ref>
<ref id="B151">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masino</surname><given-names>S. A.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Theofilas</surname><given-names>P.</given-names></name><name><surname>Sandau</surname><given-names>U. S.</given-names></name><name><surname>Ruskin</surname><given-names>D. N.</given-names></name><name><surname>Fredholm</surname><given-names>B. B.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>A ketogenic diet suppresses seizures in mice through adenosine A<sub>1</sub> receptors.</article-title>
<source/><italic>J. Clin. Invest.</italic>
<volume>121</volume>
<fpage>2679</fpage>–<lpage>2683</lpage>. <pub-id pub-id-type="doi">10.1172/JCI57813</pub-id>
<pub-id pub-id-type="pmid">21701065</pub-id></mixed-citation>
</ref>
<ref id="B152">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>D. B.</given-names></name><name><surname>Morrow</surname><given-names>A. L.</given-names></name><name><surname>Tokunaga</surname><given-names>S.</given-names></name><name><surname>McDaniel</surname><given-names>J. R.</given-names></name></person-group> (<year>2002</year>). <article-title>Acute ethanol administration and acute allopregnanolone administration impair spatial memory in the Morris water task.</article-title>
<source/><italic>Alcohol. Clin. Exp. Res.</italic>
<volume>26</volume>
<fpage>1747</fpage>–<lpage>1751</lpage>. <pub-id pub-id-type="doi">10.1097/01.ALC.0000037219.79257.17</pub-id>
<pub-id pub-id-type="pmid">12436065</pub-id></mixed-citation>
</ref>
<ref id="B153">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGraw</surname><given-names>C. M.</given-names></name><name><surname>Samaco</surname><given-names>R. C.</given-names></name><name><surname>Zoghbi</surname><given-names>H. Y.</given-names></name></person-group> (<year>2011</year>). <article-title>Adult neural function requires MeCP2.</article-title>
<source/><italic>Science</italic>
<volume>333</volume>
<fpage>186</fpage>–<lpage>186</lpage>. <pub-id pub-id-type="doi">10.1126/science.1206593</pub-id>
<pub-id pub-id-type="pmid">21636743</pub-id></mixed-citation>
</ref>
<ref id="B154">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medrihan</surname><given-names>L.</given-names></name><name><surname>Tantalaki</surname><given-names>E.</given-names></name><name><surname>Aramuni</surname><given-names>G.</given-names></name><name><surname>Sargsyan</surname><given-names>V.</given-names></name><name><surname>Dudanova</surname><given-names>I.</given-names></name><name><surname>Missler</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>Early defects of GABAergic synapses in the brain stem of a MeCP2 mouse model of Rett syndrome.</article-title>
<source/><italic>J. Neurophysiol.</italic>
<volume>99</volume>
<fpage>112</fpage>–<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1152/jn.00826.2007</pub-id>
<pub-id pub-id-type="pmid">18032561</pub-id></mixed-citation>
</ref>
<ref id="B155">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meera</surname><given-names>P.</given-names></name><name><surname>Wallner</surname><given-names>M.</given-names></name><name><surname>Otis</surname><given-names>T. S.</given-names></name></person-group> (<year>2011</year>). <article-title>Molecular basis for the high THIP/gaboxadol sensitivity of extrasynaptic GABA(A) receptors.</article-title>
<source/><italic>J. Neurophysiol.</italic>
<volume>106</volume>
<fpage>2057</fpage>–<lpage>2064</lpage>. <pub-id pub-id-type="doi">10.1152/jn.00450.2011</pub-id>
<pub-id pub-id-type="pmid">21795619</pub-id></mixed-citation>
</ref>
<ref id="B156">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meidenbauer</surname><given-names>J. J.</given-names></name><name><surname>Mantis</surname><given-names>J. G.</given-names></name><name><surname>Seyfried</surname><given-names>T. N.</given-names></name></person-group> (<year>2011</year>). <article-title>The EL mouse: a natural model of autism and epilepsy.</article-title>
<source/><italic>Epilepsia</italic>
<volume>52</volume>
<fpage>347</fpage>–<lpage>357</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1167.2010.02898.x</pub-id>
<pub-id pub-id-type="pmid">21204822</pub-id></mixed-citation>
</ref>
<ref id="B157">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melcangi</surname><given-names>R. C.</given-names></name><name><surname>Garcia-Segura</surname><given-names>L. M.</given-names></name><name><surname>Mensah-Nyagan</surname><given-names>A. G.</given-names></name></person-group> (<year>2008</year>). <article-title>Neuroactive steroids: state of the art and new perspectives.</article-title>
<source/><italic>Cell. Mol. Life Sci.</italic>
<volume>65</volume>
<fpage>777</fpage>–<lpage>797</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-007-7403-5</pub-id>
<pub-id pub-id-type="pmid">18038216</pub-id></mixed-citation>
</ref>
<ref id="B158">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melcangi</surname><given-names>R. C.</given-names></name><name><surname>Giatti</surname><given-names>S.</given-names></name><name><surname>Calabrese</surname><given-names>D.</given-names></name><name><surname>Pesaresi</surname><given-names>M.</given-names></name><name><surname>Cermenati</surname><given-names>G.</given-names></name><name><surname>Mitro</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Levels and actions of progesterone and its metabolites in the nervous system during physiological and pathological conditions.</article-title>
<source/><italic>Prog. Neurobiol.</italic>
<volume>113</volume>
<fpage>56</fpage>–<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/j.pneurobio.2013.07.006</pub-id>
<pub-id pub-id-type="pmid">23958466</pub-id></mixed-citation>
</ref>
<ref id="B159">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meletti</surname><given-names>S.</given-names></name><name><surname>Lucchi</surname><given-names>C.</given-names></name><name><surname>Monti</surname><given-names>G.</given-names></name><name><surname>Giovannini</surname><given-names>G.</given-names></name><name><surname>Bedin</surname><given-names>R.</given-names></name><name><surname>Trenti</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Decreased allopregnanolone levels in cerebrospinal fluid obtained during status epilepticus.</article-title>
<source/><italic>Epilepsia</italic>
<volume>58</volume>
<fpage>e16</fpage>–<lpage>e20</lpage>. <pub-id pub-id-type="doi">10.1111/epi.13625</pub-id>
<pub-id pub-id-type="pmid">27888513</pub-id></mixed-citation>
</ref>
<ref id="B160">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meletti</surname><given-names>S.</given-names></name><name><surname>Lucchi</surname><given-names>C.</given-names></name><name><surname>Monti</surname><given-names>G.</given-names></name><name><surname>Giovannini</surname><given-names>G.</given-names></name><name><surname>Bedin</surname><given-names>R.</given-names></name><name><surname>Trenti</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Low levels of progesterone and derivatives in cerebrospinal fluid of patients affected by status epilepticus.</article-title>
<source/><italic>J. Neurochem.</italic>
<volume>147</volume>
<fpage>275</fpage>–<lpage>284</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.14550</pub-id>
<pub-id pub-id-type="pmid">30005125</pub-id></mixed-citation>
</ref>
<ref id="B161">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mellédo</surname><given-names>J.-M. L.</given-names></name><name><surname>Baker</surname><given-names>G. B.</given-names></name></person-group> (<year>2002</year>). <article-title>Neuroactive steroids and anxiety disorders.</article-title>
<source/><italic>J. Psychiatry Neurosci.</italic>
<volume>27</volume>
<fpage>161</fpage>–<lpage>165</lpage>.<pub-id pub-id-type="pmid">12066445</pub-id></mixed-citation>
</ref>
<ref id="B162">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mellon</surname><given-names>S. H.</given-names></name></person-group> (<year>2007</year>). <article-title>Neurosteroid regulation of central nervous system development.</article-title>
<source/><italic>Pharmacol. Ther.</italic>
<volume>116</volume>
<fpage>107</fpage>–<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2007.04.011</pub-id>
<pub-id pub-id-type="pmid">17651807</pub-id></mixed-citation>
</ref>
<ref id="B163">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mersiades</surname><given-names>A. J.</given-names></name><name><surname>Tognela</surname><given-names>A.</given-names></name><name><surname>Haber</surname><given-names>P. S.</given-names></name><name><surname>Stockler</surname><given-names>M.</given-names></name><name><surname>Lintzeris</surname><given-names>N.</given-names></name><name><surname>Simes</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).</article-title>
<source/><italic>BMJ Open</italic>
<volume>8</volume>:<issue>e020745</issue>. <pub-id pub-id-type="doi">10.1136/bmjopen-2017-020745</pub-id>
<pub-id pub-id-type="pmid">30209152</pub-id></mixed-citation>
</ref>
<ref id="B164">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misane</surname><given-names>I.</given-names></name><name><surname>Kruis</surname><given-names>A.</given-names></name><name><surname>Pieneman</surname><given-names>A. W.</given-names></name><name><surname>Ögren</surname><given-names>S. O.</given-names></name><name><surname>Stiedl</surname><given-names>O.</given-names></name></person-group> (<year>2013</year>). <article-title>GABA(A) receptor activation in the CA1 area of the dorsal hippocampus impairs consolidation of conditioned contextual fear in C57BL/6J mice.</article-title>
<source/><italic>Behav. Brain Res.</italic>
<volume>238</volume>
<fpage>160</fpage>–<lpage>169</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2012.10.027</pub-id>
<pub-id pub-id-type="pmid">23098796</pub-id></mixed-citation>
</ref>
<ref id="B165">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Morales</surname><given-names>P.</given-names></name><name><surname>Hurst</surname><given-names>D. P.</given-names></name><name><surname>Reggio</surname><given-names>P. H.</given-names></name></person-group> (<year>2017</year>). “<article-title>Molecular Targets of the Phytocannabinoids: A Complex Picture</article-title>,” in <source/><italic>Phytocannabinoids</italic>, <role>eds</role>
<person-group person-group-type="editor"><name><surname>Kinghorn</surname><given-names>A. D.</given-names></name><name><surname>Falk</surname><given-names>H.</given-names></name><name><surname>Gibbons</surname><given-names>S.</given-names></name><name><surname>Kobayashi</surname><given-names>J.</given-names></name></person-group> (<publisher-loc>Cham</publisher-loc>: <publisher-name>Springer International Publishing</publisher-name>), <fpage>103</fpage>–<lpage>131</lpage>.</mixed-citation>
</ref>
<ref id="B166">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moretti</surname><given-names>P.</given-names></name><name><surname>Zoghbi</surname><given-names>H. Y.</given-names></name></person-group> (<year>2006</year>). <article-title>MeCP2 dysfunction in Rett syndrome and related disorders.</article-title>
<source/><italic>Curr. Opin. Genet. Dev.</italic>
<volume>16</volume>
<fpage>276</fpage>–<lpage>281</lpage>. <pub-id pub-id-type="doi">10.1016/j.gde.2006.04.009</pub-id>
<pub-id pub-id-type="pmid">16647848</pub-id></mixed-citation>
</ref>
<ref id="B167">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagarkatti</surname><given-names>P.</given-names></name><name><surname>Pandey</surname><given-names>R.</given-names></name><name><surname>Rieder</surname><given-names>S. A.</given-names></name><name><surname>Hegde</surname><given-names>V. L.</given-names></name><name><surname>Nagarkatti</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Cannabinoids as novel anti-inflammatory drugs.</article-title>
<source/><italic>Future Med. Chem.</italic>
<volume>1</volume>
<fpage>1333</fpage>–<lpage>1349</lpage>. <pub-id pub-id-type="doi">10.4155/fmc.09.93</pub-id>
<pub-id pub-id-type="pmid">20191092</pub-id></mixed-citation>
</ref>
<ref id="B168">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname><given-names>G.</given-names></name><name><surname>Ackerman</surname><given-names>S. L.</given-names></name></person-group> (<year>2013</year>). <article-title>Cholesterol metabolism and Rett syndrome pathogenesis.</article-title>
<source/><italic>Nat. Genet.</italic>
<volume>45</volume>
<fpage>965</fpage>–<lpage>967</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2738</pub-id>
<pub-id pub-id-type="pmid">23985682</pub-id></mixed-citation>
</ref>
<ref id="B169">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarro</surname><given-names>G.</given-names></name><name><surname>Borroto-Escuela</surname><given-names>D.</given-names></name><name><surname>Angelats</surname><given-names>E.</given-names></name><name><surname>Etayo</surname><given-names>Í.</given-names></name><name><surname>Reyes-Resina</surname><given-names>I.</given-names></name><name><surname>Pulido-Salgado</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. role of CB1 and CB2 receptors and relevance for Alzheimer’s disease and levodopa-induced dyskinesia.</article-title>
<source/><italic>Brain Behav. Immun.</italic>
<volume>67</volume>
<fpage>139</fpage>–<lpage>151</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2017.08.015</pub-id>
<pub-id pub-id-type="pmid">28843453</pub-id></mixed-citation>
</ref>
<ref id="B170">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neal</surname><given-names>E. G.</given-names></name><name><surname>Chaffe</surname><given-names>H.</given-names></name><name><surname>Schwartz</surname><given-names>R. H.</given-names></name><name><surname>Lawson</surname><given-names>M. S.</given-names></name><name><surname>Edwards</surname><given-names>N.</given-names></name><name><surname>Fitzsimmons</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2008</year>). <article-title>The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial.</article-title>
<source/><italic>Lancet Neurol.</italic>
<volume>7</volume>
<fpage>500</fpage>–<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(08)70092-9</pub-id>
<pub-id pub-id-type="pmid">18456557</pub-id></mixed-citation>
</ref>
<ref id="B171">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neul</surname><given-names>J. L.</given-names></name><name><surname>Kaufmann</surname><given-names>W. E.</given-names></name><name><surname>Glaze</surname><given-names>D. G.</given-names></name><name><surname>Christodoulou</surname><given-names>J.</given-names></name><name><surname>Clarke</surname><given-names>A. J.</given-names></name><name><surname>Bahi-Buisson</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Rett syndrome: revised diagnostic criteria and nomenclature.</article-title>
<source/><italic>Ann. Neurol.</italic>
<volume>68</volume>
<fpage>944</fpage>–<lpage>950</lpage>. <pub-id pub-id-type="doi">10.1002/ana.22124</pub-id>
<pub-id pub-id-type="pmid">21154482</pub-id></mixed-citation>
</ref>
<ref id="B172">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neul</surname><given-names>J. L.</given-names></name><name><surname>Zoghbi</surname><given-names>H. Y.</given-names></name></person-group> (<year>2004</year>). <article-title>Rett syndrome: a prototypical neurodevelopmental disorder.</article-title>
<source/><italic>Neuroscientist</italic>
<volume>10</volume>
<fpage>118</fpage>–<lpage>128</lpage>. <pub-id pub-id-type="doi">10.1177/1073858403260995</pub-id>
<pub-id pub-id-type="pmid">15070486</pub-id></mixed-citation>
</ref>
<ref id="B173">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>M. V. C.</given-names></name><name><surname>Du</surname><given-names>F.</given-names></name><name><surname>Felice</surname><given-names>C. A.</given-names></name><name><surname>Shan</surname><given-names>X.</given-names></name><name><surname>Nigam</surname><given-names>A.</given-names></name><name><surname>Mandel</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>MeCP2 is critical for maintaining mature neuronal networks and global brain anatomy during late stages of postnatal brain development and in the mature adult brain.</article-title>
<source/><italic>J. Neurosci.</italic>
<volume>32</volume>
<fpage>10021</fpage>–<lpage>10034</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1316-12.2012</pub-id>
<pub-id pub-id-type="pmid">22815516</pub-id></mixed-citation>
</ref>
<ref id="B174">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novotna</surname><given-names>A.</given-names></name><name><surname>Mares</surname><given-names>J.</given-names></name><name><surname>Ratcliffe</surname><given-names>S.</given-names></name><name><surname>Novakova</surname><given-names>I.</given-names></name><name><surname>Vachova</surname><given-names>M.</given-names></name><name><surname>Zapletalova</surname><given-names>O.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols<sup>*</sup> (sativex ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis: Sativex for refractory spasticity in MS.</article-title>
<source/><italic>Eur. J. Neurol.</italic>
<volume>18</volume>
<fpage>1122</fpage>–<lpage>1131</lpage>. <pub-id pub-id-type="doi">10.1111/j.1468-1331.2010.03328.x</pub-id>
<pub-id pub-id-type="pmid">21362108</pub-id></mixed-citation>
</ref>
<ref id="B175">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Connell</surname><given-names>B. K.</given-names></name><name><surname>Gloss</surname><given-names>D.</given-names></name><name><surname>Devinsky</surname><given-names>O.</given-names></name></person-group> (<year>2017</year>). <article-title>Cannabinoids in treatment-resistant epilepsy: a review.</article-title>
<source/><italic>Epilepsy Behav.</italic>
<volume>70</volume>
<fpage>341</fpage>–<lpage>348</lpage>. <pub-id pub-id-type="doi">10.1016/j.yebeh.2016.11.012</pub-id>
<pub-id pub-id-type="pmid">28188044</pub-id></mixed-citation>
</ref>
<ref id="B176">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onaivi</surname><given-names>E. S.</given-names></name><name><surname>Ishiguro</surname><given-names>H.</given-names></name><name><surname>Gu</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>Q.-R.</given-names></name></person-group> (<year>2012</year>). <article-title>CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity.</article-title>
<source/><italic>J. Psychopharmacol.</italic>
<volume>26</volume>
<fpage>92</fpage>–<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1177/0269881111400652</pub-id>
<pub-id pub-id-type="pmid">21447538</pub-id></mixed-citation>
</ref>
<ref id="B177">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pamplona</surname><given-names>F. A.</given-names></name><name><surname>Coan</surname><given-names>A. C.</given-names></name></person-group> (<year>2017</year>). <article-title>Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis.</article-title>
<source/><italic>bioRxiv</italic>
<pub-id pub-id-type="doi">10.1101/212662</pub-id></mixed-citation>
</ref>
<ref id="B178">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paoletti</surname><given-names>A. M.</given-names></name><name><surname>Romagnino</surname><given-names>S.</given-names></name><name><surname>Contu</surname><given-names>R.</given-names></name><name><surname>Orrù</surname><given-names>M. M.</given-names></name><name><surname>Marotto</surname><given-names>M. F.</given-names></name><name><surname>Zedda</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>Observational study on the stability of the psychological status during normal pregnancy and increased blood levels of neuroactive steroids with GABA-A receptor agonist activity.</article-title>
<source/><italic>Psychoneuroendocrinology</italic>
<volume>31</volume>
<fpage>485</fpage>–<lpage>492</lpage>. <pub-id pub-id-type="doi">10.1016/j.psyneuen.2005.11.006</pub-id>
<pub-id pub-id-type="pmid">16406349</pub-id></mixed-citation>
</ref>
<ref id="B179">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>H.-M.</given-names></name><name><surname>Choi</surname><given-names>I.-S.</given-names></name><name><surname>Nakamura</surname><given-names>M.</given-names></name><name><surname>Cho</surname><given-names>J.-H.</given-names></name><name><surname>Lee</surname><given-names>M.-G.</given-names></name><name><surname>Jang</surname><given-names>I.-S.</given-names></name></person-group> (<year>2011</year>). <article-title>Multiple effects of allopregnanolone on GABAergic responses in single hippocampal CA3 pyramidal neurons.</article-title>
<source/><italic>Eur. J. Pharmacol.</italic>
<volume>652</volume>
<fpage>46</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2010.10.097</pub-id>
<pub-id pub-id-type="pmid">21118679</pub-id></mixed-citation>
</ref>
<ref id="B180">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>L. A.</given-names></name><name><surname>Rock</surname><given-names>E. M.</given-names></name><name><surname>Limebeer</surname><given-names>C. L.</given-names></name></person-group> (<year>2011</year>). <article-title>Regulation of nausea and vomiting by cannabinoids.</article-title>
<source/><italic>Br. J. Pharmacol.</italic>
<volume>163</volume>
<fpage>1411</fpage>–<lpage>1422</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.01176.x</pub-id>
<pub-id pub-id-type="pmid">21175589</pub-id></mixed-citation>
</ref>
<ref id="B181">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pascual</surname><given-names>D.</given-names></name><name><surname>Sánchez-Robles</surname><given-names>E. M.</given-names></name><name><surname>García</surname><given-names>M. M.</given-names></name><name><surname>Goicoechea</surname><given-names>C.</given-names></name></person-group> (<year>2018</year>). <article-title>Chronic pain and cannabinoids. great expectations or a christmas carol.</article-title>
<source/><italic>Biochem. Pharmacol.</italic>
<volume>157</volume>
<fpage>33</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2018.07.033</pub-id>
<pub-id pub-id-type="pmid">30056139</pub-id></mixed-citation>
</ref>
<ref id="B182">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patankar</surname><given-names>J. V.</given-names></name></person-group> (<year>2014</year>). <article-title>Cholesterol metabolism is a potential therapeutic target for Rett syndrome.</article-title>
<source/><italic>Clin. Genet.</italic>
<volume>85</volume>
<fpage>229</fpage>–<lpage>230</lpage>. <pub-id pub-id-type="doi">10.1111/cge.12284</pub-id>
<pub-id pub-id-type="pmid">24102619</pub-id></mixed-citation>
</ref>
<ref id="B183">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patra</surname><given-names>P. H.</given-names></name><name><surname>Barker-Haliski</surname><given-names>M.</given-names></name><name><surname>White</surname><given-names>H. S.</given-names></name><name><surname>Whalley</surname><given-names>B. J.</given-names></name><name><surname>Glyn</surname><given-names>S.</given-names></name><name><surname>Sandhu</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models.</article-title>
<source/><italic>Epilepsia</italic>
<volume>60</volume>
<fpage>303</fpage>–<lpage>314</lpage>. <pub-id pub-id-type="doi">10.1111/epi.14629</pub-id>
<pub-id pub-id-type="pmid">30588604</pub-id></mixed-citation>
</ref>
<ref id="B184">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Percy</surname><given-names>A. K.</given-names></name></person-group> (<year>2016</year>). <article-title>Progress in Rett Syndrome: from discovery to clinical trials.</article-title>
<source/><italic>Wien. Med. Wochensch.</italic>
<volume>166</volume>
<fpage>325</fpage>–<lpage>332</lpage>. <pub-id pub-id-type="doi">10.1007/s10354-016-0491-9</pub-id>
<pub-id pub-id-type="pmid">27491553</pub-id></mixed-citation>
</ref>
<ref id="B185">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pertwee</surname><given-names>R. G.</given-names></name></person-group> (<year>2009</year>). <article-title>Cannabinoid pharmacology: the first 66 years: cannabinoid pharmacology.</article-title>
<source/><italic>Br. J. Pharmacol.</italic>
<volume>147</volume>
<fpage>S163</fpage>–<lpage>S171</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0706406</pub-id>
<pub-id pub-id-type="pmid">16402100</pub-id></mixed-citation>
</ref>
<ref id="B186">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perucca</surname><given-names>E.</given-names></name></person-group> (<year>2017</year>). <article-title>Cannabinoids in the treatment of epilepsy: hard evidence at last?</article-title>
<source/><italic>J Epilepsy Res.</italic>
<volume>7</volume>
<fpage>61</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.14581/jer.17012</pub-id>
<pub-id pub-id-type="pmid">29344464</pub-id></mixed-citation>
</ref>
<ref id="B187">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterman</surname><given-names>M. G.</given-names></name></person-group> (<year>1924</year>). <article-title>The ketogenic diet in the treatment of epilepsy: a preliminary report.</article-title>
<source/><italic>Am. J. Dis. Child</italic>
<volume>28</volume>
<fpage>28</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1001/archpedi.1924.04120190031004</pub-id>
<pub-id pub-id-type="pmid">19515520</pub-id></mixed-citation>
</ref>
<ref id="B188">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrosino</surname><given-names>S.</given-names></name><name><surname>Verde</surname><given-names>R.</given-names></name><name><surname>Vaia</surname><given-names>M.</given-names></name><name><surname>Allarà</surname><given-names>M.</given-names></name><name><surname>Iuvone</surname><given-names>T.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name></person-group> (<year>2018</year>). <article-title>Anti-inflammatory properties of cannabidiol, a nonpsychotropic cannabinoid, in experimental allergic contact dermatitis.</article-title>
<source/><italic>J. Pharmacol. Exp. Ther.</italic>
<volume>365</volume>
<fpage>652</fpage>–<lpage>663</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.117.244368</pub-id>
<pub-id pub-id-type="pmid">29632236</pub-id></mixed-citation>
</ref>
<ref id="B189">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfrieger</surname><given-names>F. W.</given-names></name><name><surname>Ungerer</surname><given-names>N.</given-names></name></person-group> (<year>2011</year>). <article-title>Cholesterol metabolism in neurons and astrocytes.</article-title>
<source/><italic>Prog. Lipid Res.</italic>
<volume>50</volume>
<fpage>357</fpage>–<lpage>371</lpage>. <pub-id pub-id-type="doi">10.1016/j.plipres.2011.06.002</pub-id>
<pub-id pub-id-type="pmid">21741992</pub-id></mixed-citation>
</ref>
<ref id="B190">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>F. D.</given-names></name></person-group> (<year>2002</year>). <article-title>Malformation syndromes due to inborn errors of cholesterol synthesis.</article-title>
<source/><italic>J. Clin. Invest.</italic>
<volume>110</volume>
<fpage>715</fpage>–<lpage>724</lpage>. <pub-id pub-id-type="doi">10.1172/JCI16386</pub-id>
<pub-id pub-id-type="pmid">12235098</pub-id></mixed-citation>
</ref>
<ref id="B191">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puia</surname><given-names>G.</given-names></name><name><surname>Duciæ</surname><given-names>I.</given-names></name><name><surname>Vicini</surname><given-names>S.</given-names></name><name><surname>Costa</surname><given-names>E.</given-names></name></person-group> (<year>1993</year>). <article-title>Does neurosteroid modulatory efficacy depend on GABAA receptor subunit composition?</article-title>
<source/><italic>Recept. Channels</italic>
<volume>1</volume>
<fpage>135</fpage>–<lpage>142</lpage>. <pub-id pub-id-type="pmid">8081717</pub-id></mixed-citation>
</ref>
<ref id="B192">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puia</surname><given-names>G.</given-names></name><name><surname>Mienville</surname><given-names>J.-M.</given-names></name><name><surname>Matsumoto</surname><given-names>K.</given-names></name><name><surname>Takahata</surname><given-names>H.</given-names></name><name><surname>Watanabe</surname><given-names>H.</given-names></name><name><surname>Costa</surname><given-names>E.</given-names></name><etal></etal></person-group> (<year>2003</year>). <article-title>On the putative physiological role of allopregnanolone on GABA(A) receptor function.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>44</volume>
<fpage>49</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="pmid">12559121</pub-id></mixed-citation>
</ref>
<ref id="B193">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabinowitz</surname><given-names>A.</given-names></name><name><surname>Cohen</surname><given-names>S. J.</given-names></name><name><surname>Finn</surname><given-names>D. A.</given-names></name><name><surname>Stackman</surname><given-names>R. W.</given-names></name></person-group> (<year>2014</year>). <article-title>The neurosteroid allopregnanolone impairs object memory and contextual fear memory in male C57BL/6J mice.</article-title>
<source/><italic>Horm Behav.</italic>
<volume>66</volume>
<fpage>238</fpage>–<lpage>246</lpage>. <pub-id pub-id-type="doi">10.1016/j.yhbeh.2014.05.005</pub-id>
<pub-id pub-id-type="pmid">24874172</pub-id></mixed-citation>
</ref>
<ref id="B194">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramocki</surname><given-names>M. B.</given-names></name><name><surname>Peters</surname><given-names>S. U.</given-names></name><name><surname>Tavyev</surname><given-names>Y. J.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Carvalho</surname><given-names>C. M. B.</given-names></name><name><surname>Schaaf</surname><given-names>C. P.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome.</article-title>
<source/><italic>Ann. Neurol.</italic>
<volume>66</volume>
<fpage>771</fpage>–<lpage>782</lpage>. <pub-id pub-id-type="doi">10.1002/ana.21715</pub-id>
<pub-id pub-id-type="pmid">20035514</pub-id></mixed-citation>
</ref>
<ref id="B195">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>D. S.</given-names></name></person-group> (<year>2010</year>). <source/><italic>“Neurosteroids,” in Progress in Brain Research.</italic>
<publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier</publisher-name>.</mixed-citation>
</ref>
<ref id="B196">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>D. S.</given-names></name></person-group> (<year>2011</year>). <article-title>Role of anticonvulsant and antiepileptogenic neurosteroids in the pathophysiology and treatment of epilepsy.</article-title>
<source/><italic>Front. Endocrinol.</italic>
<volume>2</volume>:<issue>38</issue>
<pub-id pub-id-type="doi">10.3389/fendo.2011.00038</pub-id></mixed-citation>
</ref>
<ref id="B197">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>D. S.</given-names></name><name><surname>Estes</surname><given-names>W. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Clinical potential of neurosteroids for CNS disorders.</article-title>
<source/><italic>Trends Pharmacol. Sci.</italic>
<volume>37</volume>
<fpage>543</fpage>–<lpage>561</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2016.04.003</pub-id>
<pub-id pub-id-type="pmid">27156439</pub-id></mixed-citation>
</ref>
<ref id="B198">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>D. S.</given-names></name><name><surname>Jian</surname><given-names>K.</given-names></name></person-group> (<year>2010</year>). <article-title>The testosterone-derived neurosteroid androstanediol is a positive allosteric modulator of GABAA receptors.</article-title>
<source/><italic>J. Pharmacol. Exp. Ther.</italic>
<volume>334</volume>
<fpage>1031</fpage>–<lpage>1041</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.110.169854</pub-id>
<pub-id pub-id-type="pmid">20551294</pub-id></mixed-citation>
</ref>
<ref id="B199">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renieri</surname><given-names>A.</given-names></name><name><surname>Mari</surname><given-names>F.</given-names></name><name><surname>Mencarelli</surname><given-names>M. A.</given-names></name><name><surname>Scala</surname><given-names>E.</given-names></name><name><surname>Ariani</surname><given-names>F.</given-names></name><name><surname>Longo</surname><given-names>I.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Diagnostic criteria for the Zappella variant of Rett syndrome (the preserved speech variant).</article-title>
<source/><italic>Brain Dev.</italic>
<volume>31</volume>
<fpage>208</fpage>–<lpage>216</lpage>. <pub-id pub-id-type="doi">10.1016/j.braindev.2008.04.007</pub-id>
<pub-id pub-id-type="pmid">18562141</pub-id></mixed-citation>
</ref>
<ref id="B200">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rett</surname><given-names>A.</given-names></name></person-group> (<year>1966</year>). <article-title>[On a unusual brain atrophy syndrome in hyperammonemia in childhood].</article-title>
<source/><italic>Wien. Med. Wochenschr.</italic>
<volume>116</volume>
<fpage>723</fpage>–<lpage>726</lpage>.<pub-id pub-id-type="pmid">5300597</pub-id></mixed-citation>
</ref>
<ref id="B201">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rice</surname><given-names>J.</given-names></name><name><surname>Cameron</surname><given-names>M.</given-names></name></person-group> (<year>2018</year>). <article-title>Cannabinoids for treatment of MS symptoms: state of the evidence.</article-title>
<source/><italic>Curr. Neurol. Neurosci. Rep.</italic>
<volume>18</volume>:<issue>50</issue>. <pub-id pub-id-type="doi">10.1007/s11910-018-0859-x</pub-id>
<pub-id pub-id-type="pmid">29923025</pub-id></mixed-citation>
</ref>
<ref id="B202">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riss</surname><given-names>J.</given-names></name><name><surname>Cloyd</surname><given-names>J.</given-names></name><name><surname>Gates</surname><given-names>J.</given-names></name><name><surname>Collins</surname><given-names>S.</given-names></name></person-group> (<year>2008</year>). <article-title>Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.</article-title>
<source/><italic>Acta Neurol. Scand.</italic>
<volume>118</volume>
<fpage>69</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0404.2008.01004.x</pub-id>
<pub-id pub-id-type="pmid">18384456</pub-id></mixed-citation>
</ref>
<ref id="B203">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rissman</surname><given-names>R. A.</given-names></name><name><surname>Mobley</surname><given-names>W. C.</given-names></name></person-group> (<year>2011</year>). <article-title>Implications for treatment: GABAA receptors in aging, down syndrome and Alzheimer’s disease.</article-title>
<source/><italic>J. Neurochem.</italic>
<volume>117</volume>
<fpage>613</fpage>–<lpage>622</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2011.07237.x</pub-id>
<pub-id pub-id-type="pmid">21388375</pub-id></mixed-citation>
</ref>
<ref id="B204">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rock</surname><given-names>E. M.</given-names></name><name><surname>Parker</surname><given-names>L. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Cannabinoids as potential treatment for chemotherapy-induced nausea and vomiting.</article-title>
<source/><italic>Front. Pharmacol.</italic>
<volume>7</volume>:<issue>221</issue>. <pub-id pub-id-type="doi">10.3389/fphar.2016.00221</pub-id>
<pub-id pub-id-type="pmid">27507945</pub-id></mixed-citation>
</ref>
<ref id="B205">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogawski</surname><given-names>M. A.</given-names></name><name><surname>Löscher</surname><given-names>W.</given-names></name><name><surname>Rho</surname><given-names>J. M.</given-names></name></person-group> (<year>2016</year>). <article-title>Mechanisms of action of antiseizure drugs and the ketogenic diet.</article-title>
<source/><italic>Cold Spring Harb. Perspect. Med.</italic>
<volume>6</volume>:<issue>a022780</issue>. <pub-id pub-id-type="doi">10.1101/cshperspect.a022780</pub-id>
<pub-id pub-id-type="pmid">26801895</pub-id></mixed-citation>
</ref>
<ref id="B206">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogawski</surname><given-names>M. A.</given-names></name><name><surname>Loya</surname><given-names>C. M.</given-names></name><name><surname>Reddy</surname><given-names>K.</given-names></name><name><surname>Zolkowska</surname><given-names>D.</given-names></name><name><surname>Lossin</surname><given-names>C.</given-names></name></person-group> (<year>2013</year>). <article-title>Neuroactive steroids for the treatment of status epilepticus.</article-title>
<source/><italic>Epilepsia</italic>
<volume>54(Suppl. 6</volume>), <fpage>93</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1111/epi.12289</pub-id>
<pub-id pub-id-type="pmid">24001085</pub-id></mixed-citation>
</ref>
<ref id="B207">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolando</surname><given-names>S.</given-names></name></person-group> (<year>1985</year>). <article-title>Rett syndrome: report of eight cases.</article-title>
<source/><italic>Brain Dev.</italic>
<volume>7</volume>
<fpage>290</fpage>–<lpage>296</lpage>. <pub-id pub-id-type="pmid">4061760</pub-id></mixed-citation>
</ref>
<ref id="B208">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rombo</surname><given-names>D. M.</given-names></name><name><surname>Ribeiro</surname><given-names>J. A.</given-names></name><name><surname>Sebastião</surname><given-names>A. M.</given-names></name></person-group> (<year>2016</year>). <article-title>Hippocampal GABAergic transmission: a new target for adenosine control of excitability.</article-title>
<source/><italic>J. Neurochem.</italic>
<volume>139</volume>
<fpage>1056</fpage>–<lpage>1070</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.13872</pub-id>
<pub-id pub-id-type="pmid">27778347</pub-id></mixed-citation>
</ref>
<ref id="B209">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenthal</surname><given-names>E. S.</given-names></name><name><surname>Claassen</surname><given-names>J.</given-names></name><name><surname>Wainwright</surname><given-names>M. S.</given-names></name><name><surname>Husain</surname><given-names>A. M.</given-names></name><name><surname>Vaitkevicius</surname><given-names>H.</given-names></name><name><surname>Raines</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Brexanolone as adjunctive therapy in super-refractory status epilepticus.</article-title>
<source/><italic>Ann. Neurol.</italic>
<volume>82</volume>
<fpage>342</fpage>–<lpage>352</lpage>. <pub-id pub-id-type="doi">10.1002/ana.25008</pub-id>
<pub-id pub-id-type="pmid">28779545</pub-id></mixed-citation>
</ref>
<ref id="B210">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenthaler</surname><given-names>S.</given-names></name><name><surname>Pöhn</surname><given-names>B.</given-names></name><name><surname>Kolmanz</surname><given-names>C.</given-names></name><name><surname>Huu</surname><given-names>C. N.</given-names></name><name><surname>Krewenka</surname><given-names>C.</given-names></name><name><surname>Huber</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures.</article-title>
<source/><italic>Neurotoxicol. Teratol.</italic>
<volume>46</volume>
<fpage>49</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/j.ntt.2014.09.003</pub-id>
<pub-id pub-id-type="pmid">25311884</pub-id></mixed-citation>
</ref>
<ref id="B211">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossetti</surname><given-names>M. F.</given-names></name><name><surname>Varayoud</surname><given-names>J.</given-names></name><name><surname>Moreno-Piovano</surname><given-names>G. S.</given-names></name><name><surname>Luque</surname><given-names>E. H.</given-names></name><name><surname>Ramos</surname><given-names>J. G.</given-names></name></person-group> (<year>2015</year>). <article-title>Environmental enrichment attenuates the age-related decline in the mRNA expression of steroidogenic enzymes and reduces the methylation state of the steroid 5α-reductase type 1 gene in the rat hippocampus.</article-title>
<source/><italic>Mol. Cell. Endocrinol.</italic>
<volume>412</volume>
<fpage>330</fpage>–<lpage>338</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2015.05.024</pub-id>
<pub-id pub-id-type="pmid">26021641</pub-id></mixed-citation>
</ref>
<ref id="B212">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruskin</surname><given-names>D. N.</given-names></name><name><surname>Fortin</surname><given-names>J. A.</given-names></name><name><surname>Bisnauth</surname><given-names>S. N.</given-names></name><name><surname>Masino</surname><given-names>S. A.</given-names></name></person-group> (<year>2017</year>). <article-title>Ketogenic diets improve behaviors associated with autism spectrum disorder in a sex-specific manner in the EL mouse.</article-title>
<source/><italic>Physiol. Behav.</italic>
<volume>168</volume>
<fpage>138</fpage>–<lpage>145</lpage>. <pub-id pub-id-type="doi">10.1016/j.physbeh.2016.10.023</pub-id>
<pub-id pub-id-type="pmid">27836684</pub-id></mixed-citation>
</ref>
<ref id="B213">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruskin</surname><given-names>D. N.</given-names></name><name><surname>Ross</surname><given-names>J. L.</given-names></name><name><surname>Kawamura</surname><given-names>M.</given-names></name><name><surname>Ruiz</surname><given-names>T. L.</given-names></name><name><surname>Geiger</surname><given-names>J. D.</given-names></name><name><surname>Masino</surname><given-names>S. A.</given-names></name></person-group> (<year>2011</year>). <article-title>A ketogenic diet delays weight loss and does not impair working memory or motor function in the R6/2 1J mouse model of huntington’s disease.</article-title>
<source/><italic>Physiol. Behav.</italic>
<volume>103</volume>
<fpage>501</fpage>–<lpage>507</lpage>. <pub-id pub-id-type="doi">10.1016/j.physbeh.2011.04.001</pub-id>
<pub-id pub-id-type="pmid">21501628</pub-id></mixed-citation>
</ref>
<ref id="B214">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>E.</given-names></name><name><surname>Guy</surname><given-names>G. W.</given-names></name></person-group> (<year>2006</year>). <article-title>A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.</article-title>
<source/><italic>Med. Hypoth.</italic>
<volume>66</volume>
<fpage>234</fpage>–<lpage>246</lpage>. <pub-id pub-id-type="doi">10.1016/j.mehy.2005.08.026</pub-id>
<pub-id pub-id-type="pmid">16209908</pub-id></mixed-citation>
</ref>
<ref id="B215">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samaco</surname><given-names>R. C.</given-names></name><name><surname>Hogart</surname><given-names>A.</given-names></name><name><surname>LaSalle</surname><given-names>J. M.</given-names></name></person-group> (<year>2005</year>). <article-title>Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3.</article-title>
<source/><italic>Hum. Mol. Genet.</italic>
<volume>14</volume>
<fpage>483</fpage>–<lpage>492</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddi045</pub-id>
<pub-id pub-id-type="pmid">15615769</pub-id></mixed-citation>
</ref>
<ref id="B216">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scala</surname><given-names>E.</given-names></name><name><surname>Ariani</surname><given-names>F.</given-names></name><name><surname>Mari</surname><given-names>F.</given-names></name><name><surname>Caselli</surname><given-names>R.</given-names></name><name><surname>Pescucci</surname><given-names>C.</given-names></name><name><surname>Longo</surname><given-names>I.</given-names></name><etal></etal></person-group> (<year>2005</year>). <article-title>CDKL5/STK9 is mutated in Rett syndrome variant with infantile spasms.</article-title>
<source/><italic>J. Med. Genet.</italic>
<volume>42</volume>
<fpage>103</fpage>–<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1136/jmg.2004.026237</pub-id>
<pub-id pub-id-type="pmid">15689447</pub-id></mixed-citation>
</ref>
<ref id="B217">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sebastião</surname><given-names>A. M.</given-names></name><name><surname>Ribeiro</surname><given-names>J. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Neuromodulation and metamodulation by adenosine: impact and subtleties upon synaptic plasticity regulation.</article-title>
<source/><italic>Brain Res.</italic>
<volume>1621</volume>
<fpage>102</fpage>–<lpage>113</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2014.11.008</pub-id>
<pub-id pub-id-type="pmid">25446444</pub-id></mixed-citation>
</ref>
<ref id="B218">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segatto</surname><given-names>M.</given-names></name><name><surname>Trapani</surname><given-names>L.</given-names></name><name><surname>Di Tunno</surname><given-names>I.</given-names></name><name><surname>Sticozzi</surname><given-names>C.</given-names></name><name><surname>Valacchi</surname><given-names>G.</given-names></name><name><surname>Hayek</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Cholesterol metabolism is altered in Rett syndrome: a study on plasma and primary cultured fibroblasts derived from patients.</article-title>
<source/><italic>PLoS One</italic>
<volume>9</volume>:<issue>e104834</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0104834</pub-id>
<pub-id pub-id-type="pmid">25118178</pub-id></mixed-citation>
</ref>
<ref id="B219">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selye</surname><given-names>H.</given-names></name></person-group> (<year>1941</year>). <article-title>On the hormonal activity of a steroid compound.</article-title>
<source/><italic>Science</italic>
<volume>94</volume>:<issue>94</issue>. <pub-id pub-id-type="doi">10.1126/science.94.2430.94</pub-id>
<pub-id pub-id-type="pmid">17774030</pub-id></mixed-citation>
</ref>
<ref id="B220">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selye</surname><given-names>H.</given-names></name><name><surname>Masson</surname><given-names>G.</given-names></name></person-group> (<year>1942</year>). <article-title>Additional steroids with luteoid activity.</article-title>
<source/><italic>Science</italic>
<volume>96</volume>:<issue>358</issue>. <pub-id pub-id-type="doi">10.1126/science.96.2494.358</pub-id>
<pub-id pub-id-type="pmid">17843907</pub-id></mixed-citation>
</ref>
<ref id="B221">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shahbazian</surname><given-names>M. D.</given-names></name></person-group> (<year>2002</year>). <article-title>Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation.</article-title>
<source/><italic>Hum. Mol. Genet.</italic>
<volume>11</volume>
<fpage>115</fpage>–<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/11.2.115</pub-id>
<pub-id pub-id-type="pmid">11809720</pub-id></mixed-citation>
</ref>
<ref id="B222">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Gong</surname><given-names>Q. H.</given-names></name><name><surname>Aoki</surname><given-names>C.</given-names></name><name><surname>Yuan</surname><given-names>M.</given-names></name><name><surname>Ruderman</surname><given-names>Y.</given-names></name><name><surname>Dattilo</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Reversal of neurosteroid effects at alpha4beta2delta GABAA receptors triggers anxiety at puberty.</article-title>
<source/><italic>Nat. Neurosci.</italic>
<volume>10</volume>
<fpage>469</fpage>–<lpage>477</lpage>. <pub-id pub-id-type="doi">10.1038/nn1868</pub-id>
<pub-id pub-id-type="pmid">17351635</pub-id></mixed-citation>
</ref>
<ref id="B223">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>H.</given-names></name><name><surname>Ishizuka</surname><given-names>Y.</given-names></name><name><surname>Yamazaki</surname><given-names>H.</given-names></name><name><surname>Shirao</surname><given-names>T.</given-names></name></person-group> (<year>2015</year>). <article-title>Allopregnanolone increases mature excitatory synapses along dendrites via protein kinase A signaling.</article-title>
<source/><italic>Neuroscience</italic>
<volume>305</volume>
<fpage>139</fpage>–<lpage>145</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.07.079</pub-id>
<pub-id pub-id-type="pmid">26241343</pub-id></mixed-citation>
</ref>
<ref id="B224">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shulyakova</surname><given-names>N.</given-names></name><name><surname>Andreazza</surname><given-names>A. C.</given-names></name><name><surname>Mills</surname><given-names>L. R.</given-names></name><name><surname>Eubanks</surname><given-names>J. H.</given-names></name></person-group> (<year>2017</year>). <article-title>Mitochondrial dysfunction in the pathogenesis of Rett syndrome: implications for mitochondria-targeted therapies.</article-title>
<source/><italic>Front. Cell. Neurosci.</italic>
<volume>11</volume>:<issue>58</issue>. <pub-id pub-id-type="doi">10.3389/fncel.2017.00058</pub-id>
<pub-id pub-id-type="pmid">28352216</pub-id></mixed-citation>
</ref>
<ref id="B225">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sieghart</surname><given-names>W.</given-names></name></person-group> (<year>2006</year>). <article-title>Structure, pharmacology, and function of GABAA receptor subtypes.</article-title>
<source/><italic>Adv. Pharmacol.</italic>
<volume>54</volume>
<fpage>231</fpage>–<lpage>263</lpage>.<pub-id pub-id-type="pmid">17175817</pub-id></mixed-citation>
</ref>
<ref id="B226">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>J. M.</given-names></name><name><surname>Irwin</surname><given-names>R. W.</given-names></name><name><surname>Yao</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>Allopregnanolone restores hippocampal-dependent learning and memory and neural progenitor survival in aging 3xTgAD and nonTg mice.</article-title>
<source/><italic>Neurobiol. Aging</italic>
<volume>33</volume>
<fpage>1493</fpage>–<lpage>1506</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.06.008</pub-id>
<pub-id pub-id-type="pmid">21803451</pub-id></mixed-citation>
</ref>
<ref id="B227">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>S. S.</given-names></name></person-group> (<year>2002</year>). <article-title>Withdrawal properties of a neuroactive steroid: implications for GABAA receptor gene regulation in the brain and anxiety behavior.</article-title>
<source/><italic>Steroids</italic>
<volume>67</volume>
<fpage>519</fpage>–<lpage>528</lpage>. <pub-id pub-id-type="doi">10.1016/S0039-128X(01)00170-2</pub-id><pub-id pub-id-type="pmid">11960630</pub-id></mixed-citation>
</ref>
<ref id="B228">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solymosi</surname><given-names>K.</given-names></name><name><surname>Kofalvi</surname><given-names>A.</given-names></name></person-group> (<year>2017</year>). <article-title>Cannabis: a treasure trove or pandora’s box?</article-title>
<source/><italic>Mini Rev. Med. Chem.</italic>
<volume>17</volume>
<fpage>1223</fpage>–<lpage>1291</lpage>. <pub-id pub-id-type="doi">10.2174/1389557516666161004162133</pub-id>
<pub-id pub-id-type="pmid">27719666</pub-id></mixed-citation>
</ref>
<ref id="B229">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stearns</surname><given-names>N. A.</given-names></name><name><surname>Schaevitz</surname><given-names>L. R.</given-names></name><name><surname>Bowling</surname><given-names>H.</given-names></name><name><surname>Nag</surname><given-names>N.</given-names></name><name><surname>Berger</surname><given-names>U. V.</given-names></name><name><surname>Berger-Sweeney</surname><given-names>J.</given-names></name></person-group> (<year>2007</year>). <article-title>Behavioral and anatomical abnormalities in Mecp2 mutant mice: a model for Rett syndrome.</article-title>
<source/><italic>Neuroscience</italic>
<volume>146</volume>
<fpage>907</fpage>–<lpage>921</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2007.02.009</pub-id>
<pub-id pub-id-type="pmid">17383101</pub-id></mixed-citation>
</ref>
<ref id="B230">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sticozzi</surname><given-names>C.</given-names></name><name><surname>Belmonte</surname><given-names>G.</given-names></name><name><surname>Pecorelli</surname><given-names>A.</given-names></name><name><surname>Cervellati</surname><given-names>F.</given-names></name><name><surname>Leoncini</surname><given-names>S.</given-names></name><name><surname>Signorini</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Scavenger receptor B1 post-translational modifications in Rett syndrome.</article-title>
<source/><italic>FEBS Lett.</italic>
<volume>587</volume>
<fpage>2199</fpage>–<lpage>2204</lpage>. <pub-id pub-id-type="doi">10.1016/j.febslet.2013.05.042</pub-id>
<pub-id pub-id-type="pmid">23711372</pub-id></mixed-citation>
</ref>
<ref id="B231">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoffel-Wagner</surname><given-names>B.</given-names></name></person-group> (<year>2003</year>). <article-title>Neurosteroid biosynthesis in the human brain and its clinical implications.</article-title>
<source/><italic>Ann. N. Y. Acad. Sci.</italic>
<volume>1007</volume>
<fpage>64</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="pmid">14993041</pub-id></mixed-citation>
</ref>
<ref id="B232">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talbot</surname><given-names>F. B.</given-names></name><name><surname>Metcalf</surname><given-names>K. M.</given-names></name><name><surname>Moriarty</surname><given-names>M. E.</given-names></name></person-group> (<year>1927</year>). <article-title>Epilepsy: chemical investigations of rational treatment by production of ketosis.</article-title>
<source/><italic>Am. J. Dis. Child.</italic>
<volume>33</volume>
<fpage>218</fpage>–<lpage>225</lpage>. <pub-id pub-id-type="doi">10.1001/archpedi.1927.04130140038005</pub-id></mixed-citation>
</ref>
<ref id="B233">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>A.</given-names></name><name><surname>Baillie</surname><given-names>G. L.</given-names></name><name><surname>Phillips</surname><given-names>A. M.</given-names></name><name><surname>Razdan</surname><given-names>R. K.</given-names></name><name><surname>Ross</surname><given-names>R. A.</given-names></name><name><surname>Pertwee</surname><given-names>R. G.</given-names></name></person-group> (<year>2009</year>). <article-title>Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro: Cannabinoid antagonism by cannabidiol.</article-title>
<source/><italic>Br. J. Pharmacol.</italic>
<volume>150</volume>
<fpage>613</fpage>–<lpage>623</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0707133</pub-id>
<pub-id pub-id-type="pmid">17245363</pub-id></mixed-citation>
</ref>
<ref id="B234">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tietz</surname><given-names>E. I.</given-names></name><name><surname>Zeng</surname><given-names>X. J.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Lilly</surname><given-names>S. M.</given-names></name><name><surname>Rosenberg</surname><given-names>H. C.</given-names></name><name><surname>Kometiani</surname><given-names>P.</given-names></name></person-group> (<year>1999</year>). <article-title>Antagonist-induced reversal of functional and structural measures of hippocampal benzodiazepine tolerance.</article-title>
<source/><italic>J. Pharmacol. Exp. Ther.</italic>
<volume>291</volume>
<fpage>932</fpage>–<lpage>942</lpage>. <pub-id pub-id-type="pmid">10565808</pub-id></mixed-citation>
</ref>
<ref id="B235">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tint</surname><given-names>G. S.</given-names></name><name><surname>Irons</surname><given-names>M.</given-names></name><name><surname>Elias</surname><given-names>E. R.</given-names></name><name><surname>Batta</surname><given-names>A. K.</given-names></name><name><surname>Frieden</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>T. S.</given-names></name><etal></etal></person-group> (<year>1994</year>). <article-title>Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome.</article-title>
<source/><italic>N. Engl. J. Med.</italic>
<volume>330</volume>
<fpage>107</fpage>–<lpage>113</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM199401133300205</pub-id>
<pub-id pub-id-type="pmid">8259166</pub-id></mixed-citation>
</ref>
<ref id="B236">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Todorova</surname><given-names>M. T.</given-names></name><name><surname>Tandon</surname><given-names>P.</given-names></name><name><surname>Madore</surname><given-names>R. A.</given-names></name><name><surname>Stafstrom</surname><given-names>C. E.</given-names></name><name><surname>Seyfried</surname><given-names>T. N.</given-names></name></person-group> (<year>2000</year>). <article-title>The ketogenic diet inhibits epileptogenesis in EL mice: a genetic model for idiopathic epilepsy.</article-title>
<source/><italic>Epilepsia</italic>
<volume>41</volume>
<fpage>933</fpage>–<lpage>940</lpage>. <pub-id pub-id-type="pmid">10961617</pub-id></mixed-citation>
</ref>
<ref id="B237">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turkmen</surname><given-names>S.</given-names></name><name><surname>Lundgren</surname><given-names>P.</given-names></name><name><surname>Birzniece</surname><given-names>V.</given-names></name><name><surname>Zingmark</surname><given-names>E.</given-names></name><name><surname>Backstrom</surname><given-names>T.</given-names></name><name><surname>Johansson</surname><given-names>I.-M.</given-names></name></person-group> (<year>2004</year>). <article-title>3β-20β-dihydroxy-5α-pregnane (UC1011) antagonism of the GABA potentiation and the learning impairment induced in rats by allopregnanolone.</article-title>
<source/><italic>Eur. J. Neurosci.</italic>
<volume>20</volume>
<fpage>1604</fpage>–<lpage>1612</lpage>. <pub-id pub-id-type="doi">10.1111/j.1460-9568.2004.03610.x</pub-id>
<pub-id pub-id-type="pmid">15355327</pub-id></mixed-citation>
</ref>
<ref id="B238">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlemann</surname><given-names>E. R.</given-names></name><name><surname>Neims</surname><given-names>A. H.</given-names></name></person-group> (<year>1972</year>). <article-title>Anticonvulsant properties of the ketogenic diet in mice.</article-title>
<source/><italic>J. Pharmacol. Exp. Ther.</italic>
<volume>180</volume>
<fpage>231</fpage>–<lpage>238</lpage>.<pub-id pub-id-type="pmid">5010672</pub-id></mixed-citation>
</ref>
<ref id="B239">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ure</surname><given-names>K.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Ito-Ishida</surname><given-names>A.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>He</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Restoration of Mecp2 expression in GABAergic neurons is sufficient to rescue multiple disease features in a mouse model of Rett syndrome.</article-title>
<source/><italic>eLife</italic>
<volume>5</volume>:<issue>e14198</issue>. <pub-id pub-id-type="doi">10.7554/eLife.14198</pub-id>
<pub-id pub-id-type="pmid">27328321</pub-id></mixed-citation>
</ref>
<ref id="B240">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uusi-Oukari</surname><given-names>M.</given-names></name><name><surname>Korpi</surname><given-names>E. R.</given-names></name></person-group> (<year>2010</year>). <article-title>Regulation of GABAA receptor subunit expression by pharmacological agents.</article-title>
<source/><italic>Pharmacol. Rev.</italic>
<volume>62</volume>
<fpage>97</fpage>–<lpage>135</lpage>. <pub-id pub-id-type="doi">10.1124/pr.109.002063</pub-id>
<pub-id pub-id-type="pmid">20123953</pub-id></mixed-citation>
</ref>
<ref id="B241">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaitkevicius</surname><given-names>H.</given-names></name><name><surname>Husain</surname><given-names>A. M.</given-names></name><name><surname>Rosenthal</surname><given-names>E. S.</given-names></name><name><surname>Rosand</surname><given-names>J.</given-names></name><name><surname>Bobb</surname><given-names>W.</given-names></name><name><surname>Reddy</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>First-in-man allopregnanolone use in super-refractory status epilepticus.</article-title>
<source/><italic>Ann. Clin. Transl. Neurol.</italic>
<volume>4</volume>
<fpage>411</fpage>–<lpage>414</lpage>. <pub-id pub-id-type="doi">10.1002/acn3.408</pub-id>
<pub-id pub-id-type="pmid">28589168</pub-id></mixed-citation>
</ref>
<ref id="B242">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaz</surname><given-names>S. H.</given-names></name><name><surname>Lérias</surname><given-names>S. R.</given-names></name><name><surname>Parreira</surname><given-names>S.</given-names></name><name><surname>Diógenes</surname><given-names>M. J.</given-names></name><name><surname>Sebastião</surname><given-names>A. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Adenosine A2A receptor activation is determinant for BDNF actions upon GABA and glutamate release from rat hippocampal synaptosomes.</article-title>
<source/><italic>Purinerg. Signal</italic>
<volume>11</volume>
<fpage>607</fpage>–<lpage>612</lpage>. <pub-id pub-id-type="doi">10.1007/s11302-015-9476-1</pub-id>
<pub-id pub-id-type="pmid">26452489</pub-id></mixed-citation>
</ref>
<ref id="B243">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vendel</surname><given-names>E.</given-names></name><name><surname>de Lange</surname><given-names>E. C. M.</given-names></name></person-group> (<year>2014</year>). <article-title>Functions of the CB1 and CB2 receptors in neuroprotection at the level of the blood–brain barrier.</article-title>
<source/><italic>NeuroMol. Med.</italic>
<volume>16</volume>
<fpage>620</fpage>–<lpage>642</lpage>. <pub-id pub-id-type="doi">10.1007/s12017-014-8314-x</pub-id>
<pub-id pub-id-type="pmid">24929655</pub-id></mixed-citation>
</ref>
<ref id="B244">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vigli</surname><given-names>D.</given-names></name><name><surname>Cosentino</surname><given-names>L.</given-names></name><name><surname>Raggi</surname><given-names>C.</given-names></name><name><surname>Laviola</surname><given-names>G.</given-names></name><name><surname>Woolley-Roberts</surname><given-names>M.</given-names></name><name><surname>De Filippis</surname><given-names>B.</given-names></name></person-group> (<year>2018</year>). <article-title>Chronic treatment with the phytocannabinoid cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome.</article-title>
<source/><italic>Neuropharmacology</italic>
<volume>140</volume>
<fpage>121</fpage>–<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2018.07.029</pub-id>
<pub-id pub-id-type="pmid">30056123</pub-id></mixed-citation>
</ref>
<ref id="B245">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vining</surname><given-names>E. P.</given-names></name><name><surname>Freeman</surname><given-names>J. M.</given-names></name><name><surname>Ballaban-Gil</surname><given-names>K.</given-names></name><name><surname>Camfield</surname><given-names>C. S.</given-names></name><name><surname>Camfield</surname><given-names>P. R.</given-names></name><name><surname>Holmes</surname><given-names>G. L.</given-names></name><etal></etal></person-group> (<year>1998</year>). <article-title>A multicenter study of the efficacy of the ketogenic diet.</article-title>
<source/><italic>Arch. Neurol.</italic>
<volume>55</volume>
<fpage>1433</fpage>–<lpage>1437</lpage>. <pub-id pub-id-type="pmid">9823827</pub-id></mixed-citation>
</ref>
<ref id="B246">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voituron</surname><given-names>N.</given-names></name><name><surname>Hilaire</surname><given-names>G.</given-names></name></person-group> (<year>2011</year>). <article-title>The benzodiazepine Midazolam mitigates the breathing defects of Mecp2-deficient mice.</article-title>
<source/><italic>Respir. Physiol. Neurobiol.</italic>
<volume>177</volume>
<fpage>56</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.resp.2011.02.002</pub-id>
<pub-id pub-id-type="pmid">21315849</pub-id></mixed-citation>
</ref>
<ref id="B247">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walton</surname><given-names>J. C.</given-names></name><name><surname>McNeill</surname><given-names>J. K.</given-names></name><name><surname>Oliver</surname><given-names>K. A.</given-names></name><name><surname>Albers</surname><given-names>H. E.</given-names></name></person-group> (<year>2017</year>). <article-title>Temporal regulation of GABAA receptor subunit expression: role in synaptic and extrasynaptic communication in the suprachiasmatic nucleus.</article-title>
<source/><italic>eNeuro</italic>
<volume>4</volume>:<issue>ENEURO.0352-16.2017</issue>. <pub-id pub-id-type="doi">10.1523/ENEURO.0352-16.2017</pub-id>
<pub-id pub-id-type="pmid">28466071</pub-id></mixed-citation>
</ref>
<ref id="B248">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J. M.</given-names></name><name><surname>Singh</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Irwin</surname><given-names>R. W.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Chung</surname><given-names>E. J.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer’s disease.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>107</volume>
<fpage>6498</fpage>–<lpage>6503</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1001422107</pub-id>
<pub-id pub-id-type="pmid">20231471</pub-id></mixed-citation>
</ref>
<ref id="B249">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name></person-group> (<year>2011</year>). <article-title>Neurosteroids and GABA-A receptor function.</article-title>
<source/><italic>Front. Endocrinol.</italic>
<volume>2</volume>:<issue>44</issue>. <pub-id pub-id-type="doi">10.3389/fendo.2011.00044</pub-id>
<pub-id pub-id-type="pmid">22654809</pub-id></mixed-citation>
</ref>
<ref id="B250">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waterham</surname><given-names>H. R.</given-names></name></person-group> (<year>2006</year>). <article-title>Defects of cholesterol biosynthesis.</article-title>
<source/><italic>FEBS Lett.</italic>
<volume>580</volume>
<fpage>5442</fpage>–<lpage>5449</lpage>. <pub-id pub-id-type="doi">10.1016/j.febslet.2006.07.027</pub-id>
<pub-id pub-id-type="pmid">16876788</pub-id></mixed-citation>
</ref>
<ref id="B251">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>D.</given-names></name><name><surname>Allsop</surname><given-names>S.</given-names></name><name><surname>Tye</surname><given-names>K.</given-names></name><name><surname>Piomelli</surname><given-names>D.</given-names></name></person-group> (<year>2017</year>). <article-title>Endocannabinoid signaling in the control of social behavior.</article-title>
<source/><italic>Trends Neurosci.</italic>
<volume>40</volume>
<fpage>385</fpage>–<lpage>396</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2017.04.005</pub-id>
<pub-id pub-id-type="pmid">28554687</pub-id></mixed-citation>
</ref>
<ref id="B252">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>Y.</given-names></name><name><surname>Matsuishi</surname><given-names>T.</given-names></name><name><surname>Ishibashi</surname><given-names>M.</given-names></name><name><surname>Kimura</surname><given-names>A.</given-names></name><name><surname>Onishi</surname><given-names>Y.</given-names></name><name><surname>Yonekura</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>1998</year>). <article-title>Decrease in benzodiazepine receptor binding in the brains of adult patients with Rett syndrome.</article-title>
<source/><italic>J. Neurol. Sci.</italic>
<volume>154</volume>
<fpage>146</fpage>–<lpage>150</lpage>. <pub-id pub-id-type="pmid">9562304</pub-id></mixed-citation>
</ref>
<ref id="B253">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yudkoff</surname><given-names>M.</given-names></name><name><surname>Daikhin</surname><given-names>Y.</given-names></name><name><surname>Horyn</surname><given-names>O.</given-names></name><name><surname>Nissim</surname><given-names>I.</given-names></name><name><surname>Nissim</surname><given-names>I.</given-names></name></person-group> (<year>2008</year>). <article-title>Ketosis and brain handling of glutamate, glutamine, and GABA.</article-title>
<source/><italic>Epilepsia</italic>
<volume>49(Suppl. 8)</volume>, <fpage>73</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1167.2008.01841.x</pub-id>
<pub-id pub-id-type="pmid">19049594</pub-id></mixed-citation>
</ref>
<ref id="B254">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaheer</surname><given-names>S.</given-names></name><name><surname>Kumar</surname><given-names>D.</given-names></name><name><surname>Khan</surname><given-names>M. T.</given-names></name><name><surname>Giyanwani</surname><given-names>P. R.</given-names></name><name><surname>Kiran</surname><given-names>F. N. U.</given-names></name></person-group> (<year>2018</year>). <article-title>Epilepsy and cannabis: a literature review.</article-title>
<source/><italic>Cureus</italic>
<volume>10</volume>:<issue>e3278</issue>. <pub-id pub-id-type="doi">10.7759/cureus.3278</pub-id>
<pub-id pub-id-type="pmid">30443449</pub-id></mixed-citation>
</ref>
<ref id="B255">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zamberletti</surname><given-names>E.</given-names></name><name><surname>Gabaglio</surname><given-names>M.</given-names></name><name><surname>Piscitelli</surname><given-names>F.</given-names></name><name><surname>Brodie</surname><given-names>J. S.</given-names></name><name><surname>Woolley-Roberts</surname><given-names>M.</given-names></name><name><surname>Barbiero</surname><given-names>I.</given-names></name><etal></etal></person-group> (<year>2019</year>). <article-title>Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male Mecp2 mutant mice.</article-title>
<source/><italic>J. Psychopharmacol.</italic>
<pub-id pub-id-type="doi">10.1177/0269881119844184</pub-id>
<comment>[Epub ahead of print]</comment>. <pub-id pub-id-type="pmid">31084246</pub-id></mixed-citation>
</ref>
<ref id="B256">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zappella</surname><given-names>M.</given-names></name></person-group> (<year>1992</year>). <article-title>The Rett girls with preserved speech.</article-title>
<source/><italic>Brain Dev.</italic>
<volume>14</volume>
<fpage>98</fpage>–<lpage>101</lpage>.<pub-id pub-id-type="pmid">1621933</pub-id></mixed-citation>
</ref>
<ref id="B257">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Jugloff</surname><given-names>D. G. M.</given-names></name><name><surname>Eubanks</surname><given-names>J. H.</given-names></name></person-group> (<year>2008</year>). <article-title>The MeCP2-null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability.</article-title>
<source/><italic>Hippocampus</italic>
<volume>18</volume>
<fpage>294</fpage>–<lpage>309</lpage>. <pub-id pub-id-type="doi">10.1002/hipo.20389</pub-id>
<pub-id pub-id-type="pmid">18058824</pub-id></mixed-citation>
</ref>
<ref id="B258">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Bao</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Novel FOXG1 mutations in Chinese patients with Rett syndrome or Rett-like mental retardation.</article-title>
<source/><italic>BMC Med. Genet.</italic>
<volume>18</volume>:<issue>96</issue>. <pub-id pub-id-type="doi">10.1186/s12881-017-0455-y</pub-id>
<pub-id pub-id-type="pmid">28851325</pub-id></mixed-citation>
</ref>
<ref id="B259">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Cui</surname><given-names>N.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Su</surname><given-names>J.</given-names></name><name><surname>Tadepalli</surname><given-names>J. S.</given-names></name><name><surname>Sekizar</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>Intrinsic membrane properties of locus coeruleus neurons in Mecp2-null mice.</article-title>
<source/><italic>Am. J. Physiol. Cell Physiol.</italic>
<volume>298</volume>
<fpage>C635</fpage>–<lpage>C646</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.00442.2009</pub-id>
<pub-id pub-id-type="pmid">20042730</pub-id></mixed-citation>
</ref>
<ref id="B260">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z.-W.</given-names></name><name><surname>Zak</surname><given-names>J. D.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name></person-group> (<year>2010</year>). <article-title>MeCP2 is required for normal development of GABAergic circuits in the thalamus.</article-title>
<source/><italic>J. Neurophysiol.</italic>
<volume>103</volume>
<fpage>2470</fpage>–<lpage>2481</lpage>. <pub-id pub-id-type="doi">10.1152/jn.00601.2009</pub-id>
<pub-id pub-id-type="pmid">20200124</pub-id></mixed-citation>
</ref>
<ref id="B261">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Bao</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Cao</surname><given-names>G.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Clinical features and gene mutational spectrum of CDKL5-related diseases in a cohort of Chinese patients.</article-title>
<source/><italic>BMC Med. Genet.</italic>
<volume>15</volume>:<issue>24</issue>. <pub-id pub-id-type="doi">10.1186/1471-2350-15-24</pub-id>
<pub-id pub-id-type="pmid">24564546</pub-id></mixed-citation>
</ref>
<ref id="B262">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Cui</surname><given-names>N.</given-names></name><name><surname>Jin</surname><given-names>X.</given-names></name><name><surname>Oginsky</surname><given-names>M. F.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Methyl CpG binding protein 2 gene disruption augments tonic currents of γ-aminobutyric acid receptors in locus coeruleus neurons: impact on neuronal excitability and breathing.</article-title>
<source/><italic>J. Biol. Chem.</italic>
<volume>290</volume>
<fpage>18400</fpage>–<lpage>18411</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M115.650465</pub-id>
<pub-id pub-id-type="pmid">25979331</pub-id></mixed-citation>
</ref>
<ref id="B263">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Johnson</surname><given-names>C. M.</given-names></name><name><surname>Cui</surname><given-names>N.</given-names></name><name><surname>Oginsky</surname><given-names>M. F.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name></person-group> (<year>2017</year>). <article-title>Effects of early-life exposure to THIP on brainstem neuronal excitability in the Mecp2-null mouse model of Rett syndrome before and after drug withdrawal.</article-title>
<source/><italic>Physiol. Rep.</italic>
<volume>5</volume>:<issue>e13110</issue>. <pub-id pub-id-type="doi">10.14814/phy2.13110</pub-id>
<pub-id pub-id-type="pmid">28108647</pub-id></mixed-citation>
</ref>
<ref id="B264">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuardi</surname><given-names>A. W.</given-names></name><name><surname>Antunes Rodrigues</surname><given-names>J.</given-names></name><name><surname>Cunha</surname><given-names>J. M.</given-names></name></person-group> (<year>1991</year>). <article-title>Effects of cannabidiol in animal models predictive of antipsychotic activity.</article-title>
<source/><italic>Psychopharmacology</italic>
<volume>104</volume>
<fpage>260</fpage>–<lpage>264</lpage>. <pub-id pub-id-type="doi">10.1007/BF02244189</pub-id>
<pub-id pub-id-type="pmid">1678894</pub-id></mixed-citation>
</ref>
<ref id="B265">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuardi</surname><given-names>A. W.</given-names></name><name><surname>Crippa</surname><given-names>J. A. S.</given-names></name><name><surname>Hallak</surname><given-names>J. E. C.</given-names></name><name><surname>Bhattacharyya</surname><given-names>S.</given-names></name><name><surname>Atakan</surname><given-names>Z.</given-names></name><name><surname>Martin-Santos</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2012</year>). <article-title>A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.</article-title>
<source/><italic>Curr. Pharm. Des.</italic>
<volume>18</volume>
<fpage>5131</fpage>–<lpage>5140</lpage>. <pub-id pub-id-type="pmid">22716160</pub-id></mixed-citation>
</ref>
<ref id="B266">
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zuardi</surname><given-names>A. W.</given-names></name><name><surname>de Souza Crippa</surname><given-names>J. A.</given-names></name><name><surname>Hallak</surname><given-names>J. E. C.</given-names></name><name><surname>Campos</surname><given-names>A. C.</given-names></name><name><surname>Guimarães</surname><given-names>F. S.</given-names></name></person-group> (<year>2017</year>). “<article-title>Chapter e13 - The Anxiolytic Effects of Cannabidiol (CBD)</article-title>,” in <source/><italic>Handbook of Cannabis and Related Pathologies</italic>, <role>ed.</role>
<person-group person-group-type="editor"><name><surname>Preedy</surname><given-names>V. R.</given-names></name></person-group> (<publisher-loc>San Diego</publisher-loc>: <publisher-name>Academic Press</publisher-name>), <fpage>e131</fpage>–<lpage>e139</lpage>.</mixed-citation>
</ref>
</ref-list>
<glossary>
<title>Abbreviations</title>
<def-list id="DL1">
<def-item>
<term>24S-OHC</term>
<def>
<p>oxysterol 24(S)-hydroxycholesterol</p>
</def>
</def-item>
<def-item>
<term>3xTg-AD</term>
<def>
<p>triple-transgenic mouse model of AD</p>
</def>
</def-item>
<def-item>
<term>3 α-HSD</term>
<def>
<p>3 α-hydroxysteroid dehydrogenase</p>
</def>
</def-item>
<def-item>
<term>3 β-HSD</term>
<def>
<p>3 β-hydroxysteroid dehydrogenase</p>
</def>
</def-item>
<def-item>
<term>A<sub>1</sub>R</term>
<def>
<p>adenosine A<sub>1</sub> receptor</p>
</def>
</def-item>
<def-item>
<term>A<sub>2A</sub>R</term>
<def>
<p>adenosine A<sub>2A</sub> receptor</p>
</def>
</def-item>
<def-item>
<term>AED</term>
<def>
<p>anti-epileptic drugs</p>
</def>
</def-item>
<def-item>
<term>ALLO</term>
<def>
<p>allopregnanolone</p>
</def>
</def-item>
<def-item>
<term>ATP</term>
<def>
<p>adenosine triphosphate</p>
</def>
</def-item>
<def-item>
<term>BBB</term>
<def>
<p>blood brain barrier</p>
</def>
</def-item>
<def-item>
<term>BDNF</term>
<def>
<p>brain-derived neurotrophic factor</p>
</def>
</def-item>
<def-item>
<term>BHB</term>
<def>
<p>β-hydroxybutyrate</p>
</def>
</def-item>
<def-item>
<term>BZD</term>
<def>
<p>benzodiazepines</p>
</def>
</def-item>
<def-item>
<term>CA1</term>
<def>
<p>cornu ammonis 1</p>
</def>
</def-item>
<def-item>
<term>cAMP</term>
<def>
<p>cyclic adenosine monophosphate</p>
</def>
</def-item>
<def-item>
<term>CB<sub>1</sub>R</term>
<def>
<p>cannabinoid receptor 1</p>
</def>
</def-item>
<def-item>
<term>CB<sub>2</sub>R</term>
<def>
<p>cannabinoid receptor 2</p>
</def>
</def-item>
<def-item>
<term>CBC</term>
<def>
<p>cannabichromene</p>
</def>
</def-item>
<def-item>
<term>CBD</term>
<def>
<p>cannabidiol</p>
</def>
</def-item>
<def-item>
<term>CBDV</term>
<def>
<p>cannabidivarin</p>
</def>
</def-item>
<def-item>
<term>CBG</term>
<def>
<p>cannabigerol</p>
</def>
</def-item>
<def-item>
<term>CBN</term>
<def>
<p>cannabinol</p>
</def>
</def-item>
<def-item>
<term>CBV</term>
<def>
<p>cannabivarin</p>
</def>
</def-item>
<def-item>
<term>CDKL5</term>
<def>
<p>cyclin-dependent kinase-like 5</p>
</def>
</def-item>
<def-item>
<term>CGIC</term>
<def>
<p>seven-category caregiver global impression of change questionnaire</p>
</def>
</def-item>
<def-item>
<term>CNS</term>
<def>
<p>central nervous system</p>
</def>
</def-item>
<def-item>
<term>CYP11A1</term>
<def>
<p>cytochrome P450 cholesterol side-chain cleavage (P450scc) enzyme</p>
</def>
</def-item>
<def-item>
<term>Cyp46a1</term>
<def>
<p>cholesterol 24-hydroxylase</p>
</def>
</def-item>
<def-item>
<term>ECBS</term>
<def>
<p>endocannabinoid system</p>
</def>
</def-item>
<def-item>
<term>FDA</term>
<def>
<p>United States Food and Drug Administration</p>
</def>
</def-item>
<def-item>
<term>FOXG1</term>
<def>
<p>forkhead box protein G1</p>
</def>
</def-item>
<def-item>
<term>GABA</term>
<def>
<p>gamma-aminobutyric acid</p>
</def>
</def-item>
<def-item>
<term>GABA<sub>A</sub>R</term>
<def>
<p>GABA<sub>A</sub> receptor</p>
</def>
</def-item>
<def-item>
<term>GABA<sub>B</sub>R</term>
<def>
<p>GABA<sub>B</sub> receptor</p>
</def>
</def-item>
<def-item>
<term>GABR</term>
<def>
<p>GABA<sub>A</sub> receptor subunit</p>
</def>
</def-item>
<def-item>
<term>GLU</term>
<def>
<p>glutamate</p>
</def>
</def-item>
<def-item>
<term>GPR55</term>
<def>
<p>G-protein coupled receptor 55</p>
</def>
</def-item>
<def-item>
<term>HDL</term>
<def>
<p>high density lipoprotein</p>
</def>
</def-item>
<def-item>
<term>HMG-CoA</term>
<def>
<p>3-hydroxy-3-methylglutaryl-coA</p>
</def>
</def-item>
<def-item>
<term>HMG-CoA-R</term>
<def>
<p>3-hydroxy-3-methylglutaryl-coA reductase</p>
</def>
</def-item>
<def-item>
<term>IPSCs</term>
<def>
<p>post-synaptic inhibitory potentials</p>
</def>
</def-item>
<def-item>
<term>KD</term>
<def>
<p>ketogenic diet</p>
</def>
</def-item>
<def-item>
<term>LDL</term>
<def>
<p>low density lipoprotein</p>
</def>
</def-item>
<def-item>
<term>LPI</term>
<def>
<p>l- α-lysophosphatidylinositol</p>
</def>
</def-item>
<def-item>
<term>MCT</term>
<def>
<p>medium chain triglycerides</p>
</def>
</def-item>
<def-item>
<term>
<italic>MECP2</italic>
</term>
<def>
<p>methyl-CpG-binding protein 2</p>
</def>
</def-item>
<def-item>
<term>PKA</term>
<def>
<p>protein kinase A</p>
</def>
</def-item>
<def-item>
<term>RISE-SRS</term>
<def>
<p>reduced intensity status epilepticus–spontaneous recurrent seizures</p>
</def>
</def-item>
<def-item>
<term>RTT</term>
<def>
<p>Rett syndrome</p>
</def>
</def-item>
<def-item>
<term>SLOS</term>
<def>
<p>Smith–Lemli–Opitz syndrome</p>
</def>
</def-item>
<def-item>
<term>Sqle</term>
<def>
<p>squalene monooxygenase</p>
</def>
</def-item>
<def-item>
<term>SRB1</term>
<def>
<p>scavenger protein B1</p>
</def>
</def-item>
<def-item>
<term>STA</term>
<def>
<p>statins</p>
</def>
</def-item>
<def-item>
<term>StAR</term>
<def>
<p>steroidogenic acute regulatory protein</p>
</def>
</def-item>
<def-item>
<term>Tg</term>
<def>
<p>transgenic</p>
</def>
</def-item>
<def-item>
<term>THCV</term>
<def>
<p>Δ <sup>9</sup>-tetrahydrocannabivarin</p>
</def>
</def-item>
<def-item>
<term>THIP</term>
<def>
<p>GABA<sub>A</sub>R agonist gaboxadol</p>
</def>
</def-item>
<def-item>
<term>TLE</term>
<def>
<p>model of temporal lobe epilepsy</p>
</def>
</def-item>
<def-item>
<term>TRPV<sub>1</sub></term>
<def>
<p>transient receptor potential cation channel subfamily V member 1</p>
</def>
</def-item>
<def-item>
<term>Δ <sup>8</sup>-THC</term>
<def>
<p>Δ <sup>8</sup>-tetrahydrocannabinol</p>
</def>
</def-item>
<def-item>
<term>Δ <sup>9</sup>-THC</term>
<def>
<p>Δ <sup>9</sup>-tetrahydrocannabino.</p>
</def>
</def-item>
</def-list>
</glossary>
</back>
</article>
</pmc-articleset>